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MicroRNAs (miRNAs) are short non-coding RNAs that negatively regulate gene 
expression at the post-transcriptional level. The specificity of miRNA function is 
determined by complementary base-pairing of the 20-22 nucleotide miRNA sequence, 
specifically the 5’- end “seed”, to target mRNAs. Adenosine-to-inosine (A-to-I) RNA 
editing is a mechanism that modifies the sequence of some miRNAs by replacing 
specific adenosine with inosine bases. miRNAs from miR-376 cluster are subject to 
regulated A-to-I editing and in healthy brain tissues, these miRNAs are edited to high 
levels at a single base in their seed sequences, which can redirect their targeting 
specificity. Several lines of evidence suggest that A-to-I editing is perturbed in 
gliomas, due to dysfunction of the editing machinery, the ADAR enzymes. Thus, in 
this study, it was hypothesized that the normal “programmed” level of editing of 
miRNAs from miR-376 cluster does not occur in gliomas and this has functional 
consequences related to tumor development, stemming from changes to the 
sequence of miRNAs. 
Here, by sequencing of miRNAs from miR-376 cluster it was shown that compared to 
normal brain tissue, overall A-to-I editing of this cluster is significantly reduced in 
high-grade gliomas due to low expression of ADAR enzymes. As a result, in tumors, 
miRNAs are underedited or unedited. Specifically from this cluster, miR-376a* 
aberrantly accumulates entirely in the unedited form in glioblastomas (GBMs), the 
most malignant WHO grade IV gliomas. Thus, unedited miR-376a* is a tumor-
specific miRNA sequence variant generated due to altered A-to-I editing in GBMs. 
To investigate if aberrant accumulation of unedited miR-376a* in GBMs has 
functional consequences, unedited or edited miR-376a*, differing by a single base in 
the seed sequence were introduced in glioma cell lines. Through in vitro assays it 
was determined that unedited miR-376a* promotes glioma cell migration and 






Furthermore, through in vivo studies, expression of unedited miR-376a* in glioma 
cells was shown to promote aggressive growth of orthotopic gliomas, recapitulating 
features of human GBMs. By global gene expression profiling it was confirmed that a 
single base change in miR-376a*, brought about by loss of regulated A-to-I editing, is 
sufficient to direct its function towards an unfavorable target gene profile, consistent 
with aggressive glioma growth. Thus, unedited miR-376a* represents a functional 
miRNA sequence variant that promotes malignant properties of glioma cells.  
To understand the mechanism by which unedited miR-376a* promotes glioma cell 
migration and invasion, target gene specificity of this miRNA was determined, 
through a combination of microarray analysis and computational predictions. It was 
established that the cellular effects of unedited miR-376a* in glioma cells are 
mediated by its sequence-dependent ability to target STAT3 and concomitant 
inability to target AMFR. These results show that a single base change in the 
sequence of a miRNA can have profound consequences on tumor growth and 
invasion through altered target gene specification. Significantly, these findings 
uncover a novel mechanism of miRNA deregulation in cancer, based on a tumor-
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1 CHAPTER 1. Introduction 
1.1 MicroRNAs: Overview 
MicroRNAs constitute an abundant family of short, non-coding RNAs that mediate 
posttranscriptional gene expression regulation. Based on antisense complementarity 
to the 3’ untranslated regions (3’ UTR) of messenger RNAs (mRNA), miRNAs 
specifically mediate negative regulation of target gene translation impacting target 
protein output (Bartel, 2004). miRNAs are ubiquitously present and have been found 
in viruses, worms, flies, plants, mammals, indeed in all metazoan eukaryotes (Bartel, 
2009). In humans, >1000 miRNAs are annotated in the comprehensive miRNA 
registry, miRBase version 17.0 (Griffiths-Jones et al., 2008). Each mammalian 
miRNA is predicted to target ~200 genes (Krek et al., 2005) and based on 
bioinformatics analyses this amounts to a collective regulation of over 30% of all 
protein-coding genes  (Lewis et al., 2005; Xie et al., 2005). Despite having modest 
effects on protein output by fine-tuning target gene expression (Baek et al., 2008; 
Selbach et al., 2008), miRNAs can be indispensible for cellular function and are 
known to regulate differentiation, apoptosis, metabolism, and neuronal development 
as well as pathological conditions such as cancer (Kloosterman and Plasterk, 2006). 
1.2 Biogenesis of miRNAs 
1.2.1 Genomics 
The genomics of miRNA genes are closely linked to their biogenesis. Nearly half of 
the genes encoding miRNAs are found in clusters and 55 such miRNA clusters have 
been identified in the human genome (Kim and Nam, 2006; Yuan et al., 2009). Given 
their proximal genomic location, clustered miRNAs are polycistronically transcribed 
as long primary transcripts and presumably, are under similar regulatory influences 






miRNA genes can be located in intergenic genomic regions distinct from known 
transcription units where they can be clustered or monocistronic. Significantly 
however, the location of ~70% of known mammalian miRNAs is intragenic and 
overlaps with known transcription units (TUs)- either within introns of protein-coding 
genes, or within TUs lacking protein-coding potential, referred to as long non-coding 
RNAs (Rodriguez et al., 2004). Intragenic miRNAs are also often present in clustered 
arrangements such as the mir-106b~25~93 cluster found within the intron 13 of 
MCM7 gene in humans and mice (Kim and Nam, 2006).    
1.2.2 Transcription 
miRNA biogenesis begins with transcription of a long primary transcript by RNA 
polymerase II (Pol II), while a small group of miRNAs may be transcribed by Pol III 
(Kim et al., 2009). Most primary miRNAs (pri-miRNAs) are capped at the 5’ end and 
polyadenylated at the 3’ end, characteristic features of all Pol II transcripts (Lee et al., 
2004). The genomic location of miRNA loci dictates that intergenic miRNAs are 
transcribed from their own promoters while intragenic miRNAs share regulatory 
elements with their host genes (Bartel, 2004). In case of intronic and exonic miRNAs, 
the Pol II-transcribed primary transcript hosts both the pre-mRNA and the pri-miRNA.  
1.2.3 Processing 
Pri-miRNAs can range from hundreds to thousands of nucleotides in length and 
contain one or more defining local stem-loop structures (Kim et al., 2009). In the 
nucleus, the RNAse III-type endonuclease Drosha, cleaves both strands of the 
primary stem-loop at the base of the stem releasing ~60-70-nt long intermediate 
stem-loop structure termed the precursor miRNA (pre-miRNA) (Lee et al., 2003). 
Appropriate cleavage of pri-miRNAs requires the recognition of the 33-bp (double-
stranded) stem and flanking single-stranded RNA segments of pri-miRNA structure 
by DGCR8, which then aids Drosha cleavage of both strands of the stem ~11 bp 






miRNAs are characterized by a staggered base with a 5’ phosphate and ~ 2-nt 3’ 
overhang (Bartel, 2004).  For intragenic miRNAs, their release from host genes is 
assumed to involve the action of the spliceosome machinery for intron excision prior 
to further processing (Kim and Kim, 2007). 
The pre-miRNA is transported by exportin-5 out of the nucleus to the cytoplasm 
where it undergoes further processing by the RNAse III endonuclease, Dicer which 
cleaves both strands of the pre-miRNA stem ~22 nt from the pre-existing terminus 
(product of Drosha processing, which defines one end of the mature product (Bartel, 
2004)) removing the loop and terminal base pairs (Bartel, 2004). Dicer generates a 
staggered cut with a 5’ phosphate and ~ 2-nt overhang, resulting in an imperfect 16-
24 nt duplex containing the mature miRNA, termed the miRNA:miRNA* duplex with 5’ 
phosphates and ~2 nt 3’ overhangs. 
Following Dicer cleavage, the RNA duplex is assembled into a large 
ribonucleoprotein complex, known as miRNA-induced silencing complex (miRISC). 
One strand of the duplex remains associated with an AGO protein, from the highly 
conserved Argonaute family, which form the core of miRISC (Bartel, 2004). This 
strand is known as the guide strand. The other strand known as the passenger 
strand or miRNA* is degraded (Kim et al., 2009). The determination of which strand 
is incorporated is based on the thermodynamic stability of the two ends of the duplex. 
Typically, the strand with more unstable base pairs at its 5’ end is preferentially 
incorporated into RISC (Hutvagner, 2005; Khvorova et al., 2003). Figure 1.1 













1.2.3.1 miRNA* strands  
It is important to note that thermodynamic properties alone are unlikely to determine 
the choice of miRNA duplex arm incorporation into RISC because several miRNA* 
species are abundantly expressed and functional (Okamura et al., 2008; Yang et al., 
2011), and  miRNA or miRNA* incorporation and individual strand abundance can 
vary widely across tissues and developmental times (Griffiths-Jones et al., 2011). 
Some sequence determinants that dictate the preferential sorting of miRNA* strand 
Figure 1.1 Biogenesis of miRNAs. Schematic representation of the miRNA biogenesis 
pathway. Following transcription by RNA polymerase II, primary miRNA (pri-miRNA) 
transcripts are recognized and cleaved by the nuclear Microprocessor complex consisting of 
Drosha and DGCR8, to produce ~60-nt precursor miRNA (pre-miRNA) transcripts with 
characteristic stem-loop structure. The pre-miRNA is then transported to the cytoplasm by 
Ran-GTP and export receptor exportin-5. The cytoplasmic RNase, Dicer then processes the 
pre-miRNA to ~20 bp mature miRNA duplex. One strand of the duplex, the guide strand, is 
selected for incorporation into RISC while the other strand is degraded. The core component, 
of RISC, Ago protein mediates the downstream silencing effect of the incorporated guide 






of the miRNA/miRNA* duplex to AGO2 proteins have been identified (Czech et al., 
2009; Okamura et al., 2009). 
Indeed, for several pre-miRNAs, both strands of the duplex are functional mature 
miRNAs. The naming of miRNA and miRNA* strands is conventionally determined by 
the steady-state abundance of each strand. The more abundant product of a pre-
miRNA is referred to as miRNA while the rarer partner strand is referred to as 
miRNA* (Lau et al., 2001; Okamura et al., 2008). According to miRBase (Griffiths-
Jones et al., 2008), if the ratio of expression of miRNA and miRNA* strands is not yet 
determined or where both strands have an approximately equal expression, the 
mature miRNA is named with a suffix ‘-5p’ or ‘-3p’ depending on the pre-miRNA 
strand of origin. A recent development in the miRNA nomenclature system is the 
move to substitute all miR:miR* nomenclature with ‘-5p’/’-3p’ to reflect the general 
abundance and regulatory function of miRNA* species (Okamura et al., 2008; Yang 
et al., 2011).  
1.2.4 Determinants of steady-state abundance of miRNAs 
The steady-state abundance of a mature miRNA is determined by several 
posttranscriptional mechanisms and is rarely correlated to the expression or 
transcription rate of its precursor (Siomi and Siomi, 2010). Furthermore, although 
clustered miRNAs are commonly transcribed in a single transcript, their expression 
may not be coordinated due to regulation at the level of individual miRNAs (Guil and 
Caceres, 2007; Lu et al., 2007; Mineno et al., 2006). In addition to strand selection, 
degradation and turnover of mature miRNAs, association with target mRNAs are 
other posttranscriptional mechanisms that can determine the steady-state abundance 







1.3 Mechanism of action of miRNAs 
The functional core of miRISC is AGO which execute the inhibitory effects of miRNAs. 
Additionally, RISC contains other regulatory factors that control RISC assembly and 
function (Filipowicz et al., 2008). miRNAs incorporated in the RISC assembly direct 
posttranscriptional gene regulation leading to repressed target protein synthesis. At 
least three mechanisms of miRNA function in repressing protein synthesis are 
currently known but the exact mechanism by which a particular miRNA may regulate 
a particular target is difficult to predict. During regulation of target genes, miRNAs 
can mediate mRNA cleavage, deadenylation or translational repression of target 
mRNAs (Figure 1.2).  
1.3.1 mRNA cleavage 
Some miRNAs can direct endonucleolytic cleavage of their targets (Davis et al., 2005; 
Yekta et al., 2004). This is typically determined by the extensive base-pairing 
between the miRNA and target mRNA and is  rare given that most animal miRNAs 
do not have extensive complementarity to mRNAs (Valencia-Sanchez et al., 2006). 
For target cleavage to occur the RISC complex must contain  a specific Argonaute, 
AGO2, which in mammalian cells is the only AGO protein known to be capable of 
directing cleavage through its RNase H domain (Meister et al., 2004). 
1.3.2 mRNA deadenylation and decay 
In a manner independent from endonucleolytic cleavage, miRNAs can induce 
destabilization of their target mRNAs (Figure 1.2A). This is evident from specific 
examples of target mRNA degradation in the absence of perfect complementarity 
with miRNA (Bagga et al., 2005; Wu et al., 2006), and from microarray experiments 
where experimentally manipulating the level of  a miRNA leads to changes in the 
mRNA abundance of several validated and predicted targets (Krutzfeldt et al., 2005; 
Lim et al., 2005). miRNAs direct their targets for degradation by accelerating their 






protein required for P-body integrity, interacts with AGO1 of the RISC complex, and 
marks mRNA for decay by recruitment of CCR4:NOT1 deadenylase complex 
(Filipowicz et al., 2008; Pillai et al., 2007). In addition to GW182, miRNAs, miRNA 
targets and AGO proteins are also detected in cytoplasmic P-bodies, where bulk 
mRNA degradation occurs, suggesting a model where miRNA targets are 
sequestered from the translational machinery and undergo decay (Eulalio et al., 2008; 
Valencia-Sanchez et al., 2006).  
1.3.3 Translational repression 
Translational repression can be mediated by miRNAs at the initiation and post-
initiation stages of protein synthesis (Figure 1.2B). Translation initiation can be 
blocked by inhibition of cap-binding of the translation initiation factor eIF4E by direct 
competition with Argonaute for the mRNA 7-methylguanosine cap (Kiriakidou et al., 
2007). Interaction of eIF6, a crucial factor for 60S ribosome subunit biogenesis, with 
the Ago2-Dicer-TRBP (RISC) complex can also prevent ribosome assembly and 
block translation initiation (Chendrimada et al., 2007). At the post-initiation stages, 
miRNAs can interfere with the polypeptide elongation step by inducing ribosome 
‘drop-off’ (Maroney et al., 2006; Petersen et al., 2006). The association of repressed 
mRNAs with actively translating polyribosomes supports a post-initiation action of 
miRNA inhibition. Repressed ribosome-free mRNA aggregate may be exported to P-
bodies for degradation (Behm-Ansmant et al., 2006; Pillai et al., 2007).   
Recent evidence from genome-wide studies on miRNA-mediated regulation of 
protein and mRNA abundances, suggests that mRNA degradation alone can account 
for most of the repression mediated by miRNAs, at least in cell culture (Huntzinger 
and Izaurralde, 2011). Through such mRNA and protein level comparisons, it has 
been found that only a very small fraction of targets are repressed exclusively at the 
translational level, and this fraction also displays more limited levels of regulation 












1.4 Principles of miRNA target recognition 
The key determinant for miRNA-mediated regulation is the miRNA sequence. In 
plants, miRNAs bear near-perfect complementarity with their targets and induce 
endonucleolytic cleavage of mRNA (Jones-Rhoades et al., 2006). In contrast, most 
metazoan miRNAs pair with partial complementarity to their targets. Target selection 
for most miRNAs is governed by a set of rules that have been experimentally and 
computationally determined (Brennecke et al., 2005; Doench and Sharp, 2004; Lewis 
et al., 2005).  
A
B 
Figure 1.2 Mechanisms of posttranscriptional repression mediated by miRNAs . A. 
Binding of miRNA-loaded miRNP (miRISC) complex can lead to mRNA deadenylation and 
degradation through the recruitment of deadenylation complex, CCR4-NOT, right. Proteolysis 
of nascent polypeptide may also occur cotranslationally through an as yet unrecognized 
protease, left. B. miRNA targeting can lead to translational repression through an initiation 
block by hindering cap recognition by eIF4E or by preventing 60S subunit joining, left. 
Alternatively, repression can also occur at post-initiation step of translation, right. Middle, 
repressed mRNAs are transported to P-bodies for degradation or storage. Image from 







1.4.1 Seed matches in 3’UTRs 
At the core of miRNA target recognition is the requirement of contiguous and perfect 
base-pairing with nucleotides 2-8 of miRNA, termed the miRNA ‘seed’ sequence 
(Brennecke et al., 2005; Lewis et al., 2005). Lack of complementarity in the central 
part of the miRNA (positions 10 and 11) is also a feature of most mRNA-miRNA 
interactions and precludes the endonucleolytic cleavage of the target mRNA (Pillai et 
al., 2007). Most functional miRNA sites lie in the 3’UTR of target genes, and show 
high degree of conservation. The requirement for miRNA targeting sites to be 
restricted to the 3’UTR, is speculated to be due the potential displacement of the 
bound miRISC complex by ribosomes translocating through the 5’ UTR and ORF 
regions during protein translation, precluding their selection as miRNA binding sites 
(Grimson et al., 2007; Gu et al., 2009).  
1.4.2 Features of miRNA targeting sites 
Functional miRNA target sites have been classified based on the degree of pairing 
with the 5’-end of miRNA (Figure 1.3A). Three classes of miRNA target sites include 
(i) 5’ dominant canonical, (ii) 5’ dominant seed, and (iii) 3’ compensatory  (Brennecke 
et al., 2005). 5’ dominant canonical sites have good pairing with both 5’ and 3’ ends 
of miRNA, whereas 5’ dominant seed sites tend to have good pairing with the 5’ seed 
only with limited or no pairing with the 3’ end of miRNA. Due to their extensive pairing 
canonical sites may function in single copies. Whereas, seed sites are speculated to 
be more effective when present in multiple copies. The 3’ compensatory class of 
target sites involves compromised 5’ seed pairing of 4 to 6 base-pairs, seeds of 7 or 
8 bases with G:U wobbles, single nucleotide bulges or mismatches, which are then 
complemented by extensive pairing to the 3’ end of the miRNA, especially at 
nucleotides 13-16.  
The presence of multiple sites of the same miRNA within a given 3’UTR increases 






al., 2007). The distance between the sites determines their effectiveness together, 
with 10-40 nt apart being most contributory to cooperative action (Grimson et al., 
2007). 
1.4.3 Contextual determinants of targeting  
In addition to the targeting site itself, several contextual determinants of functional 
targeting have been determined. High local AU density in the immediate vicinity of 
the targeting site improves the effectiveness of targeting sites, presumably due to the 
weaker secondary structure of mRNA which increases miRNA accessibility to the 
targeting sites (Grimson et al., 2007). Indeed, lack of a local secondary structure near 
miRNA targeting site has been shown to be an essential and conserved feature 
B 
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Figure 1.3 Priniciples of miRNA target recognition. A. Three classes of miRNA target 
sites based on extent of miRNA-mRNA interaction. mRNA target sites are the upper lines 
and miRNAs are the lower lines. Canonical site with good pairing of 5’ and 3’ ends of 
miRNA (left), 5’ dominant seed site with extensive pairing of seed only (middle), and 3’ 
compensatory site with compromised 5’ seed pairing complemented by extensive pairing 
of the 3’ end of miRNA (right). Image from (Brennecke et al., 2005). B. Generalized 
principles of miRNA interaction with targets. Contiguous base-pairing at miRNA positions 
2-8, is enhanced by the presence of A at target position 1 and A or U at target position 9. 
Bulge at the central region of miRNA-mRNA duplex precludes endonucleolytic cleavage 
by Argonaute. Complementarity at 3’ end of miRNA stabilizes the interaction. Image from 







across genomes (Kertesz et al., 2007). Effective sites also lie preferentially at the 
ends of long 3’UTRs (>1300 nt), that is, close to the ORF or to the poly(A) tail, while 
the region within 15 nt of the stop codon of the ORF is generaly not suitable for 
targeting (Grimson et al., 2007). 
Quantitative analysis of microarray data of messages down-regulated after 
introducing a miRNA has shown that efficacy of targeting sites follows a hierarchy: 
8mer>>7mer-m8>7mer-A1>>6mer (Bartel, 2009; Grimson et al., 2007). The degree 
of mRNA down-regulation is therefore, to an extent determined by the type of 
targeting site present in the 3’UTR. The same hierarchy applies when protein levels 
are examined (Baek et al., 2008; Selbach et al., 2008). However, whether a given 
miRNA triggers mRNA decay or translation repression seems to be specified by the 
mRNA target (Eulalio et al., 2008). The involvement of accessory proteins, structural 
determinants of the miRNA-mRNA duplex may dictate the outcome (Filipowicz et al., 
2008). 
There are notable exceptions to many of the miRNA targeting rules. Offset 6mer sites, 
that is, seed matches at positions 3-8 of miRNA are variant seeds that are often 
conserved and functional (Friedman et al., 2009; Wu and Belasco, 2005). Contrary to 
expectation, some functional miRNA sites are located in the ORFs of target mRNAs 
rather than their 3’UTRs (Duursma et al., 2008; Forman et al., 2008; Lal et al., 2008; 
Tay et al., 2008). Furthermore, using artificial sensor constructs miRNA-mediated 
repression was shown to be effective when sites were located in the 5’UTR of the 
reporter (Lytle et al., 2007). The absolute requirement for Watson-Crick base-pairing 
in the miRNA seed sequence has been overturned by the presence of mismatches in 
the seed and G:U wobble pairs in functional non-seed matches in mouse and C. 
elegans targets (Didiano and Hobert, 2006; Tay et al., 2008).  Furthermore, 
functional “seedless” target sites for a particular miRNA, miR-24 have also been 






al., 2009). Rather than being exceptions, these examples may represent a general 
scenario which is yet to be defined and is independent of seed site and conservation. 
1.5 miRNAs in cancer 
Majority of identified miRNAs are evolutionarily conserved in related species such as 
humans and mouse with  some (e.g. let-7 family) being found conserved across 
many lineages (Bartel, 2004), suggesting critical functions for miRNAs. Studies 
suggest a general involvement of miRNAs in regulation of developmental pathways 
and differentiation of cells. At least three features of miRNA genomics and 
expression support a role for miRNAs in cancers: 
1. Location of human miRNA genes in cancer-associated sites : about 50% of the 
annotated human miRNAs are located in specific cancer-associated genomic 
regions or fragile sites (Calin et al., 2004).  
2. Tissue-specific expression profiles of miRNAs : a microarray study of 154 human 
miRNAs revealed that most miRNAs are expressed in a tissue-specific manner, 
and that adult organs (more differentiated) express many more miRNAs than 
embryonic tissues (Babak et al., 2004a; Babak et al., 2004b).  
3. General downregulation of miRNAs in cancers : a systematic expression analysis 
of 217 miRNAs across multiple human cancer samples, showed that there is a 
general downregulation of miRNA expression in tumors compared to the normal 
tissue counterparts (Lu et al., 2005) and in tumor-derived cell lines (Gaur et al., 
2007). A general role for down-regulated miRNA expression in tumorigenesis 
was supported by enhanced tumorigenesis mediated by global miRNA loss due 
to Dicer knockdown (Kumar et al., 2007). 
Cancer-specific miRNA expression patterns, termed ‘miRNA signatures’ have been 
identified by miRNA expression profiling for every type of cancer analyzed (Calin and 






cancers, populating an ever-expanding list (Table 1.1). The current model proposes a 
direct role of miRNAs in cancer as either oncogenes or tumor suppressors by virtue 
of their over- or under-expression. In this scenario, due to miRNA misexpression, 
several target genes become misregulated being under the negative regulatory 
influence of miRNAs.   














Overexpressed in B-cell lymphoma 
and lung cancer 




Overexpressed in T-cell leukemia, 
colon, pancreatic and prostate tumors 
Retinoblastoma protein, 






Overexpressed in CLL, B-cell, 
Hodgkin’s and Burkitt lymphomas 
and in human breast cancer 
SHIP1, CEBPB, MAF 
miR-21 
Overexpressed in breast cancer, 
glioblastomas, CLL and in cervical 
cancer 
SPOCK1, TPM1 and 
PTEN, PDCD4 
miR-221 
Overexpressed in thyroid cancer, 
glioblastoma, pancreatic cancer and 
in prostate cancer 
p27 
miR-372, miR-373 
Overexpressed in testicular germ cell 



















let-7 Reduced in lung and colon cancers 
H-Ras, N-Ras, K-Ras, 
HMGA2 
miR-15a Lost in CLL, pituitary adenoma Bcl-2 
miR-16-1 Lost in CLL, pituitary adenoma 
Bcl-2; arginyl-tRNA 
synthetase 
miR-127 Reduced in various cancer cell lines Bcl-6 
miR-29 Reduced in CLL Tcl1, Mcl1, DNMTs 
mR-181 Reduced in CLL Tcl1 
miR-124a 









Reduced in colon, lung, breast, kidney and 
bladder cancer 
CDK4, CDK6, CCNE2, 
CCND1, MET, MYC, BCL-2 
miR-26a Reduced in liver cancer CCND2, CCNE2 
Table 1.1 miRNAs associated with cancers as oncogenes or tumor suppressors. CLL: 
chronic lymphocytic leukemia. Adapted from (Garzon et al., 2010), (Croce, 2009) and (Gartel 







1.5.1 miRNAs involved in metastasis and invasion 
In addition to their involvement in cancer as classical tumor suppressors or 
oncogenes, miRNAs may regulate cancer cell migration, invasion and metastasis. 
miRNAs that have been found shown to promote invasion and metastasis in breast 
cancer include miR-10b, miR-373 and miR-520c, while others suppressing 
metastasis and invasion include miR-335, miR-206 and miR-146a/b (Aigner, 2011; 
Dykxhoorn, 2010). Some miRNAs can be specifically involved in metastatic 
development and not linked to primary tumor development, such as miR-31 
(Valastyan et al., 2009). A key regulator of metastasis is miR-103/107 family that 
regulates Dicer expression by targeting its 3’UTR and through this induces a global 
down-regulation of miRNAs during breast cancer progression (Martello et al., 2010). 
Like other differentially expressed miRNAs, most metastatic-promoting or 
suppressing miRNAs have been identified by their differential expression in highly 
metastatic cancer cell lines to parental non-metastatic cell lines through profiling 
studies (Ma et al., 2007; Tavazoie et al., 2008; Valastyan et al., 2009). Furthermore, 
in these studies the two major aspects of metastatic behaviour that have been shown 
to be governed by miRNAs are cellular motility and invasion (Hurst et al., 2009). 
1.5.2 Mechanisms of miRNA expression deregulation in cancers 
As currently understood, the primary mode of miRNA deregulation in cancer is rooted 
in their altered expression levels which may arise by four main mechanisms. 
1. Genomic abnormalities: deletion, amplification and translocation can lead to copy 
number changes of miRNA genomic loci changing miRNA expression levels e.g. 
miR-15 and miR-16-1 (Calin et al., 2004; Zhang et al., 2006). 
2. Epigenetic factors: Aberrant CpG hypermethylation of miRNA promoters in 
cancer cells relative to normal tissue leading to silencing to miRNA expression 
e.g. miR-9-1, miR-124a and miR-127 (Lehmann et al., 2008; Lujambio et al., 






3. Transcriptional regulation: Dysregulation of transcription factors can lead to 
aberrant miRNA expression. This is especially true for tissue-specific miRNAs or 
those with roles in differentiation and development e.g. miR-17-92 cluster 
(transactivated by MYC) (O'Donnell et al., 2005), let-7 and miR-29 familes 
(repressed by MYC) (Chang et al., 2008) and miR-34 family (induced by p53) 
(Raver-Shapira et al., 2007).  
4. miRNA processing defects: Aberrant processing of pri-miRNAs can lead to 
changes in mature miRNA levels. In tumor samples, no correlation was observed 
between pri-miRNA and mature miRNA expression while in normal tissues there 
was a positive correlation, suggesting aberrant post-trancriptional regulation of 
miRNAs in cancers, especially at Drosha processing step (Thomson et al., 2006). 
Dicer expression is altered in some lung cancers and correlated with poor 
prognosis (Karube et al., 2005). 
1.5.3 Mutations and polymorphisms in miRNAs 
Mutations and polymorphisms located in mature miRNAs, precursor stem-loop or the 
primary miRNA sequence can potentially also contribute to miRNA dysfunction in 
cancer. Given the sequence-based determination of miRNA function, a change in 
mature miRNA sequence composition, presents tremendous opportunities for cancer 
cells to exploit for their growth advantage. Notably however, tumor-specific mutations 
and polymorphisms in mature miRNAs, especially the seed region, are rare 
(Diederichs and Haber, 2006; Landgraf et al., 2007; Ryan et al., 2010; Shen et al., 
2009). In fact, genetic changes in the effective sequence of mature miRNAs have 
rarely been documented both in general populations and in cancers (Saunders et al., 
2007; Slaby et al., 2011). Germline mutations in the primary transcripts of miR-15 
and miR-16-1 in chronic lymphocytic leukemia and familial breast cancer were 
reported to be responsible for their low expression in these cancers (Calin et al., 






been shown to influence miRNA biogenesis, ultimately contributing to the abnormal 
abundance component of miRNA dysfunction (Duan et al., 2007; Hu et al., 2008; 
Jazdzewski et al., 2008; Sun et al., 2009; Sun et al., 2010; Wu et al., 2008; Xu et al., 
2008).  
1.5.4 Mutations and polymorphisms in miRNA target sites 
Sequence variations in miRNA target sites can play a parallel role in influencing 
miRNA function through altered miRNA-mRNA interaction. Computational analyses 
of SNPs located in the miRNA binding sites in 3’UTRs of various human genes 
indicate that variant allele frequencies for some miRNA targeting sites are 
significantly different between cancer and normal tissues (Yu et al., 2007). In a recent 
study, known genetic variants of breast cancer susceptibility were analyzed for 
potential influence on miRNA targeting and were shown to create or abrogate 
targeting sites, potentially accounting for their altered expression (Nicoloso et al., 
2010). Specific examples of target SNPs are known for KRAS 3’UTR which disrupts 
targeting by let-7 in lung cancer (Chin et al., 2008) and for CD86 targeting by miR-
582 (Landi et al., 2008).  
Besides SNPs, gain or loss of segments of 3’UTRs with attendant miRNA targeting 
sites can influence the expression of target genes, as is seen for HMGA2, which 
escapes targeting by let-7 by a chromosomal rearrangements which separates its 
ORF form its 3’UTR (Mayr et al., 2007), or by alternative splicing for TrkC which 
creates isoforms with or without 3’UTR targeting sites for miR-9, miR-125a and miR-
125b (Laneve et al., 2007). 
1.6 miRNAs in gliomas 
Gliomas arise from cells of glial origin and are the most common primary brain 
tumors. Morphological similarity of tumor cells to normal glial cells- astrocytes or 






oligodendrogliomas or mixed oligoastrocytomas (Louis, 2006). Four degrees of 
malignancies of gliomas are defined by World Health Organization (WHO): grade I, 
grade II, grade III (anaplastic) and grade IV. Grade I tumors are biologically benign, 
grades II and III display increasing malignancy and grade IV classification is reserved 
for glioblastomas (GBM), the most malignant form of astrocytomas (Furnari et al., 
2007; Louis, 2006). The median survival of patients with GBMs is significantly shorter 
(12-18 months) compared to patients with grade III tumors (3 years). Several 
common molecular lesions in GBMs have previously been implicated in oncogenic 
activation and recently been analyzed on a large scale in efforts such as TCGA 
studies (The Cancer Genome Atlas Network, 2008). Among others, mutations in 
TP53, PTEN, EGFR, RB1, and NF1 have frequently been detected in GBM tumors. 
1.7 Pathophysiological features of glioblastomas 
Proliferation, invasion and angiogenesis are the hallmark biological processes that 
underlie GBM pathogenesis (Furnari et al., 2007). Uncontrolled proliferation occurs in 
GBMs due to cell cycle dysregulation and aberrant mitogenic signaling through 
receptor tyrosine kinases (EGFR, PDGFR), which typically activate PI3K and MAPK 
signaling. Invasion is a multi-step process that is driven by cellular motility, cell-cell 
adhesion, interaction with the extracellular matrix (ECM) and its proteolytic 
degradation. Glioma cells express proteases, such as metalloproteinases (especially 
MMP2 and MMP9), that degrade the ECM, and integrins that allow interaction of the 
glioma cells with components of the ECM. Such interactions lead to altered 
cytoskeleton configuration promoting cellular migration. Overlapping with proliferative 
effects, growth factor signaling through EGF, FGF and VEGF which are 
overexpressed in GBMs also promote cell migration (Louis, 2006). Robust 
angiogenesis is also present in GBMs and is characterized by microvascular 
proliferation of glomeruloid vessels. The common angiogenic pathways in GBMs 






tumor cells, for which the receptors are expressed on endothelial cells. The presence 
of necrosis is a feature that distinguishes GBMs from grade III tumors and is thought 
to arise from rapidly increasing metabolic demands of the growing tumor mass or due 
to vascular thrombosis. Necrotic foci are surrounded by hypercellular zones known 
as pseudopalisades which consist of hypoxic cells that secrete high levels of pro-
angiogenic factors such as VEGF (Brat et al., 2004). Furthermore, pseudopalisading 
cells acquire migratory and invasive properties in response to hypoxia (Louis, 2006). 
1.7.1 Functions of specific miRNAs in glioblastomas 
Key miRNAs that are over- or under-expressed in GBMs have been shown to 
regulate the above-mentioned tumor characteristics and will be briefly discussed here. 
miR-21 is highly expressed in GBMs and is an anti-apoptotic miRNA that directly 
inhibits tumor suppressors PTEN, PDCD4 and TPM1 (Moore and Zhang, 2010). 
Knockdown of miR-21 by locked nucleic acid (LNA) or 2’O-Me-miR-21 antagomir was 
shown to increase caspase-3-dependent apoptosis (Chan et al., 2005b), and its 
antagonism represses glioma formation in vivo (Corsten et al., 2007). miR-21 also 
promotes invasion by targeting inhibitors of MMPs (Gabriely et al., 2008). Thus, miR-
21 has been considered an oncogene in GBMs.  
miR-296 is upregulated in tumor-associated endothelial cells, and its antagonization 
reduces angiogenesis in tumor xenografts (Wurdinger et al., 2008). The targeting of 
hepatocyte growth factor-regulated tyrosine kinase substrate by miR-296 leads to the 
increased expression of receptors of pro-angiogenic factors VEGFR2 and PDGFR2.  
miR-26a is overexpressed in a subset of high-grade gliomas due to genomic 
amplification of the pri-miR-26a-2 locus, and directly targets the tumor suppressor 






miR-10b is one of the most highly up-regulated miRNAs in high- and low-grade 
gliomas. Inhibition of miR-10b induces cell cycle arrest and apoptosis and also 
suppresses xenograft tumor growth in vivo (Gabriely et al., 2011).  
Specific miRNAs have been shown to promote tumor growth due their effect on 
angiogenesis. For example, in an orthotopic U87 glioma model, miR-378 promotes 
tumor growth and angiogenesis and was shown to target tumor suppressors SuFu 
and Fus-1 (Lee et al., 2007a). Similarly, miR-93 from the oncogenic miR-106b~25 
cluster, promotes endothelial cell spreading in vitro and tumor growth and 
angiogenesis in vivo by targeting an integrin, ITGB8 (Fang et al., 2010). Figure 1.4 
gives an overview of some of the key oncogenic pathways under the control of 
miRNAs characterized in GBMs. 
 
Figure 1.4 miRNA-mediated regulation of key oncogenic pathways in gliomas. Over-
expressed miRNAs are shown in black and down-regulated miRNAs are shown in gray. 
Invasion, apoptosis, cell cycle progression and protein synthesis are major functions affected. 







1.8 Adenosine-to-Inosine RNA editing 
Adenosine-to-inosine (A-to-I) RNA editing is the best-characterized of post-
transcriptional events that modify RNA molecules by altering their sequence. It 
involves the conversion of specific adenosines (A) to inosines (I) in the RNA 
sequence by the action of adenosine deaminases acting on RNA (ADAR) enzymes 
(Bass, 2002). In eukaryotes, A-to-I editing generates transcriptome and proteome 
diversity by expanding the repertoire of gene products to beyond those encoded by 
the genome (Farajollahi and Maas, 2010). 
 A-to-I editing can modify protein coding genes, 5’UTR and 3’UTR sequences, 
intronic retransposon elements (Alu and LINEs) and miRNAs. In contrast to other 
forms of post transcriptional regulation, such as splicing and polyadenylation that 
alter a large portion of nucleotide sequences, A-to-I editing is site-specific in nature 
(Gott and Emeson, 2000). In fact, for most substrates that are specifically edited at 
one or two positions, editing leads to a “recoding” of the substrate (Heale et al., 2011). 
A-to-I modification is also irreversible.  
Editing involves the hydrolytic deamination of the adenine base of adenosine leading 
to its conversion to inosine (Figure 1.5A) (Nishikura, 2010). As a result the base-
pairing specificities are altered from Watson-Crick adenosine-uracil pair to an 







Figure 1.5 Adenosine deamination to inosine by ADAR. A. Hydrolytic 
deamination converts adenosine to inosine B. Base-pairing of adenosine to uridine 









1.8.1 A-to-I editing enzymes ADARs 
In humans, the ADAR family consists of ADAR1, ADAR2 and ADAR3. These are 
also known as ADAR, ADARB1 and ADARB2, respectively. Two isoforms of ADAR1, 
full-length ADAR1 p150 and the shorter N-terminal truncated ADAR1 p110 are 
known (Patterson and Samuel, 1995). Structurally, all ADARs contain a catalytic 
deaminase domain at the C-terminal (Figure 1.6). They also possess one to three 
repeats of dsRNA-binding domain (dsRBD). This domain is required for ADAR 
interaction and binding to dsRNA (Valente and Nishikura, 2007).  
             
 
           
 
       
 
         
 
Figure 1.6 Structural organization of ADAR enzymes. Four ADAR enzymes are shown. 
ADAR1p150 and ADAR1p110 are isoforms of ADAR1. Functional domains common to 
ADARs are the double-stranded RNA binding domain (dsRBD) and the catalytic deaminase 
domain. Z DNA binding domains are unique to ADAR1 and R domain is unique to ADAR3. 
Adapted from (Nishikura, 2010). 
 
The cellular distribution of the different ADARs is unique. ADARp150 is mainly 
cytoplasmic, whereas ADARp110 is mainly nuclear (Valente and Nishikura, 2005). 
ADAR2 and ADAR3 are localized to the nucleus by nuclear import by the importin α 
family (Nishikura, 2010). Evidence suggests that nucleolar accumulation of 
ADARp110 and ADAR2 also occurs, and is proposed to be a mechanism to 
sequester enzymatic activity from potential RNA targets until appropriate substrates 
are present in the nucleus (Nishikura, 2010). 











Only ADAR1 and ADAR2 have editing activity in vivo and also appear to undergo 
homodimerization (Nishikura, 2010). ADAR3 is catalytically invactive and does not 
undergo homodimerization. ADARs are essential for normal development, as 
ADAR1-/- mouse embryos die at embryonic day 11.5 (Wang et al., 2004) while 
ADAR2-/- mice are prone to seizures and die young (Higuchi et al., 2000). 
1.8.2 Features of substrates of ADARs 
Structural requirements constrain the selectivity of RNA molecules undergoing 
editing by ADARs. A dsRNA structure rather than any specific RNA sequence is 
required for editing by ADARs (Heale et al., 2011). Inter- and intramolecular dsRNAs 
of >20 bp, which represents two turns of the dsRNA helix, can serve as substrate for 
ADARs. Short duplexes are therefore not edited. Stretches of double-stranded RNA 
of more than 100 bp length are subject to promiscuous editing by both ADAR1 and 
ADAR2 with about 50% adenosines present being edited in a non-selective manner 
(Valente and Nishikura, 2005). On the other hand, dsRNA with extensive secondary 
structures such as hairpins containing mismatches, bulges and loops are subject to 
more site-selective editing. Based on the number of dsRBDs, it has been speculated 
that ADAR2 is mainly responsible for site-selective editing whereas ADAR1 is more 
prone to promiscuous editing. Nonetheless, ADAR1 and ADAR2 show overlapping 
but unique site specificities (Bass, 2002). 
The editing efficiency of a particular site in a substrate is determined by a 
combination of factors, including the identity of the nucleotides neighbouring the 
edited sites, the nucleotide opposing the edited site, and the length and 
thermodynamic stability of the RNA duplex (Wahlstedt and Öhman, 2011). In general, 
editing efficiency at individual sites within hyper-edited substrates tends to be lower 
than in site-selective substrates, but even the specificity and efficiency of editing 
shows limited variation among healthy individuals, suggesting a non-random editing 






1.8.3 A-to-I editing of coding and non-coding substrates 
Although, ADAR1 and ADAR2 are expressed in many tissues, A-to-I editing is 
particularly active in the central nervous system  (Mehler and Mattick, 2007). Most 
site-specific editing substrates are expressed in the brain and include ion channels 
and neurotransmitter receptors. In general, majority of pre-mRNA editing are 
localized to non-coding regions of transcripts including introns (73%) and UTRs 
(25%), specifically within Alu repeats (Athanasiadis et al., 2004; Kiran and Baranov, 
2010; Levanon et al., 2004). 
A-to-I editing within coding sequences of mRNAs can give rise to alternate codons 
and can change primary protein structure/sequence, given that the translational 
machinery interprets inosine as guanosine. For coding sequence editing substrates, 
the requisite dsRNA structure is usually formed by base-pairing between the exon 
sequence harbouring the editing site and complementary intronic sequence (Valente 
and Nishikura, 2005). The best characterized substrate undergoing sequence 
change due to editing is the GluR-B subunit of the AMPA glutamate receptor. Within 
exon 11 of the GluR-B subunit, a single adenosine undergoes editing in 99% of 
transcripts changing the genomically encoded Gln (Q) codon to Arg (R) codon 
(Sommer et al., 1991). Whereas AMPA receptors assembled from GluR-B(Q) subunit 
are highly  Ca2+-permeable, those assembled from GluR-B(R) are Ca2+-impermeable, 
altering the kinetic properties of the receptor (Lomeli et al., 1994; Sommer et al., 
1991).  
Inosine is also interpreted as guanosine by the splicing machinery (Valente and 
Nishikura, 2005). A-to-I editing therefore can regulate splicing by creating or 
abolishing consensus splice site recognition sequences (AG-GG change or AU-GU 
change) in the pre-mRNA. The ADAR2 pre-mRNA transcript is an example of an 
editing substrate affected by splice site alteration (Rueter et al., 1999). Due to the 






created in an intron, which leads to the production of a non-functional protein lacking 
the dsRBD and deaminase domains (Feng et al., 2006).  
Despite the prevalence of A-to-I editing in non-coding RNAs, its biological 
significance is generally poorly understood but is speculated to play a role in gene 
expression regulation (Nishikura, 2010). For example, as discussed for coding 
sequences, the creation or destruction of splice recognition sites can lead to 
alternatively spliced Alu-containing exons, generating variant proteins with distinct 
functions (Nishikura, 2010). Alternatively, structural changes in Alu hairpin due to 
editing creating RNA base-pair matches or mismatches may alter the stability of the 
dsRNA (Valente and Nishikura, 2005). 
1.8.4 A-to-I editing of miRNAs 
During the processing steps of miRNA biogenesis, primary and precursor miRNAs 
possess several features of A-to-I editing substrates. The short, dsRNA stem-loop 
structures within primary miRNAs (pri-miRNAs) with bulges and loops are 
prototypical of site-specific substrates of ADARs (Wahlstedt and Öhman, 2011). The 
primarily nuclear localization of ADARs and of pri-miRNAs led to the hypothesis that 
pri-miRNAs may be subject to A-to-I RNA editing. The hypothesis was validated by 
the editing, although to low levels, of positions within the pri-miR-22 sequence in 
samples isolated from human and mouse brain (Luciano et al., 2004). Subsequently, 
in a survey of editing of 99 primary miRNAs in various tissues carried out by 
sequencing cDNAs corresponding to each pri-miRs, it was estimated that at least 6% 
of all human miRNAs may be edited (Blow et al., 2006). All detected editing sites 
were localized to the predicted stem-loop structures and some were within the 22-
nucleotide mature miRNA sequences. Editing frequencies varied from 10 to 70% and 
displayed tissue-specificity. Additionally, some pri-miRNAs were edited at more than 






It was clear that some pri-miRNAs are highly edited and others are not, suggesting 
selectivity of editing for specific miRNAs. 
A-to-I editing of pri-miRNAs has been shown to affect several aspects of miRNA 
biology: expression, localization and targeting. First, editing of pri-miR-142 (highly 
expressed in hematopoietic cells) by ADAR1 and ADAR2 was detected to high-levels 
in an vitro editing assay (Yang et al., 2006). Subsequently, it was shown that ‘pre-
edited’ pri-miRNAs with ‘G’ substituted at identified editing sites were unable to 
generate corresponding pre-edited mature miRNAs or pre-miRNAs. Using in vitro 
processing assays it was determined that processing was most affected by editing of 
sites in the stem-loop structure close to Drosha cleavage site, i.e. positions +4 and 
+5 of the dsRNA fold-back stem, presumably due to disruption of cleavage by 
Drosha (Lee et al., 2003; Zeng and Cullen, 2003). Furthermore, the failure to detect 
highly edited pri-miR-142 in vivo was attributed to degradation of highly edited 
inosine-containing dsRNAs by Tudor-SN, a ribonuclease specific to inosine-
containing dsRNA., although this is not a general outcome of miRNA editing.  
 In addition to inhibiting Drosha processing, editing of pri-miRNAs can also affect 
downstream processing by Dicer. This was shown for pri-miR-151 for which Dicer 
cleavage was inhibited by editing of two sites near the terminal loop close to Dicer 
cleavage site (Kawahara et al., 2007a). The pre-miR-151 was found 100% edited in 
the brain but no edited mature miR-151 was detected and this was attributed to the 
inhibition of Dicer cleavage.  
For majority of pri-miRNAs that undergo editing in the human brain, the consequence 
of editing appears to be alteration of their processing by Drosha or Dicer and it has 
been suggested that 16% of pri-miRNAs are edited in the human brain (Kawahara et 
al., 2008). Although these studies biochemically characterized the consequences of 






settings, in terms of miRNA function regulation has not been explored. It is possible 
that normally editing of pri-miR-142 and pri-miR-151 serve to regulate expression 
levels of mature miRNAs in certain tissues under specific conditions – regulating 
downstream targets. However, these possibilities remain unexplored. 
1.8.4.1 A-to-I editing of primary miRNAs from miR-376 cluster 
To date, the most direct consequence of miRNA editing on downstream miRNA 
activity has only been reported for miRNAs from the miR-376 cluster (Kawahara et al., 
2007b). This cluster encodes four pri-miRNAs which undergo high-level and site-
specific editing in the human and mouse brain tissue, with detectable levels of editing 
in mouse kidney and heart. The major editing sites are located near the 5’-end of 
either stem arm in the stem-loop structure, a location corresponding to the seed 
sequence of encoded mature miRNAs. The stem-loop structure and location of 
editing site within pri-miR-376 resemble that of site-specifially edited coding 








Figure 1.7 Stem-loop configuration of dsRNA structures undergoing site-specific 
editing. Similarity of structures and location of editing sites in coding sequences of Gabra-3 
and GluR-B, and non-coding sequences of pri-miR-376c and pri-miR-376a2. Adapted from 







Editing of pri-miRNAs from the miR-376 cluster produces edited mature miRNAs at 
similarly high frequencies, suggesting that editing of pri-miR-376 transcripts does not 
affect Drosha or Dicer cleavage. In support of this, in tissues from ADAR2-/- mice, the 
total expression of one of the mature miRNAs, miR-376a-5p was similar to that in 
tissue from wild-type mice. This is in contrast to the increase in abundance of mature 
miR-142 (the primary precursor of which undergoes editing) in spleen from ADAR2-/- 
mice compared to wild-type mice (Yang et al., 2006). 
Given the critical role of miRNA seed sequence in target gene recognition, the 
altered target gene specificity of edited mature miRNAs was predicted and confirmed. 
First, it was demonstrated that due to the single base modification of seed sequence 
(A-to-I, for computational purposes A-to-G), the computationally predicted target 
gene repertoire of edited miR-376a-5p and unedited miR-376a-5p, were widely 
different with limited overlap. Conclusively, editing of miR-376a-5p redirected its 
silencing activity, by rendering it unable to regulate targets of unedited miR-376a-5p, 
while acquiring the ability to regulate a new set of target genes. One of the target 
genes of edited miR-376a-5p, PRPS1, was shown to accumulate in ADAR2-/- mouse 
cortex, because of the lack of expression of edited miR-376a-5p in this tissue. It was 
also shown that in terms of base-pairing specificity for miRNA target gene selection, 
a guanosine was equivalent to inosine, as both G-containing and I-containing edited 
miR-376a-5p showed similar 3’UTR targeting affinities, confirming  functional 
equivalencies of inosine and guanosine in miRNAs by base-pairing to cytosine 
(Yoshida et al., 1968).   
Thus, A-to-I editing of miR-376 represents a post-transcriptional mechanism by which 
miRNA sequence and targeting ability and function is altered. The edited and 
unedited miR-376-5p sequence variants are representative of mature miRNA 
sequence diversity that can be generated through A-to-I. In general, depending on 






expressed as a mixture of edited and unedited transcripts (by <100% editing), in a 
particular cell type or tissue. 
So far, in the human brain, editing of only four other pri-miRNAs is known to lead to 
the generation of mature miRNAs with edited seed sequence, including miR-379-5p, 
miR-411-5p, miR-607-3p and miR-99-3p (Kawahara et al., 2008). In mice, by deep 
sequencing, the expression of 16 edited mature miRNAs in the brain has been 
identified, with 8 miRNAs edited in the seed (Chiang et al., 2010). Overall, in humans, 
the generation of variant mature miRNAs by A-to-I editing is relatively rare (de Hoon 
et al., 2010) although many (~16%) pri-miRNAs undergo editing (Kawahara et al., 
2008). The major impact of epigenetic miRNA sequence variation by editing appears 
to be on the abundance of mature miRNA. The possible outcomes of ADAR-
mediated regulation by A-to-I editing of miRNAs on the overall miRNA pathway are 
summarized in Figure 1.8. 
 
Figure 1.8 Consequences of A-to-I editing of miRNAs. A-to-I editing of pri-miRNA can lead 
to A. inhibition of Drosha cleavage and degradation, B. inhibition of Dicer cleavage or C. 










1.8.5 Regulation of A-to-I editing 
Substrates of ADARs, including miRNAs, demonstrate a tissue-specific pattern of 
editing (Athanasiadis et al., 2004; Blow et al., 2006). Despite the nearly ubiquitous 
expression of ADARs in various tissues  (Nishikura, 2010), and the simultaneous 
expression of a substrate with potential editing sites, similar levels or even presence 
of editing for a  given substrate is not observed in all tissues (He et al., 2011). This 
suggests that while tissue-specific editing patterns play a role in tissue-specific 
functions, editing may be regulated by factors other than ADARs themselves. This is 
line with findings that editing levels can increase or decrease even ADAR protein 
levels remain constant (Osenberg et al., 2010; Wahlstedt et al., 2009). 
Editing of particular substrates, especially protein-coding genes like glutamate 
receptors in the brain, has been investigated during the course of rat brain 
development (Bernard et al., 1999; Lomeli et al., 1994; Paschen et al., 1994; Schmitt 
et al., 1996; Wahlstedt et al., 2009). For these site-selective edited substrates, the 
consensus was that editing is low during embryogenesis and increases through the 
course of development, although in a substrate-specific pattern of increase. 
Generally, although expression of ADARs does not substantially change, ADAR 
activity increases during brain development (Wahlstedt et al., 2009). The seeming 
departure of correlation between ADAR expression levels and editing activity that is 
generally observed is proposed to be due to the action of regulatory factors 
(Wahlstedt et al., 2009). However, as ADARs are enzymatically competent without 
requiring any other proteins, as demonstrated through in vitro studies (Jacobs et al., 
2009), few factors that can regulate ADAR activity function have been identified. 
ADAR1 can be modified by SUMoylation that reduces its editing activity presumably 
by interfering with dsRNA binding and dimerization (Desterro et al., 2005). The 
binding of co-factors such as zinc ion or IP6, an inositol polyphosphate has also been 






1.8.6 A-to-I RNA editing and cancer 
The widespread impact of editing on a variety of substrates, at tightly controlled 
levels under normal circumstances, suggests that perturbation of A-to-I editing will 
have profound consequences in disease settings. Especially in cancer, the 
consequence of altering the finely controlled spectrum of post-transcriptional 
regulation by A-to-I editing can be particularly deleterious. 
The first evidence of altered A-to-I editing in cancer came from a study in acute 
myeloid leukemia. mRNA transcripts of the tumor suppressor, protein tyrosine 
phosphatase (PTPN), from patients was aberrantly edited creating a novel splice site 
that would hypothetically produce non-functional protein (Beghini et al., 2000).  
ADARs have particularly high level activity in the brain, and also a disproportionately 
high abundance of highly-edited site-specific substrates compared to other tissues 
(Mehler and Mattick, 2007). Perhaps due to this or due to the specific nature of post-
transcriptional gene regulation in the brain, altered A-to-I editing has most frequently 
been observed in brain tumors, gliomas. The Q/R site of GluR-B subunit was found 
to be edited to lower levels (69-88%) in seven glioblastomas (GBMs, grade IV 
gliomas) down from its 100% editing in normal brain cortex and white matter (Maas 
et al., 2001). However, ADAR2 expression was normal in tumors. Underediting of 
various sites in GluR-B and GluR-6 subunits was detected in ten pediatric 
astrocytomas of WHO grades I-IV (Cenci et al., 2008). Surprisingly, in tumors ADAR2 
expression was unchanged while expression of ADAR1 was highly increased. It was 
shown that in HEK293 cells, high levels of ADAR1 can inhibit ADAR2 site-specific 
editing activity by heterodimerizing with it, although formal evidence for 
heterodimerization among different ADARs is lacking  (Cho et al., 2003). 
A computational analysis of expressed sequence tags (EST) derived from normal 
and cancer tissues determined that editing within ESTs was significantly lower in 






was not reported (Paz et al., 2007).  This was the first demonstration of altered A-to-I 
editing of Alu sequences (non-coding RNA) in GBMs. Furthermore, it was determined 
by analysis of RNA sequencing data that global hypoediting also occurs in prostate, 
lung, kidney and testis tumors, but is most significant in GBMs. To account for the 
general reduction in editing, ADAR mRNA levels were measured and contrary to 
previous studies were found to be significantly lower in GBMs and grade III 
anaplastic astrocytomas.  
These studies have laid the backdrop for speculating a crucial role of altered A-to-I 
editing in cancers, especially in GBMs. However, specific editing substrates playing a 
role in GBM pathophysiology have not been identified. Two posttranscriptional 
regulatory mechanisms – A-to-I editing and miRNA-mediated regulation- are 
particularly active in the brain (Christensen and Schratt, 2009; Mehler and Mattick, 
2007). In GBMs, dysregulation of either mechanism has been identified separately; it 
is a viable notion that a mechanism linking these two critical processes underlies 
development and progression of GBMs. 
1.9 Aims of thesis 
Due to the potent multi-gene targeting ability of miRNAs, specified by their sequence, 
it has been speculated that an alteration to miRNA sequence can be highly 
deleterious. However, no disease- or tumor-specific functional miRNA sequence 
variants have thus far been identified. Some miRNAs, such as the miR-376 cluster, 
are subject to regulated “seed” sequence modification by A-to-I editing in the normal 
human brain. Evidence suggests that global A-to-I editing is misregulated in gliomas, 
especially glioblastomas (GBMs) due to dysfunction of the editing machinery, the 
ADAR enzymes. Thus, it is a possibility that as substrates of ADARs, miRNAs might 
also be the subject of editing dysfunction in gliomas. The aim of this thesis was 
therefore, to investigate if A-to-I editing of miRNAs is altered in gliomas, in particular 






to-I editing, can potentially regulate malignant properties of GBMs, such as growth 
and invasiveness.  
The current study is based on the hypothesis that altered editing activity in GBMs 
leads to altered editing of some miRNAs changing their sequence and function in 
tumors. The miR-376 cluster was selected to address this hypothesis as editing of 
primary miRNAs from this cluster generates highly edited mature miRNAs in the 
normal brain, and thus likely to be prominently affected by altered A-to-I editing. 
Three lines of investigation were pursued in this study: 
1. Editing analysis was carried out to determine editing status of miR-376 cluster in 
gliomas and identify candidate miRNAs for characterization of altered A-to-I 
miRNA editing 
2. Analysis of functional consequences of aberrant editing of candidate miRNAs in 
gliomas, including effects on tumor growth and invasiveness 
3. Identification of target genes subject to regulation by candidate miRNAs in cancer 
cells to understand the mechanism of action of aberrantly edited miRNAs in 
gliomas  
Findings from this investigation identify for the first time, tumor-specific miRNA 
sequence variants generated due to altered A-to-I editing, and uncover novel modes 
of deregulation of miRNA function in GBMs. Furthermore, candidate miRNAs subject 
to aberrant editing, identified in this study, represent potential therapeutic targets for 







2 CHAPTER 2. Materials and methods 
2.1 Tumor tissues and cells 
Twenty four human brain tumor samples were used in this study. Seventeen samples 
were obtained from National Neuroscience Institute, Singapore in compliance with a 
study protocol approved by the institutional review board (CIRB# 2010/337/A). The 
remaining samples (GBMs 1-4 and AAs 17, 19, 20) were purchased (Asterand and 
Capital Biosciences). Patient information, where available, are reported in Table 2.1. 
Five human brain total RNA samples were purchased from Ambion, Clontech and 
Stratagene to serve as normal brain tissue controls. Human glioma cell lines, U87, 
U251, SW1088, and SW1783, and human cervical cancer cell line HeLa were from 
American Type Culture Collection. Frozen normal human astrocytes pellet was 





Age Sex Treatment Tumor Site 
1 GBM ― ― ― ― 
2 GBM ― ― ― ― 
3 GBM ― ― ― ― 
4 GBM ― ― ― ― 
5 GBM 48 F S+Rt+Ct Left Anterior Temporal 
6 GBM 60 M S+Rt+Ct Left Temporal lobe 
7 GBM 75 F S+Rt Left Frontal lobe 
8 GBM 59 F S+Rt+Ct Right Temporal lobe 
9 GBM 51 F S+Rt+Ct Left Temporal lobe 
10 GBM 46 M S+Rt+Ct Left Parietal tumor 
11 GBM 80 F S+Rt Right Occipital lobe 
12 GBM 51 M S+Rt+Ct Left Frontal lobe 
13 GBM 46 M S Right Temporal lobe 
14 GBM 75 F S+Rt+Ct Left Frontal lobe 
15 GBM/GS 52 F Biopsy+Rt Cerebellar & Brain Stem 
tumor 
16 GBM/GS 52 M S Left Frontal lobe 
17 AA ― ― ― ― 
18 AA 56 F S+Rt Left frontal Parietal tumor  
19 AA ― ― ― ― 
20 AA ― ― ― ― 
21 AOA 44 F S+Rt+Ct Left Frontal lobe 
22 AOA 42 F S+Rt+Ct Left Frontal Temporal lobes 
23 AOA 33 M S+EVD Left Frontal lobe 






Table 2.1 Clinicopathological details of primary human tumor samples used in this 
study. WHO classification of gliomas, AOA: anaplastic oligoastrocytoma (WHO grade III), 
AOG: anaplastic oligodendroglioma (WHO grade III), AA: anaplastic astrocytoma (WHO 
grade III), GBM: glioblastoma multiforme (WHO grade IV), GS: gliosarcoma. Treatment 
regime, S: surgery, Rt: radiotherapy, Ct: chemotherapy, EVD: external ventricular drainage. 
“―” details not available. 
 
2.2 RNA extraction 
Total RNA from cultured cells, cell pellets or tissue samples was prepared using 
TRIzol (Invitrogen). For frozen tumor samples, tissues were rapidly homogenized in 
appropriate volume of TRIzol using an ultrasonic processor (Vibra-Cell, Sonics & 
Materials). For xenograft tumors, tumor tissue in paraformaldehyde-fixed, OCT-
embedded cryosections was separated from normal brain tissue and processed 
using FFPE RNA Isolation Kit (SA Bioscience) to remove paraformaldehyde cross-
links and isolate RNA. Enrichment of small RNA fraction from total RNA was done 
using RNeasy Mini Kit (Qiagen) with a modified RNA cleanup protocol to retain small 
RNA species.  
2.3 DNAse treatment of RNA samples 
Total RNA was DNAse-treated to remove traces of genomic DNA contamination. 
Typically, two micrograms of total RNA was treated with 1 µl (2 units) of Turbo 
DNAse (Ambion) in 20 µl for 30 min at 37°C, followed by addition of another 1 µl of 
Turbo DNAse to the sample for further 30 min incubation at 37°C. 
2.4 Primary miRNA editing analysis 
For editing analysis of primary miRNAs the protocol described previously by 
Kawahara et al was adopted with slight modifications (Kawahara et al., 2007b).  
cDNA synthesis One microgram of DNAse-treated total RNA was used for cDNA 
synthesis with random hexamer primers (instead of gene-specific priming) and 






PCR amplification Primary miRNAs were PCR-amplified using miRNA-specific 






pri-miR-376a1 159 ACAGGTGCACGCTTTCCT TCCATGGCGACTTCACGT 
pri-miR-376a2 159 GGATTGTACTTAGGTTCGTGC TGGCTTCAGTCCAGCCAT 






Table 2.2 Primers used for amplification of primary miRNAs. The expected size of the 
PCR product for each primary miRNA amplified from random hexamer cDNA is specified. 
 
Sequencing analysis Purified RT-PCR products were directly sequenced by 
dideoxy Sanger sequencing at AITBiotech, Singapore. For each primary miRNA, 
both forward and reverse sequencing primers were used for sequencing (Table 2.2). 
Sequencing chromatograms (.ab1 files) generated from the forward and reverse 
primers were exported to Vector NTI’s Contig Express (Informax) and aligned with 
the expected genomic sequence for each primary miRNA. During cDNA synthesis of 
primary miRNA transcripts, inosine (I) bases present in the RNA are interpreted as 
guanosine (G) by reverse transcriptase enzyme and subsequently represented by ‘G’ 
in the RT-PCR product (Nishikura, 2006). For known editing sites, the ‘G’ peak height 
(represented by the ‘G’ trace quantification at the specific site) and the ‘A’ peak 
height at the same site were noted. A-to-I editing frequency was determined as the % 
ratio of ‘G’ peak at the editing site over the sum of ‘A’ and ‘G’ peaks at the same site. 
Sequencing chromatograms used for direct quantification were of high quality with 
minimal background ‘noise’ throughout the sequence. This method of editing 
frequency analysis has been reported to be sensitive enough to accurately quantify 







2.5 Mature miRNA editing analysis 
A library of small RNA molecules was constructed by addition of 5’ and 3’ adapter 
sequence and mature miRNA editing analysis was subsequently done by sequencing 
of miRNA clones. 
Small RNA purification Fifty micrograms of total RNA was first purified to enrich the 
small RNA fraction using the method described for purification of small RNA fraction 
from total RNA (Section 2.2). 
Poly (A) tailing of small RNAs The Poly(A) tailing kit (Ambion) was used to add 
poly(A) tails to 1.5 µg of the purified small RNA fraction with 2 µl poly(A) polymerase 
(PAP) enzyme in a 50 µl reaction which were subsequently purified using the 
RNeasy Mini Kit (Qiagen) using a modified cleanup protocol.  
Ligation of 5’ RNA adapter A 5’ RNA adapter was ligated to poly(A)-tailed RNA 
molecules using T4 RNA ligase (Promega) :  
5'-CGACUGGAGCACGAGGACACUGACAUGGACUGAAGGAGUAGAAA-3'.  
The ligation reaction consisted of 1.5 µg donor RNA (poly(A)-tailed small RNA) and 
0.75 µg acceptor RNA (5’ adapter). Unligated 5’ RNA adapters and other 
constituents from the ligation reaction were removed using RNeasy Mini Kit. 
cDNA synthesis of small RNA library 5’-adapter-ligated, poly(A)-tailed RNA was 
then used in a cDNA synthesis reaction using the following 3’ oligo(dT) adapter 
sequence: 5'-ATTCTAGAGGCCGAGGCGGCCGACATG-d(T)30 VN-3' V: A/G/C and 
N: A/G/C/T 
PCR amplification of mature miRNAs Two-step amplification protocol was adopted 
for amplifying specific mature miRNAs. For the first step, common forward (cFW) and 
reverse primers (cRV) corresponding to the 5’- and 3’- adapters respectively were 
used to amplify the pool of  mature miRNA species present in the cDNA library 






were purified using the QIAEX II Gel Extraction Kit (Qiagen) to ensure recovery of 
DNA molecules less than 100 bp in size (Figure 2.1A). Subsequently, specific 
miRNAs were amplified in a second step using the purified amplified mature miRNA 
library as template. For each mature miRNA, miRNA-specific reverse primer and 
cFW forward primer was used (Table 2.3). Specific PCR products of ~50 bp size 













miR-376c RV 5'-TAAACGTGGAATTTCCTC-3' 
miR-376a1-5p RV 5’-CAGCACTCATAGAAGGA-3’ 
miR-376a/b RV 5'-TTTTWACRTGGATTTTCCTC-3' 
miR-376a2-5p RV 5'- CACGTAACCATAGAAGG-3' 
Table 2.3 Primers used for amplifying mature miRNAs from small RNA cDNA library. W: 
A or T; R: A or G.  
 
Sequencing of mature miRNAs TOPO TA cloning (Invitrogen) of individual PCR 
products, corresponding to single mature miRNA. Fifty clones or more were 
sequenced for each mature miRNAs. Sequences were aligned to expected mature 
miRNA sequences to identify clones containing ‘G’ at editing sites for each mature 
50 bp  
ladder 
50 bp  
ladder 
A B 
Figure 2.1 PCR amplification of mature miRNAs for sequencing. A. cFW and cRV 
primers used to amplify total miRNA pool from small RNA cDNA library. B. cFW and miRNA-







miRNA. Frequency of editing was determined as the % of clones containing an A-to-
G change at editing site among the total number (>50) of clones sequenced. 
2.6 Plasmids and contructs 
For expression of ADAR2, pCMV-SPORT6-ADAR2 was purchased from Open 
Biosystem. pCMV-SPORT6-EGFP was constructed by amplifying the 720 bp EGFP 
coding sequence from pcDNA6.2-GW/EmGFP vector (Invitrogen), which was 
inserted between EcoRV and NotI sites of pCMV-SPORT6. The miR-376 cluster 
expression vector was constructed using the Block-iT Pol II miR RNAi system 
(Invitrogen). The genomic region corresponding to the 1570 bp miR-376 cluster was 
amplified from human genomic DNA (Biochain Institute) and inserted between SalI 
and BglII sites of pcDNA6.2-GW/EmGFP. Primers are listed in Table 2.4. 
Primer Sequence 
EGFP FP 5’- ATCGGATATCATGGTGAGCAAGGG -3’ 
EGFP RP 5’- TAGTGCGGCCGCTTACTTGTA -3’  
miR-376 cluster FP 5’- ATGTCGACGAGAGTGATGGAAGGT-3’ 
miR-376 cluster  RP 5’- ATAGATCTATACTGAGAACACAGCCTTG-3’ 
Table 2.4 PCR primers used for expression vector construction. Underlined sequence: 
restriction enzyme site used for cloning. 
 
2.7 miRNA duplexes and miRNA expression vectors 
All miRNA duplexes corresponding to mature miRNAs were synthesized by 
Dharmacon. The sequences of mature miRNAs used in this study were as follows: 
miR-376a*A: GUAGAUUCUCCUUCUAUGAGUA 
miR-376a*G: GUGGAUUCUCCUUCUAUGAGUA 











mIRIDIAN microRNA Mimic Negative Control #2, corresponding to C. elegans 
miRNA cel-miR-239b was also purchased from Dharmacon. 
For stable (non-transient) expression of miR-376a*, the expression vector was 
designed using Block-iT Pol II miR RNAi expression system (Invitrogen). In the stem-
loop design, only miR-376a* guide strand is active and the inactive passenger strand 
does not correspond to miR-376a.  The top strand of the duplex encoded miR-376a* 
with ‘A’ or ‘G’ at position 3 of the mature miRNA. The bottom strand sequence design 
followed from the top strand. The two strands were annealed and ligated to the 
linearized pcDNA™6.2-GW/EmGFP-miR vectors to generate pmiR-376a* plasmids 
or pmiR-control plasmids (Table 2.5). EGFP is co-cistronically expressed with the 




















Table 2.5 Design of top and bottom strands for constructing miRNA expression vectors 
encoding stem-loop precursors. Red: sequence of mature miRNA of interest; blue: 
sequence complementary to the mature miRNA in the fold-back structure of pre-miRNA; 
underlined sequence: recommended overhands for ligation to linearized vector. 
 
For generation of stable U87 cell lines, pmiR-376a*A or G plasmids were transfected 
using Lipofecatmine 2000. Stable clones were selected over 2 weeks using 6 μg/ml 
blasticidin (Invitrogen). Four clones were selected and characterized for each 







The sequence of siRNA against STAT3 has been previously described (Konnikova et 
al., 2003), and was synthesized at Dharmacon.  
STAT3 siRNA 5'-AAC AUC UGC CUA GAU CGG CUA dTdT-3' 
5’- U AGC CGA UCU AGG CAG AUG dTdT-3’ 
siRNA against AMFR was a predesigned HP GenomeWide siRNA (Qiagen) of 
product ID: SI00022533. siGENOME Non-Targeting siRNA #5  from Dharmacon was 
used as control siRNA for all experiments.   
2.9 Locked nucleic acids 
Locked nucleic acid oligonucleotide (LNA) inhibitors against miR-376a*A were 
custom-designed and purchased from Exiqon. LNA against a scrambled sequence 
(LNA-scr) was used a control in all experiments.   
2.10 Chemicals 
Specific STAT3 inhibitor, Stattic was purchased from Merck and dissolved in 100% 
DMSO to prepare a 100 mM stock and stored at 4°C. 
2.11 Quantitative RT-PCR of mRNAs 
For mRNAs, total RNA was reverse transcribed using random hexamers by 
Superscript III RT-PCR kit (Invitrogen). Resulting cDNA was used for PCR using 
SYBR-Green PCR Mix. PCR and data collection was done on Bio-Rad iCycler Bio-
Rad. Expression levels were normalized to 18S rRNA. For quantification of ADAR2 
and ADAR1, pre-designed primer sets were purchased from SA Biosciences. All 
primer sequences are listed in Table 2.6. RT-PCR for primary miRNAs was done 
using random hexamer cDNAs and primers used in primary miRNA editing analysis.  
Gene Forward Reverse 
STAT3 ACCTGCAGCAATACCATTGAC AAGGTGAGGGACTCAAACTGC 
AMFR TTCCTACACAGCGGTCAGATAGC GCCGAAGTCCAGCGTCTCC 






PDGFRβ CAGGAGAGACAGCAACAGCA AACTGTGCCCACACCAGAAG 
PDGFα GATACCTCGCCCATGTTCTG CAGGCTGGTGTCCAAAGAAT 
PDGFβ TCGAGTGGTCACTCAGCATC GCGCTCTTCCTGTCTCTCTG 
VEGFA AGCCTTGCCTTGCTGCTCTA GTGCTGGCCTTGGTGAGG 
TGFβR1 TTGTCTTTTGTACAGAGGTGGC GCTGCTCCTCCTCGTGCT 
TGFβR2 GGAAACTTGACTGCACCGTT CTGCACATCGTCCTGTGG 
TGFα GGGCAGTCATTAAAATGGGA GCTCTGGGTATTGTGTTGGC 
TGFβ1 CTTCCAGCCGAGGTCCTT CCCTGGACACCAACTATTGC 
TGFβ2 CTCCATTGCTGAGACGTCAA ATAGACATGCCGCCCTTCTT 
EGFR TCCTCTGGAGGCTGAGAAAA GGGCTCTGGAGGAAAAGAAA 
ANGPT1 CCGACTTCATGTTTTCCACA ACCGGATTTCTCTTCCCAGA 
ANGPTL2 GGTAGATGGAGCTGGTGTCG CACTATGCCCACTCTCACCA 
ANGPTL4 TAGTCCACTCTGCCTCTCCC GAGATGGCCCAGCCAGTT 
CXCL12 TGGGCTCCTACTGTAAGGGTT TTGACCCGAAGCTAAAGTGG 
ITGB3 TCATCAGAGCACCAGGCA TCTGGGCGACTGTGCTG 
FN1 ACCTCGGTGTTGTAAGGTGG CCATAAAGGGCAACCAAGAG 
HIF1α TGGCTGCATCTCGAGACTTT GAAGACATCGCGGGGAC 
NTNG1 GGGTACTCGCATCACACTCA AAGTGAAACTCGATCCTCCG 
TNXB TCTCAGCTTCATTTCCGTGA TCTACGGGAGCACAGTGGAC 
MMP2 GGAAAGCCAGGATCCATTTT ATGCCGCCTTTAACTGGAG 
PLAU CCAGCTCACAATTCCAGTCA TGACCCACAGTGGAAAACAG 
HGF CCCTGTAGCCTTCTCCTTGA CGCTGGGAGTACTGTGCAAT 
NRP2 TGCTCCAGTCCACCTCGTAT AACTGCATGGAACCCATCTC 
RRAS2 CGGGCTGCTCTGTCATCTAT TCACCATCCAGTTCATCCAG 
PEX19 ATTCCCGATGACTCTGCAAC TGCAGAACCTACTCTCCAAGG 
FAM55C TGGGAGGAAACAAACTGTCC TGGTGCTGGTCATCAATGTT 
ELOVL5 GTATCTCGAGGGCCTAGCAA TGCTGCTCAAAGCTGCTG 
ACVR1 GGAACCACATCGTAGAACGG TATTTGGGCCTTTGGACTTG 
TCF7 AGAGAGAGAGTTGGGGGACA TCTGCTCATGCATTACCCAC 
18S rRNA AACTTTCGATGGTAGTCGCCG CCTTGGATGTGGTAGCCGTTT 
Table 2.6 Sequences of primers used for qRT-PCR of genes. 
 
2.12 Quantitative RT-PCR of miRNAs 
Real-time PCR quantification of mature miRNAs was done as described previously 
(Wu et al., 2009) except the sequence of the poly (T) adaptor used for cDNA 
synthesis was modified to 5’-
CGATAGCGACGATACAGACTTGTCACTATAGG(T)12VN*-3’ and sequence of 
reverse primer was: 5’-CGATAGCGACGATACAGACTTG-3’. The forward primers 






miR-376a*A: 5’- GTAGATTCTCCTTCTATGAGTAAA 
miR-376a*G: 5’- GTGGATTCTCCTTCTATGAGTAAA 
miR-376a: 5’- ATCATAGAGGAAAATCCACGTAAA 
miR-376b: 5’- ATCATAGAGGAAAATCCATGTTAAA 
miR-376a2-5p: 5’- GTAGATTTTCCTTCTATGGTTAAA 
miR-376c: 5’-ACATAGAGGAAATTCCACGTAAA 
miR-127: 5’- TCGGATCCGTCTGAGCTTGGCTAAA 
miR-154: 5’- TAGGTTATCCGTGTTGCCTTCGAAA 
miR-432: 5’- TCTTGGAGTAGGTCATTGGGTTGGAAA 






5S rRNA: 5'-CCGCCTGGGAATACCGGGTGCTGTAGGCTTT-3' (internal control) 
2.13 Cell invasion assay 
For in vitro invasion assay, the Boyden chamber assay with Matrigel-coated inserts 
with 8-μm pores was used (BD Falcon). Three days after transfection with 10 nM 
miRNA or with 2.5 nM siRNA using Lipofectamine LTX (Invitrogen), glioma cells were 
starved overnight in unsupplemented OPTI-MEM (Invitrogen). On the day of the 
assay, cells were stained with Calcein-AM (Invitrogen), trypsinized and seeded onto 
the upper chamber (1X105 cells in 200 μl of unsupplemented OPTI-MEM media). 
Lower chambers were filled with 700 μl of supplemented OPTI-MEM (10% FBS). 
After 24 hours of incubation at 37ºC, fluorescence readings of invaded cells at the 
bottom of inserts were measured with Victor3 1420 Multilabel Counter (Perkin Elmer) 
or number of labeled invading cells was manually counted from 4-5 imaged fields. 
2.14 Wound healing assay 
For wound healing assay, cells were cultured in 6-well plates, transfected and 






transfections: miRNA: 10 nM, siRNA: 0.625 nM, LNA miRNA inhibitor: 50 nM. An 
artificial homogenous wound was made using a sterile p200 tip. Cell debris was 
removed by washing cells with DPBS and medium was replaced with 1% FBS-
containing DMEM. The wound borders were imaged just after wounding (t = 0 h) and 
again after 24 or 36 hours to measure the wound gap distance. Wound coverage was 
determined as percentage of the gap width covered during incubation from 4-6 
measurements for each treatment condition. 
2.15 Cell viability, proliferation, and cell cycle assays 
Cell viability was measured in 96-well plates using the Cell-Titer Glo Assay 
(Promega). For growth rate assessment of stable U87 cells or parental and ELM-
selected cells, 3000 cells were seeded per well of 96-well plates. Viability was 
measured from day 0 (day of seeding) until day 7. Cell proliferation was quantified 
using the colorimetric BrdU cell proliferation assay (Roche). Briefly, at indicated times 
after transfection, cells were labeled with BrdU for 12 hrs. Labeled cells were fixed 
and BrdU incorporation was measured as per the protocol using the anti-BrdU-
peroxidase immunodetection. Absorbance of the colored product was measured at 
370 nm (reference wavelength 492 nm) in a microplate reader (Bio-Rad). For cell 
cycle analysis, cells treated as indicated were trypsinized and fixed in ice-cold 70% 
ethanol. Fixed cells were resuspended in PBS containing 0.1% Triton X-100, 20 
μg/ml propidium iodide and 200 μg/ml RNase A and incubated in the dark for 30 
minutes before analysis by flow cytometry (Beckman Coulter). 
2.16 Morphological assessment by flow cytometry 
Flow cytometry was used to assess cell morphology of transfected glioma cells. Cells 
were transfected in 6-well plates as per standard methods. Seventy-two hours after 






of   PBS containing 5% FBS. Unfixed cells were assessed for side and front-scatter 
profiles by flow cytometry (Beckman Coulter).  
2.17 Luciferase reporter assays 
Plasmid encoding firefly luciferase under CMV promoter, pMIR-Report Luciferase, 
was purchased from Ambion. Reporter plasmids for STAT3 and AMFR were 
constructed by cloning the corresponding 3’UTR fragments downstream of the 
luciferase coding sequence in the MCS of pMIR-Report. All 3’UTR fragments were 
amplified from human genomic DNA (BioChain Institute) (Table 2.7). pMir-Report ß-
galactosidase control plasmid, encoding ß-galactosidase under the control of CMV 




































Table 2.7 Primers used for amplifying 3’UTR regions of target genes. Underlined 
sequence: restriction enzyme site used for cloning. 
 
 
For luciferase reporter assay, HeLa cells in 96-well plates were transfected with 30 
ng of reporter plasmid, 30 ng of CMV-ß-galactosidase and 20 nM miRNA mimics 
using Lipofectamine 2000. After 48 hours, luciferase activity was measured using the 
Luciferase Assay system (Promega). Luciferase readings were normalized to ß-
galactosidase activity in the same lysate, quantified by the ß-galactosidase Enzyme 
Assay System (Promega). For each group, data was collected from at least 4 







2.18 Gene expression microarray analysis 
Total RNA from U87 and SW1783 cell lines transfected as indicated was isolated 
using Trizol. For each cohort, three independent RNA samples were isolated. 
Following clean-up with Qiagen RNeasy column, amplification and labeling was done 
by Kreatech ULS labeling kit as per protocol. Fifteen μg of each labeled RNA sample 
was hybridized to Affymetrix Human Genome U133 Plus 2.0 arrays. CEL files were 
imported into GeneSpring GX 11 (Agilent) and signal intensities normalized using 
MAS5 algorithm and processed to remove ‘absent’ probesets and those in the lowest 
20th percentile from analysis. Genes were filtered based on 1.5- or 2-fold change 
and P < 0.05, with respect to their respective control experiments. Enrichment of 
specific GO biological functions among the differentially expressed genes was 
evaluated by NCBI DAVID bioinformatics analysis (http://david.abcc.ncifcrf.gov/) 
using default settings. For miRNA binding site prediction, RNA 22 analysis 
(http://cbcsrv.watson.ibm.com/rna22.html) (Miranda et al., 2006) was done on whole 
3’UTR sequences and miR-376a* sequence with “A” or “G”.  
2.19 Western blot and Immunocytochemitstry 
Protein was extracted from cells using Cellytic M buffer (Sigma). Protease inhibitor 
(Fermentas) and phosphatase inhibitor cocktails (Santa Cruz) were added to the lysis 
buffer at appropriate concentrations. For all transfection experiments, protein 
extraction was done 72 hrs after transfection. For cells treated with Stattic, protein 
extraction was done 5 hrs after treatment with Stattic. Protein was quantified by DC 
protein assay (Bio-Rad). Twenty to forty micrograms of protein was separated on 
SDS-PAGE and transferred to nitrocellulose membrane using the iBlot system 
(Invitrogen). Membrane was blocked with 5% BSA and incubated overnight with 
mouse anti-STAT3 (1:2000, Cell Signaling), rabbit anti-AMFR (1:5000, Novus 
Biologicals) and mouse anti-ß-actin (1:2000, Abcam). Horseradish peroxidase 






dilution and HRP-conjugated anti- rabbit secondary antibody (Amersham) was used 
at 1:5000 dilution. Chemiluminescent detection of protein was done using Amersham 
ECL Plus (GE Healthcare) and band intensities were quantified using ImageJ. 
Immunostaining of actin cytoskeleton in methanol-acetone fixed cells was done using 
FITC-conjugated anti-actin antibody (1:500, Abcam). 
2.20 Xenotransplantation and immunohistochemistry 
All handling and care of animals was carried out according to the Guidelines on the 
Care and Use of Animals for Scientific Purposes issued by the National Advisory 
Committee for Laboratory Animal Research, Singapore. For xenograft experiments, 
adult male and female athymic Balb/c nude mice (weight 20 g; aged 6-8 weeks) were 
used. Brain tumor inoculation was done in the right side of striatum of anesthetized 
mice, by injecting 0.1 X 106 glioma cells, as indicated. On day 21 after tumor 
inoculation, animals were sacrificed by cardiac perfusion with PBS, followed by 4% 
paraformaldehyde in PBS. Harvested mouse brains were kept overnight in 30% 
sucrose, and embedded in Tissue-Tek OCT and cryosectioned. Hematoxylin and 
eosin staining of sections was done by standard methods. Stained sections were 
imaged using Olympus microscope. For survival experiments, xenografted animals 
were monitored until all animals were dead. Animal handling, sectioning and H&E 
staining were done by Lam Dang Hoang (IBN, A*STAR, Dr. Wang’s lab). 
Immunohistochemical detection was done on paraformaldehyde-fixed, OCT-
embedded cryosections. Following heat-induced antigen retrieval in citrate buffer, 
sections were incubated with mouse anti-Ki-67 antibody (1:100 dilution, Dako) and 
rabbit anti-vWF antibody (prediluted, Abcam). Where fluorescent detection was done, 
Alex-Fluor 568 conjugated secondary antibodies (1:200 dilution, Molecular Probes) 
were used. For immunoperoxidase staining, biotin-conjugated secondary antibodies 
(1:200 dilution, BD Biosciences) were used in a three-step detection protocol 






67 signal was done using NIH ImageJ, by first converting images to 8-bit, subtracting 
background and adjusting threshold range to 17-255 (Feuer et al., 2005). Signal 
intensities were enumerated from similar-size fields (5-6 fields for each tumor core or 
tumor edge) of different images and compared. 
2.21 Selection of invasive U87 cells by experimental lung 
metastasis (ELM) assay 
The ELM assay was performed for U87 cells as essentially done as previously 
described (Xie et al., 2008). Briefly, 1 X 106 U87 cells in 200 µl of PBS were injected 
intravenously through tail vein of nude mice. After 3 to 4 months, when signs of 
moribundity appeared, animals were euthanized and lung lesions were collected. 
Propagation of lesions was done subcutaneously in vivo for four weeks. 
Establishment of primary ELM-selected cell lines from subcutaneous tumors was 
done as previously described (Xie et al., 2008). This was done by Lam Dang Hoang. 
Three independent ELM lines were established and cultured in complete DMEM 
medium. Early passages (5-7 passages after first plating in vitro) were used for RNA 
isolation, intracranial injection and transfection. 
2.22 Statistical analysis 
Statistical significance was determined by paired or unpaired Student’s t-test and a 
two-tailed p value of < 0.05 was considered to be statistically significant. Survival 
analysis of tumor-bearing mice was carried out using the log-rank test in SigmaStat 








3 CHAPTER 3. Analysis of Adenosine-to-Inosine 
editing of miR-376 cluster in gliomas. 
3.1 Introduction and aims 
The miR-376 cluster encodes four primary miRNAs (pri-miRs) of related sequence, 
pri-miR-376a1, 376a2, 376b and 376c which are processed to generate five distinct 
mature miRNAs- miR-376a*, 376a, 376a2-5p, 376b and 376c (Figure 3.1). In the 
human brain, nine adenosines within this miRNA cluster are subject to specific and 
high-level adenosine-to-inosine (A-to-I) RNA editing (Kawahara et al., 2007b). The 
genomic organization of miR-376 cluster and location of editing sites are illustrated in 
Figure 3.1. The A-to-I editing enzymes ADAR1 (also known as ADAR) and ADAR2 
(also known as ADARB1) are responsible for all editing events within the cluster and 
demonstrate site-specific preference for activity (Kawahara et al., 2008). For miR-376 
cluster, editing of sites in regions of primary miRNA stem-loops comprising mature 
miRNAs leads to the generation of “edited” mature miRNAs (Kawahara et al., 2007b). 
Thus far miR-376 cluster members remain the only mature miRNAs found to be 







Figure 3.1 Human miR-376 cluster. Schematic representation of the four primary miRNAs, 
pri-miR-376c, 376a2, 376b, 376c that undergo site-specific A-to-I editing. The processed 
mature miRNAs are highlighted in blue and labeled. Known editing sites are shown in red. 
The 5’ end of the stem-loop sequences annotated the Sanger miRBase database is counted 
as +1. Adapted from (Nishikura, 2010). 
 
Altered editing of several substrates in gliomas and related cell lines have previously 
been identified and are listed in Table 3.1. Reduced expression of ADAR1 and 
ADAR2  (Paz et al., 2007) or reduced activity of the enzymes without any change in 
expression (Cenci et al., 2008; Maas et al., 2001) has been demonstrated for 
cancers, especially gliomas. Here only editing events and substrates from the 
nervous system are discussed, as they are most frequently observed. This is 
possibly because A-to-I editing is particularly prevalent in the brain as ADARs are 








Substrate Enzyme responsible Status of ADAR Reference 
GluR-B ADAR2 Reduced activity (Maas et al., 2001) 
GluR-B 
ADAR2 Reduced activity (Cenci et al., 2008) 
GluR-6 
Alu repeats within 






(Paz et al., 2007) 
Alu repeats within 
BRCA1 
CYFIP2 ADAR2 
FLNA ADAR1, ADAR2 
BLCAP ADAR2, ADAR1 nd (Galeano et al., 2010) 
Table 3.1 Altered A-to-I editing in gliomas of known substrates. Summary of reduced A-
to-I RNA editing events in various protein-coding and non-coding substrates in gliomas and 
related cell lines.nd: not determined.   
 
The general loss of editing in human brain tumors, manifest as underediting of a 
handful of known substrates, suggests a fundamental change in the function of the 
editing machinery. As miRNAs are also substrates of the same editing machinery, it 
is likely miRNAs also suffer abnormal editing levels in these tumors. Therefore, the 
aim of this chapter was to investigate A-to-I editing of miR-376 cluster in glioma 
tissues and cell lines to identify: a) patterns of miRNA editing in tumors and b) 
specific miRNAs that might be aberrantly edited.  
3.2 Editing analysis of primary miRNAs in gliomas 
Since transcription of the miR-376 cluster produces a long single primary transcript 
with pri-miR-376a1, 376a2, 376c and 376b and A-to-I editing occurs on the primary 
transcript (Kawahara et al., 2007b), direct sequencing of RT-PCR products 
corresponding to pri-miRNAs was done to determine the frequency of A-to-I editing 
(hereafter ‘editing’). Editing analysis was done for a set of 24 high-grade gliomas 
which included: 16 glioblastomas (GBM; grade IV), 4 anaplastic astrocytomas (AA; 
grade III), 3 anaplastic oligoastrocytoma (AOA; grade III) and 1 anaplastic 
oligodendroglioma (AOG; grade III). Total RNA was isolated from all samples. Five 






serve as normal controls and as a reference for normal editing in the human brain. 
Direct sequencing of RT-PCR products corresponding to pri-miR-376a1, 376a2, 376b 
and 376c was performed (Figure 3.2) and from sequencing chromatograms, the 
frequency of editing was determined as the % ratio of ‘G’ peak to the sum of ‘A’ and 






Sequencing of 5 normal human brain tissue samples confirmed that editing at the 
sites was high and to the same extents as described previously (Kawahara et al., 
2007b) and with low variance among samples (Table 3.2). Compared to normal brain, 
in glioma samples variable extents of altered editing were observed, appearing as 
reduced or absent ‘G’ peaks at the editing sites in sequence chromatograms (Figure 
3.3). Quantification of editing frequencies for all sites revealed that overall editing of 
miR-376 cluster was significantly reduced in human gliomas compared to normal 
brain, as summarized in Table 3.2. Baseline editing frequencies of 0-4% were 
observed for some sites in several glioma samples, representative of negligible 
editing.  
Figure 3.2 RT-PCR of pri-miRNAs from miR-376 cluster. Representative gel image of 
RT-PCR of pri-miR-376a1 from two glioma samples, AOA 22 and GBM 16. cDNA 
prepared with reverse transcriptase (+) and without reverse transcriptase (-) for each 
sample were subjected to the same PCR amplification. Absence of PCR product in (-) 
lane indicates absence of genomic DNA contamination. PCR products from (+) lanes were 






For some sites, tumor samples displayed great variability in editing levels (+48 site 
for pri-miR-376c) whereas for others, editing levels were consistently low across all 
samples (+5 site of pri-miR-376a1). Within individual tumors, there was some 
correlation between degree of reduction in editing at various sites i.e.  tumors with 
low-level editing of one site tended to have low-level editing for other sites (GBM 1, 
GBM 2 and AA 17) and vice-versa (AOG 24). This is line with a common editing 
machinery, and its dysfunction as the underlying mechanism for altered editing of 
substrates, with the degree of dysfunction reflected commonly in the factor of 
reduction of editing at distinct sites. Interestingly, some sites with normally high-




























Figure 3.3 Direct sequencing of 
RT-PCR products of primary 
miRNAs from normal human brain 
and glioblastoma samples. The 
written sequences correspond to the 
genomically encoded sequence. 
Sequencing of A. pri-miR-376a1, B. 
pri-miR-376a2, C. pri-miR-376c, and 
D. pri-miR-376b from normal brain 
(NB) and glioblastomas (GBMs).  
Regions underlined correspond to mature miRNAs: miR-376a1-5p (miR-376a*) and miR-
376a1-3p (miR-376a) processed from pri-miR-376a1, miR-376a2-5p and miR-376a from 
pri-miR-376a2, miR-376c from pri-miR-376c, and miR-376b from pri-miR-376b. For each 
primary miRNA the 5’ end of stem-loop sequence annotated in the Sanger miRBase site 
is counted as +1. Editing sites are indicated by red arrows, at which A-to-I editing is 
detected as black guanosine (G) trace, either substituting the genomically encoded A 
trace or appearing together with the A trace. Note the reduction or absence of a ‘G’ peak 











pri-miR-376a1 pri-miR-376a2 pri-miR-376c pri-miR-376b 
a













 Normal Brain (n = 5) 15.74 ± 4.32 46.56 ± 2.17 25.21 ± 3.50 52.6 ± 5.25 90.74 ± 6.58 98.52 ±1.26 24.34 ± 0.77 93.63 ± 2.02 94.40 ±1.87 
1 GBM 2.02 0.93 0 7.5 8.9 5.06 3.03 4.86 3.58 
2 GBM 2.3 2.85 2.5 5.35 7.17 13.65 4.36 6.64 2.7 
3 GBM 2.94 3.56 9.31 15.99 30.66 97.8 5.56 76.14 89.1 
4 GBM 3.57 2.4 0 10.08 16.47 36.57 1.44 3.58 – 
5 GBM 2.24 1.64 1.7 20.17 38.21 95.92 – – 66.75 
6 GBM 2.31 1.33 41.97 16.58 21.24 91.29 1.28 72.09 92.9 
7 GBM 2.35 1.55 3.68 2.64 0 92.57 – – – 
8 GBM 2.06 2.98 0 11.94 49.03 92.55 0 61.21 – 
9 GBM 0.87 3.2 0 22.86 70.02 52.25 1.79 95.43 98.47 
10 GBM 2.13 1.89 97.3 21.27 52.16 97.45 0.52 94.78  
11 GBM 2.42 2.46 2.18 6.18 3.48 69.73 1.27 71.04 63.4 
12 GBM 0.21 13.64 0 9.04 39.15 83.41 10.58 75.29 81.31 
13 GBM – – – 5.64 0.46 91.83 – – – 
14 GBM – – – 11.31 8.62 0.38 – – – 
15 GBM/GS 1.67 24.14 1.39 12.82 45.03 95.04 2.43 91.21 65.86 
16 GBM/GS 3.58 12.07 9 23.4 29.16 90.13 0.39 66.97 74.93 
17 AA 2.51 1.54 3.13 10.42 13.01 26.61 3.39 4.06  
18 AA 1.49 5.27 0 10.31 58.31 98.72 1.93 97.76 91.21 
19 AA 2.73 1.88 0 3.31 96.75 98.48 – – – 
20 AA 2.65 32.99 16.69 19.83 42.93 98.22 32.82 97.11 – 
21 AOA 9.16 16.28 14.64 16.29 16.42 92.61 3.73 72.22 88.75 
22 AOA 0.29 58.71 2.23 33.8 49.73 95.51 0.52 19.51 90.76 
23 AOA 2.46 96.71 0 7.47 36.79 97.07 40.08 64.53 66.89 
24 AOG 2.5 19.39 32.65 25.46 50.33 93.74 1.3 93.11 94.41 
Table 3.2 Quantification of A-to-I RNA editing of primary miRNAs from miR-376 cluster in normal human brain and primary gliomas. Direct 
sequencing of RT-PCR products corresponding to each pri-miRNA was done and frequency of editing was determined as the % ratio of ‘G’ peak to the sum 
of ‘A’ and ‘G’ peaks at indicated editing sites.  
GBM, glioblastoma multiforme; AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma; AOG, anaplastic oligodendroglioma; GS, gliosarcoma. 
a 
Position of editing site within each pri-miRNA. The 5’ end of the stem-loop annotated in Sanger miRBase registry is counted as +1. 
†
 Editing site in seed sequence of processed mature miRNA; 
‡ 









Of the nine editing sites within the miR-376 cluster, six lie within the seed sequences 
of processed mature miRNAs. The remaining three sites lie within the stem-loop 
sequence of pri-miRNAs just outside of mature miRNA sequence, i.e. +5 site of pri-
miR-376a1, +9 site of pri-miR-376a2 and +4 site of pri-miR-367c (Figure 3.1). 
Changes to editing frequencies of mature miRNA seed sites are expected to have 
greater consequence on miRNA function, as the seed sequence determines miRNA 
function through target selection (Bartel, 2009). Hence, altered editing at mature 
miRNA sites was considered of greater significance.  
The editing frequencies for mature miRNA seed sequence sites in grade IV glioma 
samples (GBMs) and normal brain was further compared (Figure 3.4). Overall, there 
was a broad disparity in the reduction of editing levels among the mature miRNA 
seed editing sites. The +9 site of pri-miR-376a1 and +15 site of pri-miR-376a2 
appeared most affected in terms of extent of editing loss suffered. Although +49 site 
of pri-miR-376a1, corresponding to mature miR-376a, appears to be negligibly edited 
in most GBMs, it is only moderately edited in the normal brain (~25%). Additionally, 
miR-376a is also encoded by pri-miR-376a2, site +55 of which lies within this mature 
miRNA. Cumulatively, mature miR-376a derived from pri-miR-376a1 and pri-miR-










pri-miR-376a1, +9 site 
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(miR-376c) 
























Figure 3.4 Editing frequency of sites in miR-376 cluster corresponding to mature 
miRNA seed sequences. Position of edited sites within indicated primary miRNAs are 
shown and the mature miRNA to which they correspond are specified in brackets. Editing 
levels for each site are compared between normal brain (NB) and glioblastoma samples 
(GBM). Boxplots show the median (  ), first and third quartile boxes, minimum and 






Interestingly, when tumors were grouped by histopathology, a correlation between 
editing of +9 site of pri-miR-376a1 and tumor type was revealed. Among all GBMs, 
two tumors classified as gliosarcomas (GBMs 15 and16) retained substantial editing 
of +9 site of pri-miR-376a1 (12-24%; Table 3.2). This was also observed in gliomas 
classified as anaplastic oligoastrocytomas (AOA) and anaplastic oligodendrogliomas 
(AOG) (16-97% in 4/4 tumors). However, most anaplastic astrocytomas (AAs) and 
GBMs (14/16 tumors, excluding known gliosarcomas) consistently displayed <5% 
editing at +9 site of pri-miR-376a1 (Figure 3.5A). Although site +15 or pri-miR-376a2 
is highly edited (~90%) in the normal brain, its degree of editing reduction 
demonstrated great variability among glioma grades and samples (Figure 3.5B). 
These results suggest that extent of altered editing is combinatorially dependent on 
the tumor type and the editing site itself and that reduced editing of some sites may 
be of greater significance than others in GBMs. Specifically, the +9 site of pri-miR-
376a1 displayed a tumor-type dependent editing aberration and is particularly lowly 
edited in GBMs. This site corresponds to the seed sequence of the encoded mature 
miR-376a1-5p, also known as miR-376a*. Accordingly, mature miR-376a* 
consistently displays negligible levels of editing in GBMs, in contrast to its relatively 
































































n=5 n=14 n=4 n=4
n=5 n=12 n=4 n=4
AOG


































Figure 3.5 Editing frequencies based on tumor histopathological classification. A. 
Editing frequency of +9 site of pri-miR-376a1 (corresponding to mature miR-376a*). B. 
Editing frequency of +15 site of pri-miR-376a2 (corresponding to mature miR-376a2-5p). NB: 
normal brain; GBM: glioblastoma multiforme; AA: anaplastic astrocytoma; AOA: anaplastic 
oligoastrocytoma; AOG: anaplastic oligodendroglioma. Horizontal bars designate mean 






3.3 Editing analysis of primary miRNAs in glioma cell lines 
and astrocyte cells 
To evaluate editing of miR-376 cluster at a cellular level, rather than in tumor tissue 
with mixed cell populations, a similar analysis of primary miRNA editing was carried 
out in four glioma cell lines (U87, U251, SW1783 and SW1088) (Table 3.3). In glioma 
cell lines, editing frequencies for all sites were reduced, as in tumor samples, but 
demonstrated far more consistency across cell lines. The results are in agreement 
with the low level of editing observed for GluR-B Q/R site in A172, U118 and U87 
glioma cell lines (Cenci et al., 2008) and reduced editing that characterizes 
transformed cell lines (Levanon et al., 2005).  
As the brain is a complex tissue composed of multiple cell types, editing frequencies 
obtained using the normal brain as control represents an “average”. Thus, the use of 
normal brain limits attribution of observed editing to any particular cell type in the 
brain. As gliomas, particularly astrocytomas and glioblastomas, potentially arise from 
transformed astrocytes (Huse and Holland, 2010), editing frequencies were 
investigated in normal human astrocytes isolated from adult brain cortex (Table 3.3). 
In normal astrocytes editing of all sites corresponding to mature miRNAs, was 
remarkably high at ~95%, except site +49 of pri-miR-376a1. Interestingly, for non-
mature miRNA sites even within the same pri-miRNA, editing was limited to very low 
levels in astrocytes suggesting that other cell types -neurons or oligodendrocytes- 
contribute to the detectable editing frequencies observed at these sites for the whole 
brain. Importantly, it was confirmed that in normal astrocytes as in normal brain, site 
+9 of pri-miR-376a1 (corresponding to miR-376a*) is highly edited to ~95%. The 
contrastingly low, nearly negligible, level of editing of this site in GBMs is therefore 
striking and suggests its functional importance in GBMs. Therefore, from among 
several highly edited mature miRNAs from miR-376 cluster in brain and astrocytes, 






 Frequency of Editing (%) 
Cell Type 
pri-miR-376a1 pri-miR-376a2 pri-miR-376c pri-miR-376b 
a













Normal Astrocytes 3.65 95.13 1.56 1.13 94.59 91.44 1.9 94.14 97.96 
U87 1.71 1.51 2.35 11.23 13.87 75.74 0.96 42.7 52.61 
SW1783 0 1.46 6.98 7.93 12.56 81.81 1.89 38.32 57.31 
SW1088 0 2.02 1.39 4.68 5.46 62.67 1.21 17.9 32.98 
U251 2.59 3.04 6.29 8.66 13.57 82.53 2.19 37.94 55.39 
Table 3.3 Quantification of A-to-I RNA editing of primary miRNAs from miR-376 cluster in normal astrocytes and glioma cell lines. Direct sequencing 
of RT-PCR products corresponding to each pri-miRNA was done and frequency of editing was determined as the % ratio of ‘G’ peak to the sum of ‘A’ and ‘G’ 
peaks at indicated editing sites.  
a
 Position of editing site within each pri-miRNA. The 5’ end of stem-loop transcript annotated in Sanger miRBase registry is counted as +1. 
†
 Editing site in seed sequence of processed mature miRNA; 
‡ 









3.4 Editing analysis of mature miRNAs 
Mature miRNA editing frequency was measured in glioma cell lines using the 
targeted cloning strategy developed previously by (Kawahara et al., 2007b), to 
correlate their editing frequency to that of pri-miRNAs from which they are derived. 
For each mature miRNA, the % of cDNA clones of mature miRNA RT-PCR products 
with A-to-G change at editing sites indicate the editing frequency of mature miRNAs. 
The trend of mature miRNA editing frequency corresponded to that for pri-miRNAs 
for U251, SW1088 and SW1783 cells (Figure 3.6 and Table 3.3). Indeed, the mature 
miR-376a* was negligibly edited to 0-5% in glioma cell lines, matching well with the 
editing frequency of +9 site of pri-miR-376a1, the site corresponding to seed 












 Mature miRNA 
 miR-376a* miR-376a2-5p miR-376a/376b miR-376c 
U251 1/36 1/44 13/44 2/48 
SW1088 1/44 0/39 7/17 3/49 
SW1783 0/48 0/44 8/20 1/48 
% Editing of mature miRNAs










Figure 3.6 Editing frequency of mature miRNAs. Using a targeted cloning strategy, 
editing of mature miRNAs from miR-376 cluster was measured in U251, SW1088 and 
SW1783 glioma cells A. cDNA clones (n > 50) for each miRNA were sequenced and 
frequency of editing was determined as the % of clones containing A-to-G change. miR-
376a and miR-376b cannot be distinguished by this sequencing strategy. B. For each 
mature miRNA, number of clones with A-to-G change/total number of clones containing 
positive sequences of acceptable quality is shown. This was used to calculate editing 







Although the trends of mature miRNA and primary editing frequencies were 
correlated, the editing frequency was in general lower than expected for mature 
miRNAs - assuming that edited mature miRNAs are produced at frequencies similar 
to edited pri-miRNAs. The underestimation was attributed to cloning bias, as editing 
frequencies of mature miRNAs from normal brain samples, as measured by us, were 
also measurably lower than primary miRNA editing. For miR-376a*, 13 of 47 clones 
contained A-to-G change for an estimated editing frequency of 27% in normal brain, 
compared to the 50% editing determined by Kawahara et al (Kawahara et al., 2007b). 
Nonetheless, for pri-miRNAs from normal brain, the editing frequency determined in 
this study, was completely corresponding to published data, verifying the 
methodology used for quantifying pri-miRNA editing.The discrepancy between editing 
levels of mature and primary miRNAs is deemed not to be of significant concern as:  
1. Equivalency of editing frequencies between primary and mature miRNAs from 
miR-376 cluster has been conclusively demonstrated previously (Kawahara et al., 
2007b).  
2. In the scenario of interest in this study where primary miRNAs are unedited or 
underedited as in GBMs especially for miR-376a*, mature miRNAs will 
necessarily remain unedited, as they cannot be independently edited. Hence, a 
cloning bias which underestimates editing of mature miRNAs cannot lead to any 
further underestimation of editing of ‘unedited’ miRNAs. 
Hence, based on previous findings and the current analysis, editing frequency of 
sites in primary miRNAs corresponding to mature miRNA sequences are good 
estimates of editing frequency of mature miRNAs. Therefore, among mature miRNAs 
from miR-376 cluster, miR-376a* is present almost exclusively in the unedited form in 






























































3.5 Expression of mature miRNAs in gliomas 
Transcriptional and post-transcriptional mechanisms can both regulate miRNA 
abundance which is commonly altered in cancers. In this chapter, one of the aims 
was to investigate the expression levels of mature miRNAs from miR-376 cluster. In 
the context of GBMs, where mature miRNA editing, especially for miR-376a*, is 
reduced it is important to determine if mature miRNA abundance is also affected, 
possibly due to altered editing. Therefore, quantification of mature miRNA abundance 
was done by qRT-PCR using miRNA-specific primers. It was demonstrated that ‘A’ 
and ‘G’ containing primers are equally efficient in amplifying mature miRNAs. Both 
GBMs and AAs expressed miR-376a* at variable levels (with no apparent correlation 
to editing frequency), although the tendency was for miR-376a* to be expressed 
lower than in normal brain (Figure 3.7).  Measurement of levels of other mature 
miRNAs from miR-376 cluster also revealed a general variability of expression, 




Figure 3.7 Expression and editing of miR-376a* in a panel of tumor samples. Expression 
of miR-376a* was measured by qRT-PCR and values were normalized to 5S rRNA from the 
same sample. Editing frequency (%) was obtained from the frequency of editing of site +9 of 
pri-miR-376a1 (corresponding to miR-376a*), and was normalized to the % editing in normal 
brain (NB) for the same site. Both expression and editing data are plotted on the same scale 


















Figure 3.8 Expression of mature miRNAs from miR-376 cluster in a panel of tumor 
samples. A. miR-376a2-5p, B. miR-376a, C. miR-376b, D. miR-376c. Expression of miRNAs 
was measured by qRT-PCR and values were normalized to 5S rRNA from the same sample. 
NB: Normal brain. Data represents mean ± SD. 
 
In order to conclusively establish the expression of miRNAs in a large panel of 
tumors, the Cancer Genome Atlas (TCGA) dataset on miRNA expression in GBMs 
was interrogated (The Cancer Genome Atlas Network, 2008). The Anduril framework 
was used for analysis of microarray-derived miRNA expression data from 251 GBM 
and 10 normal brain samples which is available in the TCGA dataset (Ovaska et al., 
2010). Table 3.4 summarizes these results for mature miRNAs from miR-376 cluster 


























































































































































































































































Sanger miRBase, hence expression information on this miRNA from public 
databases is unavailable. 
Overall, expression of mature miRNAs from miR-376 cluster in GBMs is similar to 
that in the normal brain, except for miR-376a which is expressed at half the 
abundance of normal brain, in agreement with earlier qRT-PCR analysis (Figure 
3.8B). Significantly, the total abundance of miR-376a* (comprising both unedited and 
edited transcripts) in GBMs is highly similar to that in normal brain tissue (0.853-fold). 
Microarray and qRT-PCR-based miRNA detection methods are unable to distinguish 
between mature miRNA isoforms differing by a single-base and hence expression 
data represents cumulative levels of both edited and unedited miRNAs.  Together, 
expression and editing data suggests that miR-376a* is expressed almost exclusively 
in the unedited form in GBMs, at abundance largely similar to that of the edited 
transcript in the normal brain. 
miRNA Fold-change in GBM p-value 
miR-376a* 0.853 2.49E-05 
miR-376a 0.517 1.18E-09 
miR-376b 0.941 0.0422 
miR-376c 0.789 8.54E-05 
Table 3.4 Expression of miR-376 cluster members in TCGA dataset. Summary of analysis 
of TCGA data using Anduril framework for miRNA expression. Samples included in the 
analysis include 251 GBMs and fold-change is relative to miRNA expression in 10 normal 
brain samples. p-value associated to fold change is also reported and obtained from the same 
analysis. 
 
The cumulative data from editing and expression analysis suggests that from miR-
376 cluster, only mature miR-376a* displays a strong tumor-type specific editing 
aberration and accumulates almost entirely as the unedited variant in GBMs. Thus, 
unedited miR-376a* is a tumor-specific miRNA sequence variant, aberrantly 







3.6 Expression of mature miRNAs in glioma cell lines 
The expression of mature miRNAs was also measured in glioma cell lines and 
compared to normal astrocytes. In contrast to GBMs, expression of all miRNAs from 
miR-376 cluster was consistently reduced several-fold in glioma cell lines (Figure 
3.9A-E). miR-376a* and miR-376a2-5p especially were negligibly expressed in U87, 
U118 and SW1783 cell lines. This data suggests that in addition to low level of 
editing, glioma cells also have low expression of miRNAs from miR-376 cluster. This 
effectively amounts to neither the edited nor the unedited mature miRNA being 
expressed in glioma cell lines in vitro, especially for miR-376a*. Interestingly, it was 
noted that normal astrocytes have highly-enriched expression of mature miRNAs 
compared even to normal brain tissue (Figure 3.9F), suggesting that from among cell 
types of the brain, astrocytes specifically express high levels of miRNAs from miR-
376 cluster. Coupled with high-level (nearly 100%) editing of mature miRNA seed 
sites in astrocytes (Table 3.3), this suggests a pertinent role for edited mature 























Figure 3.9 Expression of mature miRNAs from miR-376 cluster in glioma cell lines 
and normal astrocytes. Expression of miRNAs was measured by qRT-PCR and values 
were normalized to 5S rRNA from the same sample A. miR-376a*, B. miR-376a2-5p, C. 
miR-376a, D. miR-376b, E. miR-376c. Values are relative to normal astrocytes (NAA) F. 
Fold-enrichment of mature miRNA expression in NAA compared to normal brain (NB). Data 


































































































































































































3.7 Underediting of miR-376a* is due to ADAR2 dysfunction 
The A-to-I editing enzymes, ADAR1 and ADAR2 edit all sites within the miR-376 
cluster with varying specificities for each site. As it happens for other editing 
substrates reported in GBMs, the reduction in editing levels of miR-376 cluster sites 
necessarily stems from attenuated ADAR function either due to low expression or 
reduced activity without change in expression. Therefore to account for the changes 
in editing frequencies of miR-376 cluster sites in gliomas, mRNA levels of ADAR1 
and ADAR2 were quantified in tumors by qRT-PCR.  
ADAR1 was found to be generally underexpressed in gliomas, independent of tumor 
type, and did not show any correlation with frequency of editing at any particular site 
from miR-376 cluster (Figure 3.10A). Most GBMs showed markedly diminished levels 
(<20% of normal levels) of ADAR2 expression (Figure 3.10B). In contrast, most 
grade III gliomas (7/8 AA, AOA and AOG) retained significantly higher levels of 
ADAR2 (nearly 50% of normal levels). ADAR2 exclusively edits the +9 site of pri-
miR-376a1, which displays negligibly low-level editing specifically in GBMs, while 
retaining significant editing in AOA and AOG. Accordingly, the low expression of 
ADAR2 in GBMs is likely to be the underlying reason for underediting of site +9 of 
pri-miR-376a1 (miR-376a*) in GBM tumors. Interestingly, in GBMs 12, 15 and 16, 
despite the high-level editing of miR-376a* measured (Table 3.2), ADAR2 expression 
was low similar to other GBMs. This suggests that loss of ADAR2 expression is a 
common event in GBMs and exceptional accumulation of edited miR-376a* in some 







































































































































































































































































































































Figure 3.10 Expression of ADAR1 and ADAR2 in gliomas. A. Relative quantification of 
ADAR1 mRNA in normal brain (NB) and 24 glioma samples (GBM, AA, AOA, AOG). B. 
Relative quantification of ADAR2 mRNA by qRT-PCR. 18S rRNA was used for 







To establish a causal link between ADAR2 function and editing of miR-376a*, 
ADAR2 was ectopically expressed in glioma cells by transfecting an expression 
vector encoding ADAR2. The cells were co-transfected with an expression vector 
encoding miR-376 cluster and editing analysis was carried out. It was necessary to 
ectopically introduce the miR-376 cluster as substrate for editing, given that this 
miRNA cluster is generally lowly expressed in glioma cells (Figure 3.9). Direct 
sequencing of RT-PCR products corresponding to pri-miR-376a1, 376a2, 376b and 
376c, from U87 glioma cells over-expressing ADAR2 was done (Figure 3.11). As 
controls, U87 cells were transfected with EGFP expression plasmid instead of 
ADAR2. 
Form the sequencing chromatograms, it was seen that editing at site +9 of pri-miR-
376a1 was restored to ~95% in U87 cells in the presence of ectopic ADAR2 (Figure 
3.11), corresponding with established specificity of ADAR2 for editing this site 
(Nishikura, 2010). Within pri-miR-376a1, +49 site was edited to ~60% in the 
presence of ADAR2, compared to 5-10% in control cells. It is known that this site is 
preferentially edited by ADAR1, potentially accounting for its relatively lower editing 
levels than +9 site of pri-miR-376a1. Of note, editing remained highly specific to 
known editing sites. No spurious editing events represented by presence of ‘G’ peaks 
at non-editing ‘A’ sites were detected when ADAR2 was overexpressed. Furthermore, 
ADAR2 also edited to high levels (nearly 100%), +5 site of pri-miR-376a1, +11 and 
+15 sites of pri-miR-376a2, and +4 site of pri-miR-376c (Figure 3.11).  It is known 
that pri-miR-376b is exclusively edited by ADAR1 and accordingly, no change was 
detected in editing levels when ADAR2 was overexpressed. 
Surprisingly however, editing of +55 site of pri-miR-376a2 and +48 site of pri-miR-
376c was lesser in the presence of ADAR2 than in control cells. Similar to +49 site of 
pri-miR-376a1, the +55 site of pri-miR-376a2 is preferentially edited by ADAR1. It is 






normally highly edited even in glioma cells (Table 3.3). The diminished editing levels 
in the presence of ADAR2 could potentially be due to the degradation of hyper-edited 
transcripts. Degradation of edited pri-miRNA transcripts has previously been reported 
for pri-miR-142 (Yang et al., 2006). Thus, although editing occurs to high levels, the 
RT-PCR product derived from cDNA pools contains an over-representation of 
unedited transcripts, as edited transcripts undergo degradation.  Alternatively, the 
ectopic ADAR2 could compete with factors responsible for editing these sites in 











Figure 3.11 ADAR2 expression restores editing of pri-miR-376a1 in U87 cells. Direct 
sequencing of RT-PCR products of primary miRNAs from U87 cells overexpressing 
ADAR2. Expression vector encoding miR-376 cluster was co-transfected for higher 
expression of the editing substrates, the pri-miRNA transcripts. Editing sites are indicated 
by arrows, at which A-to-I editing is detected as black (G) trace. The 5’ end of stem-loop 
sequence annotated in the Sanger miRBase site is counted as +1 and site corresponding 
to mature miR-376a*, +9 site of pri-miR-376a1-5p is boxed. EGFP transfection served as a 
control. In ADAR2 transfectants, note the presence or greater height of ‘G’ peak at editing 















































Finally, the expression of mature miRNAs was measured under conditions of ADAR2 
overexpression to confirm that editing of pri-miRNAs from miR-376 cluster does not 
impact their processing. It was confirmed that endogenous levels of mature miRNAs 
were similar to mock-transected and EGFP-transfected cells (Figure 3.12). Thus, 

















Figure 3.12 Abundance of mature miRNAs in ADAR2-transfected U87 cells. 
Endogenous mature miRNA levels were measured after transfection of ADAR2 
expression plasmid in U87 cells. Untransfected and EGFP-transfected cells were 
used as controls. Measurement was done by qRT-PCR and values were normalized 







By direct sequencing of primary miRNAs from miR-376 cluster it was determined that 
A-to-I editing of sites in this cluster is altered in gliomas. From high-level editing in 
normal brain and astrocyte cells, editing was measurably reduced for several editing 
sites in high-grade gliomas and glioma cell lines. Processing of unedited primary 
transcripts therefore leads to an increased abundance of unedited mature miRNA at 
the expense of edited miRNA transcripts. In this chapter it was established that due 
to loss of editing of +9 site of pri-miR-376a1, miR-376a* harboured in this primary 
miRNA, displays a consistently negligible level of editing in most GBMs, 
accumulating entirely as unedited miR-376a*. 
The seed sequences of all mature miRNAs from the miR-376 cluster are edited from 
50-100% when studying the whole brain and to nearly 100% in astrocytes. The high-
level editing is reminiscent of 100% recoding of the GluR-B receptor at Q/R site, the 
only site-selective editing substrate in the brain (among ion channels and 
neurotransmitter receptors) to undergo such extensive modification (Higuchi et al., 
2000), implying an important role for A-to-I editing-mediated “recoding” of miR-376 
cluster miRNAs in normal cells. 
In agreement with previous findings made in a large cohort of gliomas (Paz et al., 
2007), a widespread reduction in ADAR1 and ADAR2 mRNA levels in high-grade 
gliomas, especially GBMs, was uncovered. However, the results were contrary to 
findings in ten pediatric astrocytomas and limited panel of seven GBMs, where 
ADAR2 mRNA levels were not changed (Cenci et al., 2008; Maas et al., 2001). This 
discrepancy is likely to be due to the difference in tumor types (GBMs vs. pediatric 
astrocytomas) or the limited number of samples examined in these previous studies. 
Interestingly, from miR-376 cluster in gliomas, the +9 site of pri-miR-376a1 
(corresponding to mature miR-376a*) suffers disparately greater loss of editing than 






and ADAR2, is responsible for editing all sites within the cluster. This outcome could 
possibly arise due to the differential sensitivity of each site to attenuated enzyme 
function, stemming from variable editing efficiencies of ADARs for different sites 
depending on RNA sequence and structure (Valente and Nishikura, 2005). Thus, 
despite limited ADAR amounts, sites such as +55 site of pri-miR-376a2 may still be 
highly edited in tumors, as it was observed through sequencing analysis. Additionally, 
the involvement of other factors that regulate ADAR activity for each site cannot be 
ruled out (Wahlstedt et al., 2009). 
As the substrates of ADARs are numerous, ADAR dysfunction will undoubtedly have 
pleiotropic effects. Notably however, even the most well-studied target of A-to-I 
editing, the GluR-B subunit of the glutamate receptor, suffered a modest loss of 
editing from 100% to 69-88% in GBMs (Maas et al., 2001), in contrast to the nearly 
complete abolishment of editing for miR-376a* in GBMs, as reported here. The global 
effects of A-to-I editing loss in GBMs are speculated to manifest through a variety of 
substrates, each contributing to the disease phenotype, but the elucidation of these 
effects need be studied for each substrate individually in the relevant context. For 
example, overexpression of ADAR1 and ADAR2 in U87  and U118 glioma cell lines 
has been shown to suppress their proliferation rates (Cenci et al., 2008; Paz et al., 
2007), but this can be ruled out as a consequence of restored editing of miRNAs 
from miR-376 cluster given their low endogenous expression in these cell lines.  
miRNAs from miR-376 cluster have never before been implicated in gliomas. While a 
relative over-abundance of unedited miR-376a* (at the expense of edited miR-376a*) 
in glioma tissue compared to normal brain is uncovered in this study, this “differential” 
expression has not been detected using either microarray or qRT-PCR techniques in 
previous miRNA profiling studies in gliomas (Ciafre et al., 2005; Godlewski et al., 
2008; Silber et al., 2008). This is attributable to the limited discriminatory power of 






edited forms of miR-376a*. This limitation was also observed in other studies 
reporting inability to discriminate miRNA sequence variants by Taqman miRNA 
qPCR assays (Christensen et al., 2010; Hoffman et al., 2009). As such, barring any 
change at the transcriptional or stability levels, which would affect overall abundance, 
many variant miRNA sequences will escape detection by traditional quantification 
methods. Importantly, precisely due to these limitations the conclusion could be 
drawn that the absolute amounts of miR-376a* are nearly unchanged in GBMs 
compared to normal brain (0.853-fold) as gathered from the analysis of TCGA 
miRNA data on GBMs. Therefore, the only component of miRNA function subject to 
change in context of altered A-to-I editing was the sequence of miR-376a*. 
Previous efforts on uncovering miRNA-sequence based changes in cancers have 
included high-throughput sequencing methods, including next-generation sequencing, 
for detection of editing of mature miRNAs. In neuroblastomas (NBs), miR-376a and 
miR-376c were found be edited but no differential editing was found between NBs 
with favorable and unfavorable outcomes (Schulte et al., 2010). In a study in breast 
cancers comparing normal and carcinoma tissues (both invasive and in situ), the 
same two miRNAs had nucleotide variations at the edited sites but no difference in 
editing levels between normal and tumor tissue was reported (Farazi et al., 2011). In 
hepatitis B-related hepatocellular carcinomas,  31% and 50% of miR-376c was edited 
in the HCC and normal liver tissue respectively and for miR-376a, 86% was edited in 
HCC compared to 50% in normal tissue (Mizuguchi et al., 2011). Whether this is 
considered a significant difference in editing frequency and sequence composition 
was not discussed. The lack of substantial change to miRNA sequence by editing in 
non-CNS tumors suggests that ADAR function is largely maintained in these tumors.  
For miR-376a*, a glioma-type dependent suppression of editing was observed. For 
grade III oligoastrocytomas (OAO) and oligodendrogliomas (OAG), and exceptionally 






frequencies were detectable corresponding with relatively higher ADAR2 mRNA 
levels (50% of normal brain). These results are partially in line with the finding that in 
mice with one functional ADAR2 allele, 99% of Q/R site of GluR-B mRNA was still 
edited, suggesting sufficiency of ADAR enzyme activity even at 50% of normal ADAR 
quantities (Higuchi et al., 2000). OAGs and OAOs generally have better prognosis 
than AAs and GBMs  (Louis, 2006); whether this is related to the presence of edited 
miR-376a* transcripts is an interesting question. From the tumor-type dependent 
editing pattern, a diagnostic value for glioma classification, and GBM 
subclassification, based on miR-376a* editing frequency is also conceivable.  Due to 
limited availability of lower-grade patient gliomas (Grade II OAO, OAG, astrocytoma), 
it was not possible to investigate grade-wise changes in editing frequencies of miR-
376 cluster. Nonetheless, overall editing levels are predicted to be higher in lower-
grade tumors as supported by relatively higher ADAR activity and levels in these 
tumors compared to GBMs (Paz et al., 2007). 
Changes in transcript editing levels due to ADAR dysfunction most likely play a role 
in progression rather than initiation of malignant growth, given that mouse models of 
ADAR dysfunction do not have increased cancer incidence (Farajollahi and Maas, 
2010), The aggregation of unedited miR-376a*, initiated by loss of A-to-I editing in 
GBMs, may be one of the cumulative lesions conferring considerable malignant 
advantage during cancer progression, accounting for its exceptionally low editing 
levels in GBMs, compared to other editing substrates, including miRNAs from miR-
376 cluster. Thus, based on the editing and expression analyses in gliomas, it can be 
concluded that unedited miR-376a* is GBM-specific miRNA sequence variant that 
accumulates in tumors due to aberrant A-to-I editing. This accumulation potentially 







4 CHAPTER 4. Regulation of growth and invasion of 
glioblastomas by miR-376a* 
4.1 Introduction and aims 
In the previous chapter it was established that A-to-I editing of miR-376a* is 
attenuated in glioblastomas (GBM), and this was associated with low expression of 
ADAR2 enzyme. As a result, the unedited miR-376a* aberrantly accumulates in 
GBMs. Furthermore, this effect was observed specifically in GBMs as grade III 
tumors (astrocytomas, oligoastrocytomas and oligodendrogliomas) retained 
significantly higher levels of editing of miR-376a*. The unedited miR-376a* seed 
sequence contains an ‘A’ at +3 position of the mature miRNA and hence differs from 
the normally occurring edited miR-376a* (in brain- astrocytes and potentially other 
cell types), which contains an ‘I’ at the same position (Figure 4.1). miRNAs are 
characterized by their ability to modulate multiple genes simulatenously and play 
crucial roles in several processes related to cancer development. A change to the 
miRNA sequence can disrupt or create target mRNA-miRNA interactions, and is 
predicted to cause widespread effects on gene regulation. The aim of this chapter 
was to understand if the aberrant accumulation of unedited miR-376a* has any 








Figure 4.1 Accumulation of unedited miR-376a* in glioblastomas. Schematic 
representation of the differential expression of edited and unedited miR-376a* in normal cells 
and glioblastoma (GBM) cells, as a result of attenuated A-to-I editing in GBMs. A: adenosine 








While all high-grade gliomas (grade III and IV) are highly proliferative, GBMs are 
especially aggressive and are characterized by extensive invasiveness into 
surrounding normal tissues (Furnari et al., 2007). Studies have linked the expression 
of molecular markers related to invasion and angiogenesis, MMP2 and VEGF, 
specifically in GBMs (in contrast to AAs) in line with their highly invasive nature 
(Dreyfuss et al., 2009; Du et al., 2008; Mayes et al., 2006; Zhou et al., 2005). 
Importantly, based on transcriptional profiling of a cohort of high-grade gliomas 
linking tumor development to neuroglial development, grade III tumors 
(oligodendrogliomas and astrocytomas) were classified as ‘proneural’ which 
generally have a tendency towards  longer survival (Phillips et al., 2006; Verhaak et 
al., 2010). On the other hand, primary GBMs are mostly classified as ‘mesenchymal’ 
with worse prognosis. These findings point to increasing aggressiveness of GBM 
tumors compared to grade III counterparts due to increased invasion, which can 
modulate other features such as angiogenesis. Therefore, given the GBM-specific 
accumulation of unedited miR-376a*, the nature of its involvement in regulation of 
GBM malignancy, was first investigated with regards to invasiveness.  
4.2 Establishment of highly invasive glioma cell line 
Although high-grade gliomas, especially GBMs, are highly invasive (Furnari et al., 
2007), human glioma-derived cell lines, such as U87 cells, often lose this property 
over in vitro culture time, and form non-invasive tumors in vivo in orthotopic models 
(Gladson et al., 2010; Radaelli et al., 2009; Xie et al., 2008). Past efforts to develop 
more representative models for human GBMs have involved the selection/enrichment 
of invasive glioma cell population from non-invasive parental cell population.  
Human GBMs xenografted subcutaneously are able to metastasize to the lung and 
liver (Huang et al., 1995). This observation alludes to the intrinsic metastatic potential 
of glioma cells. The experimental lung metastasis (ELM) assay can be used to enrich 






generally used to study the metastatic ability of cancer cells and involves the injection 
of cells into the tail-vein of immunodeficient mice. A small proportion of the injected 
cells are able to survive in circulation and over a period of time, are able to form lung 
metastases, from which the metastatic cell sub-population can be isolated. The ELM 
assay was first applied by Xie et al to enrich metastatic glioma cells from parental 
U87 cells (Xie et al., 2008).  The metastatic sub-population glioma cells displayed 
greater invasiveness and aggressive tumor growth upon orthotopic injection (Xie et 
al., 2008). Therefore in this study, to enrich highly invasive cells from U87 glioma cell 
line, an in vivo ELM assay was performed by injecting U87 cells through the tail vein 
and selecting metastatic cell populations from the lung, followed by expanding them 
in vitro (Clark et al., 2000; Xie et al., 2008). The strategy and time-lines of this assay 
are summarized in Figure 4.2A. Three independent ELM lines were established. The 
morphology of ELM derived cells was distinct from the parental U87 cells and 
exhibited different degrees of adherence to the culture dishes. In general, whereas 
parental U87 were spindle-shaped, ELM cells were flatter (Figure 4.2B). The 
established ELM cell lines were characterized for invasive properties and miRNA 







Figure 4.2 Selection of invasive glioma cells using experimental lung metastasis 
assay. A. Schematic of the ELM assay applied to enrich a population of highly invasive cells 
from U87 parental cells. Three independent ELM lines were established and named ELM 
1M1, ELM 1M2 and ELM 2M1. Details of this procedure are described in Materials and 
Methods section. B. Comparison of morphology of U87 cells and the ELM-derived cells ELM 
1M1, ELM 1M2 and ELM 2M1. miRNA editing and expression analysis was carried out. 
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Next, ELM cells were injected intracranially into nude mice brain to assess orthotopic 
tumor formation.  Histological analysis of tumors formed 21 days after glioma cell 
injection was done by H&E staining (Figure 4.3A). In agreement with previous studies, 
tumors formed by parental U87 cells appeared well-circumscribed, non-invasive and 
were confined near the injection site (Piao et al., 2009; Radaelli et al., 2009). In 
contrast, ELM 1M1 cells formed multiple tumors, including in the left hemisphere, 
despite single site of injection in the right striatum. ELM 2M1 cells formed large 
aggressive tumors which extended along multiple fronts to form highly non-uniform 
tumor mass with extensive vascularization (Figure 4.3A). At higher magnification, it 
was observed that the boundary of the U87 tumor was well-delineated from the 
normal brain tissue and lacked infiltrative projections (Figure 4.3B). On the other 
hand for ELM 1M1 cells, invasive cell foci were observable separate from the main 
tumor mass (black arrowheads, Figure 4.B). Necrosis and pseudopalisading glioma 
cells were present in ELM 2M1 tumors. This suggested that ELM-selected U87 cells 
are able to form more aggressive tumors with several features of GBMs such as 








Figure 4.3 In vivo tumor formation by U87 and ELM cells. H&E staining of tumors formed 
at day 21 after brain inoculation of U87 cells, ELM 1M1 and ELM 2M1. Cells were injected in 
the right striatum. A. Whole brain section showing aggressive tumor growth for ELM cells. 
Arrows indicate the tumor region after H&E staining. N: necrosis Scale bar = 2 mm. B.  H&E-
stained tumor sections shown at higher magnification, highlighting disseminated tumors 
(black arrowheads) for ELM 1M1  and pseudopalisading glioma cells at necrotic region for 




The cellular property selected for through the ELM assay is invasion, suggesting that 
the differences in orthotopic tumor formation between parental U87 and ELM cells 
could be due to changes to the invasive capacity of the tumor cells. Matrigel invasion 
assay was carried out to assess invasiveness of ELM cells in vitro.  Both ELM 1M1 
and 2M1 cells displayed a significantly greater invasive capacity compared to U87 
cells (Figure 4.4A). ELM 2M1 cells had a 2-fold greater (p=0.0002) invasive capacity 
and ELM 1M1 cells were 1.5-fold more invasive (p=0.0076) compared to parental 
U87 cells. Interestingly, the difference in degree of invasion between ELM 1M1 and 
ELM 2M1 cells was also significant (p=0.013).  
Additionally, wound healing scratch assay confirmed the highly migratory nature of 
ELM cells. Compared to U87 cells, both ELM 1M1 and ELM 2M1 migrated 
significantly faster, covering a greater distance of the wound gap in 24 hours 








more migratory than ELM 1M1 cells (p=0.004), paralleling the observations made in 



































































































Figure 4.4 Increased in vitro invasion and migration of ELM cells. A. Matrigel invasion assay of 
parental U87, ELM 1M1 and ELM 2M1 cells. Photomicrographs showing Calcein-AM labeled cells 
that invaded through matrigel-coated inserts. Graph shows the number of invading cells quantified 
by fluorescence relative to U87 cells. B. Wound healing assay showing increased migration ability 
of ELM 1M1 and 2M1 compared to parental U87 cells. Images were taken at indicated time-points 
and wound gap closure was assessed, for which representative images are shown. Graph shows 
the quantification of percentage wound gap closure (relative to t=0h) at end-point of observation. 





































Interestingly, in vitro proliferation rates of ELM cells in serum-containing media was 
several-fold lower than U87 cells (Figure 4.5), in agreement with the inverse 
correlation between glioma cell proliferation and motility (Giese et al., 2003; 
McDonough et al., 1998; Molina et al., 2010). Together the in vivo and in vitro 
assessment supports that ELM selection is effective in enriching glioma cells that are 
















Figure 4.5 Reduced in vitro proliferation rates of ELM cells. In vitro growth curves for 
parental U87 and ELM cells. For each cohort, number of cells in five wells was counted for 
7 days as indicated and plotted relative to cell number on day 0. Data are presented as 







4.3 Editing analysis of miR-376 cluster in ELM cells 
To investigate if extent of A-to-I editing of miRNAs from the miR-376 cluster, 
especially miR-376a*, correlate with tumor cell invasiveness, editing analysis of pri-
miRNAs from miR-376 cluster was performed for ELM-selected U87 cells.  By direct 
sequencing of pri-miRNAs it was determined that overall editing levels for all sites 
within miR-376 cluster in 3 ELM cell lines were similar to U87 cells (Figure 4.6A). 
Negligible ‘G’ trace at +9 site of pri-miR-376a1, confirmed that miR-376a* remained 
unedited in ELM cells, as in parental U87 cells. Similar ratio of ‘G’ peak heights to ‘A’ 
and ‘G’ peaks at editing sites were observed for all sites, the quantification for which 
is presented in Figure 4.6B. Furthermore, the mRNA levels of editing enzymes, 
ADAR1  and ADAR2,  in ELM cells did not differ significantly from that in U87 cells 
(Figure 4.6C), accounting for the lack of any significant changes to overall A-to-I 
editing in ELMs cells. Specifically, ADAR2 which is responsible for editing of +9 site 
of pri-miR-376a1, corresponding to miR-376a*, remained unchanged between U87 






































Frequency of Editing (%) 
Cell line 
 pri-miR-376a1 pri-miR-376a2 pri-miR-376b pri-miR-376c 
site +5 +9 
‡
 +49  +11  +15 +55 +67 +4 +48 
U87 1.61 3.6 4.69 11.23 14.62 75.74 52.61 0.96 42.69 
ELM 1M1 1.68 5.82 5.02 20.5 19.82 78.55 61.72 1.02 42.78 
ELM 1M2 2.11 3.89 7.02 14.91 13.89 69 55.75 3.95 30.69 





























Figure 4.6 Editing analysis of pri-miRNAs from miR-376 cluster in ELM cells. A. 
Chromatograms of direct sequencing of RT-PCR products from parental U87 and three ELM 
cell lines. All editing sites are highlighted by arrows. For each pri-miRNA, the 5’ end of stem-
loop sequence annotated in the Sanger miRBase site is counted as +1 and +9 site of pri-miR-
376a1 corresponding to miR-376a* is boxed. B. Quantification of editing frequencies of pri-
miRNAs. Editing frequency is calculated as the % ratio of ‘G’ peak over the sum of ‘A’ and ‘G’ 
peaks for the editing site.
 ‡
 Editing site corresponding to miR-376a* C. Relative mRNA levels 
of editing enzymes, ADAR1 and ADAR2, in parental U87 and ELM cells measured by qRT-







4.4 Unedited miR-376a* accumulates in invasive glioma cells 
Although editing levels were unchanged for miR-376 cluster in ELM cells, the 
expression of miRNAs from this cluster could potentially be related to the 
invasiveness of the cells. Therefore, the expression of pri-miRNAs and mature 
miRNAs from miR-376 cluster was measured in ELM cells to assess changes in 
transcript abundance. Transcripts corresponding to pri-miR-376a1, 376a2, 376b and 
376c were amplified by RT-PCR and expression was compared between parental 
U87 and ELM cells. All pri-miRNAs were moderately but not consistently increased in 
ELM cells (Figure 4.7A). Quantification of pri-miR-376a1 showed that it was 
increased 1.5 to 1.8-fold in ELM cells and the other pri-miRNAs were variably 
increased between 1.5 to 4-fold (Figure 4.7B). 
Significantly, when mature miRNA levels were quantified by qRT-PCR, miR-376a* 
was found to be enriched 7-fold in ELM 1M1 and 1M2 cells and was increased 75-
fold in ELM 2M1 cells (Figure 4.7C). Surprisingly, none of the other mature miRNAs 
from miR-376 cluster, which are co-transcribed with miR-376a*, were significantly 
enriched in ELM cells (Figure 4.7C). Furthermore, the fold-increase of miR-376a* 
correlated with the increase in invasion and migration capacity of ELM 1M1 and 1M2 
cells, determined earlier (Figure 4.4). Also, the relative expression of selected 
miRNAs from chromosome 14q32.31 miRNA locus (where miR-376 cluster lies), 
those ubiquitously expressed (miR-16) and those with known functions in gliomas 
(miR-21, miR-221, miR-10b, miR-206), did not show significant changes in ELM cells 
(Figure 4.7C). Given that editing of miR-376a* does not change in ELM cells and it 
remains unedited, the miRNA expression data indicates that it is the unedited miR-
376a* that is significantly increased in ELM cells. Collectively, this study suggests a 
mechanism for highly specific enrichment of unedited miR-376a* in invasive glioma 

























































































































Figure 4.7 Expression of miR-376 cluster members in ELM cells. A. RT-PCR analysis 
of transcripts corresponding to indicated primary miRNAs from miR-376 cluster in U87 and 
ELM cells. B. Semi-quantitative expression analysis of RT-PCR products of pri-miRNAs 
from A.. Densitometric analysis was done using ImageJ and values were normalized to 18S 
rRNA.C. Relative abundance of various mature miRNAs in U87 and ELM cells measured 
by qRT-PCR. miR-376a*, 376a, 376b, 376c and 376a2-5p are from miR-376 cluster. miR-
127, 154, 432, 654 are from chromosome 14q32.31 miRNA cluster- the larger cluster of 
miRNAs including miR-376 sub-cluster. miR-16 is ubiquitously expressed in several cell 
types. miR-21, 221, 10b, 206 are implicated in gliomas. Expression was normalized to 5S 
rRNA. Data represents mean ± SD. **p<0.01 by t-test for ELM 1M1, 1M2 vs. U87 and 







It was surprising to note that among mature miR-376 miRNAs, only miR-376a* was 
specifically up-regulated, especially considering that miR-376a is processed from the 
same pri-miRNA as miR-376a*(pri-miR-376a1) and together they constitute a mature 
miRNA duplex. As such, it is expected that miR-376a would be similarly affected by 
regulatory processes affecting miR-376a*. In U87 cells, the absolute abundance of 
miR-376a is several-fold higher than that of miR-376a* as evidenced by its 
significantly lower threshold detection cycle (Ct) during qRT-PCR compared to Ct of 
miR-376a* (Figure 4.8).  A more negative delta Ct indicates lower miRNA abundance. 
During selection of ELM cells, delta Ct of miR-376a* becomes less negative (as it 
becomes more abundant) but that of miR-376a remains unchanged. The relative 
ratios of miR-376a* to miR-376a increases in ELM cells as the difference in their 
delta Cts becomes smaller (Figure 4.8), approaching that of normal astrocytes which 
have the highest expression of both miRNAs and also nearly similar expression 
levels of miR-376a* and miR-376a (although miR-376a* is nearly 100% edited in 
normal astrocytes). As miR-376a* and miR-376a are processed from the same 
precursor and the expression of pri-miR-376a1 is changed only 1-5-1.8-fold in ELM 
cells, this suggests that the miR-376a* expression increases in ELM cells due to 
increased stability of the mature miRNA, while there is no change in stability of miR-
376a strand. Together, this suggests a highly-specific stabilizing mechanism for 
enrichment of miR-376a* during the selection of ELM cells, independent of 
transcription of the long miR-376 cluster or its own primary transcript, pri-miR-376a1. 
Cumulatively, editing and expression analyses show that abundance of unedited 
miR-376a* is increased in invasive ELM cells. Although by a distinct mechanism, this 
increase in unedited miR-376a* expression parallels the accumulation of unedited 


















































Figure 4.8 Relative abundance of mature miR-376a and miR-376a* in normal and glioma 
cells. qRT-PCR quantification of miRNAs in  U87 and ELM cells. Delta Ct represents the 
difference between the threshold detection cycle (Ct) of 5S rRNA (endogenous normalization 
control) and Ct of miRNA. A less negative delta Ct value indicates higher abundance. All 
miRNAs are expressed at lower abundance than 5S rRNA. The accumulation of miR-376a* in 
ELM cells is indicated by the increasing delta Ct values. There is no change in the abundance 
of miR-376a in ELM cells compared to parental U87 cells. Normal astrocytes (NAA) have 
higher delta Ct for both miR-376a* and miR-376a and also the most similar expression for the 







4.5 Unedited miR-376a* promotes glioma cell invasion and 
migration in vitro 
 
The specific accumulation of unedited miR-376a* in high-grade invasive GBMs and 
in selected invasive glioma cells, suggested that this miRNA may modulate the 
invasive behaviour of glioma cells. As glioma cell lines have low endogenous levels 
of either variant of miR-376a*, ectopic expression of miRNAs in glioma cells was first 
employed to study its cellular effects. The pri-miR-376a1 encodes two mature 
miRNAs: miR-376a* and miR-376a (Figure 4.9A). Although both undergo editing in 
the brain, editing of miR-376a is negligibly altered in GBMs and thus unlikely to be of 
functional significance in this context. To delineate the function of miR-376a* in 
GBMs, the native precursor-based expression could not be used as both mature 
miRNAs would be processed from this precursor.  
Hence, synthesized miRNA mimics were employed. In the miR-376a* mimic duplex, 
the passenger strand is not equivalent to miR-376a and will not act as miR-376a. 
Cellularly, editing of miR-376a* substitutes a single adenosine (A) for inosine (I), and 
previous works have shown equivalency of inosine and guanosine (G) in preferential 
base-pairing with cytosine (Borchert et al., 2009; Maas, 2010). Mimics for miR-376a* 
in the unedited form, hereafter “miR-376a*A”, and in edited forms, hereafter “miR-
376a*G” and “miR-376a*I” were designed (Figure 4.9B). For stable expression of 
miR-376a*, a stem-loop construct was engineered such that the passenger strand of 
the processed duplex is not equivalent to miR-376a, and was incorporated 
downstream of EGFP reporter which is polycistronally expressed (Figure 4.9C). In 
this construct, at the appropriate position “A” or “G” was substituted so that the 
processed mature miRNA is miR-376a*A or miR-376a*G, respectively.  As it is not 
possible to encode the incorporation of inosine in DNA, for stable expression of 






i.e. miR-376a*G using plasmid-based expression. For overexpression experiments, a 
miRNA mimic corresponding to C. elegans miRNA, cel-miR-293b was used as a 
control. The corresponding control mature miRNA sequence was incorporated into 
the stem-loop construct described in Figure 4.9C for stable expression of control 
miRNA.  Expression of miR-376a* in glioma cells by miRNA mimics and in cells 




































































































Figure 4.9 Strategy for ectopic expression of miR-376a*. A. Schematic diagram of stem-loop 
of precursor-miR-376a1. miR-376a* is highlighted in black bold and the site undergoing A-to-I 
editing is indicated by red arrow. miR-376a is highlighted in blue. B. Three versions of miR-
376a* miRNA mimics used in subsequent experiments are indicated with A, G or I at the site of 
editing. C. Schematic of design of stem-loop constructs for stable expression of 376a*A, miR-
376a*G and miR-control (cel-miR-293b). The position of mature miRNA in the engineered 
precursor is shown in red. For prmiR-376a* the opposing precursor arm does not encode miR-
376a. Constructs were used to generate U87 cells stably expressing miR-376a* or control 
mIRNA. D. Confirmation of expression of miR-376a*A or miR-376a*G in U87 cells transiently 
transfected with 10 nM miRNA mimics. Measurement was done by qRT-PCR using forward 
primers corresponding to A- or G- version of miR-376a*. Results are displayed on the same 
scale for miR-376a*A and miR-376a*G. U87 cells transfected with control miRNA serve as 
baseline of expression of miR-376a*. E. Expression of miR-376a*A or miR-376a*G in stably 
transfected U87 cell lines. Values are relative to miRNA expression in U87 cells stably 
transfected with control miRNA. For D. and E. expression was normalized to 5S rRNA. Data 







Upon transfection of different forms of miR-376a*, dramatic and distinct 
morphological changes in U87 and SW1783 glioma cells were observed. miR-
376a*A caused cells to adopt a flatter morphology with a highly organized actin 
cytoskeleton, visualized by actin-FITC immunostaining (Figure 4.10A). In contrast, 
both miR-376a*G and miR-376a*I caused cells to become more spindle-shaped, 
retract membrane projections and lose actin cytoskeleton organization (Figure 4.10A). 
In terms of cell morphology, miR-376a*G and miR-376a*I were indistinguishable 
(Figure 4.10A). These changes were highly specific to the properties of miR-376a*A 
and miR-376a*G and not due to the mere presence of ‘G’ or ‘I’ in the seed sequence 
as other miRNAs, miR-376a and miR-376a2-5p which also undergo seed sequence 
editing, did not induce distinct morphological changes when transfected in U87 cells 
as unedited (with ‘A’ in seed sequence) or edited (with ‘G’ in seed sequence) 
miRNAs (Figure 4.10B). Flow cytometry was used to confirm these morphological 
changes in six glioma cell lines, as from the side-scatter profile of cells, changes to 
intracellular density and complexity (a measure of cytoskeletal organization) can be 
measured. The forward-scatter profile in flow cytometry indicates the size or volume 
of cells. Compared to control- transfected cells, an increase in side-scatter 
distribution was consistently seen for all miR-376a*A-transfected glioma cells 
whereas a decrease in side-scatter was seen for miR-376a*G-transfected cells, while 
the forward-scatter profiles remained unchanged (Figure 4.11). This shows that the 
morphological phenotypes induced by miR-376a*A and miR-376a*G are not 
restricted to U87 or SW1783 cells but are reproducible in a larger panel of glioma cell 


































Figure 4.10 Morphological changes induced by miR-376a*. A. Morphology of U87 and 
SW1783 glioma cells transiently transfected with miRNA mimics corresponding to miR-
376a*A/G/I or control miRNA. Actin-FITC labeling highlights the organized actin cytoskeleton 
in miR-376a*A transfected cells. Loss of cytoskeletal organization is observed in both miR-
376a*G and miR-376a*I transfected cells. Scale bar = 60 µm. B. Morphology of U87 cells 
transfected with miR-376a or miR-376a2-5p with ‘A’ or ‘G’ in seed sequence, the unedited 

































  Figure 4.11 Characterization of morphology of transfected glioma cells by flow 
cytometry. Side scatter and forward scatter data was collected for six glioma cell lines. Note 
the opposite shifts in side scatter profiles for cells transfected with miR-376a*A and miR-
376a*G. Side scatter is proportional to intracellular complexity and granularity while forward 
























Changes in cell morphology and actin cytoskeleton organization are well-
documented to be intimately linked with migration of glioma cells (Bigarella et al., 
2009; Chan et al., 2005a; Chandrasekar et al., 2003; Chintala et al., 1999). As 
migration is a prerequisite for cancer cell invasion, a matrigel invasion assay was 
used to assess the invasiveness of glioma cells ectopically expressing miR-376a*. 
Transient or stable ectopic expression of miR-376a*A significantly enhanced the 
invasiveness of three glioma cell lines by 1.5-1.8-fold (Figure 4.12). In contrast, under 
the same experimental conditions, miR-376a*G suppressed glioma cell invasion to 
























































Figure 4.12 Modulation of glioma cell invasion by miR-376a*. Matrigel invasion assay of 
glioma cells transfected with miR-376a* or control miRNA. U87, SW1783 and A172 cells 
were transiently transfected with miRNA mimics. U87 stable cells represent U87 cells that 
stably express miR-376a*A or miR-376a*G. Number of seeded cells that invaded the 
matrigel were quantified by measurement of fluorescence of labeled cells. Values are 
normalized to control for each cell line. Data are presented as mean ± SD. *p<0.05, 






Wound-healing assay was carried out to assess the effect of miR-376a* on cell 
migration. Similar to changes in the invasive capacity, miR-376a*A promoted the 
migration of glioma cells whereas miR-376a*G potently suppressed the ability to 

























Figure 4.13 Modulation of glioma cell migration by miR-376a*. Wound-healing assay of 
glioma cells expressing miR-376a*. U87, SW1783 and A172 cells were transiently 
transfected with miRNA mimics. U87 stable cells represent U87 cells that stably express 
miR-376a*A or miR-376a*G. Scratches were made to confluent monolayers of transfected 
cells and photographs taken at indicated time-points. Graph shows the relative percentage 
wound gap closure (relative to t=0h) at end-point of observation. Data are presented as 
mean ± SD. *p<0.05, **p<0.01by t-test relative to control. 
 













































Additionally, when miR-376a*A was  specifically knocked down in ELM 2M1 cells 
(which have the highest expression of miR-376a* among glioma cell lines) by 
transfecting lock-nucleic acid (LNA)-modified oligonucleotides against miR-376a*A 
(LNA-376a*A), their ability to migrate in a wound-healing assay was significantly 
abrogated, reversing their inherent highly migratory phenotype (Figure 4.14). This 
effect was confirmed to be not non-specific due to the introduction of LNA oligos, as 
LNA-376a*A did not affect motility of U87 cells, which have negligible expression of 
miR-376a* (Figure 4.14). Thus, the over-expression and knockdown experiments 

























































Figure 4.14 Knockdown of miR-376a*A suppresses migration of ELM cells. Wound 
healing migration assay of ELM 2M1 and U87 cells after LNA-mediated knockdown of miR-
376a*A. scr, scrambled control. Graph shows the relative % wound gap coverage. Data are 







4.6 Effects of miR-376a* on cell proliferation 
The effects of miR-376a* on cell proliferation were investigated in order to assess if 
changes in proliferation contribute to the increased migration and invasion of glioma 
cells. By BrdU incorporation assay it was determined that miR-376a*A in fact 
suppressed proliferation rates of U87 and A172 glioma cells, while miR-376a*G 
exerted the opposite effect (Figure 4.15A), limiting the possibility that the observed 
increase or decrease in invasion or migration was due to a similar change in cell 
proliferation. Cell cycle analysis supported these effects on proliferation as miR-
376a*A caused an accumulation of cells in the G1-phase of cell cycle, while miR-
376a*G exerted the opposite effect on proliferation and caused a shift towards S and 
G2/M phases, suggestive of hastened cell cycle progression (Figure 4.15B). 
Collectively, these results suggest that miR-376a*A and 376a*G have distinct and 
opposing functions in glioma cells. Significantly, introduction of miR-376a*A in glioma 
cells, recapitulating the presence of unedited miR-376a* in GBMs, is able to promote 


























































































































Figure 4.15 Effects of miR-376a* on cell proliferation. A. Measurement of cell proliferation 
of transiently transfected U87 and A172 glioma cells, using the BrdU incorporation assay.  
BrdU incorporation was measured at indicated time-points after transfection and five wells 
were used for each group. miR-376a*A decreases proliferation based on decreased BrdU 
incorporation (at 48 and 72 h), while miR-376a*G promotes proliferation (at 48 h). Data is 
shown relative to control cells at each time point and represents mean ± SD. **p<0.01 and 
***p<0.001 by t-test relative to control. B. Flow cytometry of propidium iodide-stained cells to 
assess cell cycle distribution of transfected U87, SW1783 and A172 glioma cells. While miR-
376a*A causes an increase in cells in G1 phase, miR-376a*G results in an increase in cells in 






4.7 Overexpression of unedited miR-376a* promotes 
aggressive growth of orthotopic gliomas 
Having established that in vitro migration and invasion is regulated by miR-376a*, the 
potential for in vivo modulation of tumor growth by miR-376a* was investigated next. 
For this purpose, the orthotopic U87 cell glioma mouse model was employed as 
these cells are tumorigenic but non-invasive in the brain and would help address if 
unedited miR-376a* promotes tumor aggressiveness. U87 cells stably expressing 
miR-376a*A, hereafter U87/376a*A, or miR-376a*G, hereafter U87/376a*G or control 
miRNA were injected into the brains of nude mice. Measurement of in vitro 
proliferation rates of stable cell lines confirmed that U87/376a*A cells grew slower in 
vitro than control cells, while U87/376a*G cells were more proliferative similar to 
observations made for transiently transfected glioma cells (Figure 4.16A). At day 21 
after tumor inoculation, brains were collected and sectioned for histological 
analysis.The formation of tumors U87/376a*A and U87/376a*G and the expression of 
miRNAs at this time-point was confirmed by fluorescent imaging of sections which 






































































Figure 4.16 In vitro and in vivo growth of U87 cells expressing miR-376a*. A. In vitro 
growth curves of U87 cells stably transfected with miR-376a*A, miR-376a*G or control 
miRNA. Growth curves in red correspond to U87/376a*A stable clones, those in blue are for 
U87/376a*G stable clones and growth curve in black is for control U87 cells. For each cohort, 
number of cells in five wells was counted for 7 days as indicated and plotted relative to cell 
number on day 0. Data represents mean ± SD. ***p<0.001 by t-test compared to control U87 
cells. B. Representative fluorescent images of sections from U87/376a*A or U87/376a*G 
tumors showing EGFP from EGFP-miRNA polycistronic expression cassette detectable at 






Histological analysis of the tumors formed at day 21 after injection of U87/376a*A or 
U87/376a*G cells was done by H&E staining. U87/376a*A cells caused the formation 
of large aggressive tumors of irregular shape, with extensive intratumoral necrosis 
(Figure 4.17A(i)). In contrast, tumors formed by U87/376a*G cells were highly 
uniform and well-circumscribed, characteristic of expansile growth of non-invasive 
tumors like U87 tumors (Radaelli et al., 2009). Boundaries of U87/376a*A tumors 
were marked by infiltrative projections associated with vascular structures and 
satellite tumors, while U87/376a*G tumors were well-delineated from the normal 
brain (Figure 4.17A(ii)). 
U87/376a*A tumors stained for Ki-67 proliferation marker showed high but non-
uniform distribution of Ki-67+ cells which especially colonized regions around blood 
vessels (Figure 4.17A(iii)), indicating perivascular invasion (Winkler et al., 2009). A 
roughly two-fold enrichment of Ki-67 signal at the invasion fronts of U87/376a*A 
tumors in relation to the core was noted, while U87 and U87/376a*G tumors showed 
uniform distribution of Ki-67+ cells consistent with expansile growth (Figure 4.17B). 
As the in vitro proliferation rates of all stable cell lines were similar (Figure 4.16A),   
the aggressive tumor growth caused by U87/376a*A cells was not due to higher 
intrinsic proliferation, necessitating the involvement of the microenvironment such as 
angiogenesis for supporting this growth. In line with the ability of invasive glioma cells 
to induce vascular remodeling and angiogenesis (Nowacki and Kojder, 2001; 
Vajkoczy et al., 1999; Winkler et al., 2009), staining for von Willebrand factor (vWF), 
an angiogenesis marker, revealed the presence of abundant blood vessels in and 















































Figure 4.17 Histological and immunostaining analysis of orthotopic tumors formed on 
day 21 after injection of stably transfected U87 cells – U87/376a*A and U87/376a*G. A. (i) 
H&E staining of tumor sections. Three individual stable cell lines were injected for each 
miRNA; representative images from two are shown. Arrows indicate tumors after H&E 
staining; N: necrosis in U87/376a*A #D5. (ii) H&E staining showing tumor boundaries at 
higher magnification. Black arrowheads indicate peritumoral vascular structures (capillaries 
and blood vessels) (# D5) and disseminated tumors in the brain adjacent to the invading 
edge of tumor (# D3) for U87/376a*A tumors. Scale bar: 200 μm. (iii) Immunostaining of 
tumor sections for Ki-67. BV: blood vessel. Scale bar: 100 μm. (iv) Immunostaining of 
tumor sections for vWF. Distinct vascular structures are observed for U87/miR-376a*A. 
Using similar detection methods no staining for vWF was observed in U87/miR-376a*G. 
Scale bar: 100 μm. B. Fluorescent detection of Ki-67 in tumor sections. Scale bar: 200 μm. 
Right: Quantification of fluorescent Ki-67 signals using ImageJ. Bar graphs show relative 
Ki-67 signals at tumor edge (invasive front) and core. Data represents mean ± SD. **p<0.01 
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Conclusive evidence of the ability of miR-376a*A to promote aggressive tumor 
growth came from the survival rates of mice bearing tumors formed by U87 cells with 
higher expression of miR-376a*A. Indeed, both U87/376a*A and U87/ELM cells, with 
enrichment of miR-376a*A, caused a significantly shortened survival time of animals 
compared to control U87 cells (Figure 4.18A). Importantly, as invasiveness was the 
only property selected for by the ELM assay, the observed differences in survival are 
chiefly attributable to enhanced tumor burden through invasive dissemination of 
tumor cells. Furthermore, there was an inverse correlation between the fold-
enrichment of miR-376a*A in ELM cells and survival rates of tumor-bearing mice. 
ELM 2M1 with a 75-fold increase in miR-376a*A, had a median survival time of 21 
days, whereas ELM 1M1 with a 7-fold increase, had a significantly higher median 
survival time of 28 days (p=0.8E6), although survival times for both ELM 1M1 and 
ELM 2M1 were shorter than the control group (Figure 4.18B). Although, miR-376a*G 
suppresses cell invasion in vitro, tumors formed in vivo by U87/376a*G and the 
associated survival rates were similar to control tumors (Figure 4.18), probably due to 






























Figure 4.18 Survival of tumor-bearing mice in orthotopic glioma model. A. Kaplan-
Meier survival analysis after intracranial implantation of various glioma cell lines. Cells stably 
expressing miR-376a* are U87/376a*A #D5, and U87/376a*G #2A2. ELM 1M1 and ELM 
2M1 cells were enriched from U87 cells by ELM assay. B. Median survival of animals 
receiving intracranial injection of glioma cells in A.. Statistical analysis was done using log-
rank test (n = 10). Error bars represent SE. ***p<0.001 and **p<0.01 vs. U87/control, 




























































Days after tumor inoculation

























qRT-PCR analysis of tumor samples collected from mouse brain was carried out to 
quantify expression of factors known to be involved in glioma growth and 
invasiveness. RNA was extracted from tumor sections for analysis. Components of 
growth factor signalling pathways, PDGF, VEGF, TGFB and their receptors were 
found to be enriched (5- to 45-fold) in U87/376a*A tumors (Figure 4.19A), together 
with mRNAs of several glioma invasion-promoting factors, which were expressed 5- 
to 20-fold higher (Figure 4.19B). For example, VEGF is a pro-angiogenic factor in 
gliomas and was increased nearly 25-fold in U87/376a*A tumors. MMP2, a protease 
that is involved in the degradation of ECM, is expressed only in GBMs and is absent 
in grade III astrocytomas (Du et al., 2008) was 2.5-fold enriched in U87/376a*A 
tumors (Figure 4.20B). Other factors that were expressed at higher levels in 
U87/376a*A tumors included integrins (ITGB3), ECM proteins (TNXB, FN1), 
















































Collectively, these results show that expression of miR-376a*A (unedited miR-376a*) 
in otherwise non-invasive U87 cells promotes aggressive tumor growth characterized 
by invasion, angiogenesis and necrosis, hallmarks of human GBMs. Coincident with 
the aggregation of unedited miR-376a* in GBMs, the data supports a major pro-
invasive role for this miRNA in GBMs. 
Figure 4.19 Quantification of factors involved in glioma invasion and angiogenesis in 
orthotopic tumors. qRT-PCR measurement of A. components of upstream growth factor 
signaling pathways and B. factors promoting glioma cell invasion and angiogenesis. RNA 
was isolated from tumors formed in vivo. 18S rRNA was used for normalization. Data 













































































































































































In the previous chapter, it was established that due to loss of A-to-I editing, unedited 
miR-376a* accumulates in GBMs. Changes in transcript editing levels due to ADAR 
dysfunction most likely play a role in progression rather than initiation of malignant 
growth (Farajollahi and Maas, 2010). As increased aggressivesenes due to invasion 
and angiogenesis distinguish GBMs from grade III gliomas (Louis, 2006), the impact 
of aberrant accumulation of unedited miR-376a* with respect to the malignant 
property of invasion was investigated. In vivo and in vitro analysis showed that 
unedited miR-376a*, the aberrant tumor-specific variant promotes migration and 
invasion, in stark contrast to the normal ‘edited’ variant that suppresses these 
features. 
A role for unedited miR-376a* in malignant progression was supported by its specific 
enrichment in selected invasive U87 cells (ELM cells), as in GBMs. Undoubtedly, 
during the selection of ELM cells in vivo, several factors that collectively aid survival 
and metastatic colonization of glioma cells would accumulate, deriving from a sub-
population of surviving cells with the relevant intrinsic properties that aid such 
behavior in vivo. As such, miR-376a* represents only one of many contributing 
factors to the phenotypic differences between ELM and parental U87 cells. 
Nonetheless, the specific knockdown of miR-376a* in ELM cells was able to inhibit 
their migratory capacity, suggesting among other factors, miR-376a* may play a 
central role in glioma cell migration.  
The miR-376 cluster encodes four primary miRNAs that are polycistronically 
transcribed and generate five mature miRNAs (Kawahara et al., 2007b). In ELM cells, 
although expression was increased marginally for all primary miRNAs, mature miR-
376a* accumulated disparately more. Mechanistically, this specific accumulation is 
likely due to a post-transcriptional selective bias for miR-376a*.  It has been 






could possibly account for disparity in abundance of mature miR-376a* and miR-
376a (Siomi and Siomi, 2010). Additionally, miRNA degradation and stability are also 
subject to individual control by the target mRNAs themselves and other factors that 
recognize specific sequence elements of the miRNA. The observation that even in 
different tissues the ratio of miRNA/miRNA* strands are widely different is in line with 
the presence of factors that regulate individual miRNA strand stability and hence 
function (Hu et al., 2009). Importantly, the studies in ELM cells showed that by 
completely independent means, the abundance of unedited miR-376a* increased in 
selected invasive gliomas. In GBMs, a parallel increase in unedited miR-376a* also 
occurs but is mediated by the loss of A-to-I editing, while transcription rates remained 
unaffected. The convergence of independent study systems on the same 
phenomenon of increased abundance of unedited miR-376a* points to a crucial role 
of this miRNA in invasiveness. 
Using synthetic mimics and engineered pre-miRNAs the function of miR-376a* in 
glioma cells was dissected independent from that of miR-376a, which is naturally 
encoded in pri-miR-376a1. Because of the tumor-type dependent and extensive 
reduction in editing of miR-376a*, its function is likely to be most impacted due to 
altered editing and hence this was the primary subject of investigation. Nonetheless, 
it cannot be ruled out that miR-376a and miR-376a* or other miRNAs from the cluster 
at their respective editing frequencies have a combinatorial role in glioma 
pathogenesis. 
Ectopic expression of miR-376a*A (unedited) and miR-376a*G (edited) produced 
obvious but distinct morphological changes which correlated with the in vitro 
migration and invasion ability of glioma cells. miR-376a*A promoted motility and 
invasion of glioma cells while miR-376a*G suppressed these to below basal levels. 
The polarizing effects of the two forms of miR-376a* on glioma cell migration was 






sufficient to reverse certain functions of miRNAs. The role of edited miR-376a* will 
need to be more thoroughly investigated in the context of normal cells where it is 
normally expressed. 
The pro-migratory and pro-invasive phenotype induced by miR-376a*A was 
reproducible in vivo. In contrast to tumors typically produced by orthotopic 
implantation of U87 glioma cells, the U87/376a*A-expressing tumors bore a far 
greater resemblance to human malignant gliomas with central necrosis and viable 
tumor rim (Giese et al., 2003). Also, the distribution of proliferating Ki-67+ cells in 
miR-376a*A-expressing tumors coincided with characteristics of invasive tumor 
growth (Ma et al., 2007; Nilsson et al., 2004; Silber et al., 2009). Higher degree of 
vascularization was concomitantly observed in these tumors, which was attributed to 
the ability of invasive glioma cells to induce vascular remodeling and angiogenesis 
for gaining further invasive advantage traversing perivascular spaces (Louis, 2006; 
Nowacki and Kojder, 2001; Vajkoczy et al., 1999; Winkler et al., 2009). The 
peritumoral angiogenesis observed in these tumors likely supports both invasive 
spread and the main tumor growth resulting in the larger main tumor mass formed by 
the more invasive U87/376*A cells (Winkler et al., 2009). Additionally, several 
cytokines and growth factors that are known to promote both migration and 
angiogenesis, e.g. PDGF, VEGF, TGFβ were upregulated in U87/376a*A tumors 
(Louis, 2006). On the other hand, U87/376a*G and control tumors lacking population 
of invasive cells were unable to remodel the brain vasculature for a growth 
advantage and remained confined within well-delineated boundaries. The shortened 
survival of mice bearing the aggressive tumors is reminiscent of the unfavorable 
prognosis faced by GBM patients. A correlative analysis between editing frequency 
of miR-376a* and survival of patients from a large cohort, will provide conclusive 






Besides increased invasiveness, a common thread that emerged between ELM cells 
and glioma cells overexpressing miR-376a*A was their suppressed proliferation rate. 
This is in agreement with previous findings that in glioma cells, positive modulators of 
migration (miR-376a*A in this thesis) usually inhibit proliferation, and inhibition of 
migration (as by miR-376a*G) promotes cell proliferation (Godlewski et al., 2010; 
Lipinski et al., 2005). Among miRNAs, miR-451 in GBMs is known to promote cell 
proliferation while suppressing cell migration and serves as a switch to balance 
proliferation and migration in response to metabolic stress (Godlewski et al., 2010). 
The inverse relation between cell migration and proliferation falls under the 
hypothesis of “go or grow” that proposes that cell division and cell migration are 
temporally exclusive events that dictates that proliferating cells cannot migrate and 
vice-versa (Lipinski et al., 2005). However, the distinction between proliferation and 
invasion is not clear in vivo as depending on the anatomic sites, invasive cells in 
human gliomas showed higher or lower proliferation rates (Giese et al., 2003). 
Evidently, invasive glioma cells also retain the property of proliferation but have 
temporarily lowered proliferation rate during migration, as they can reestablish 
recurrent tumor masses (Giese et al., 2003). In addition to the ability of invasive 
glioma cells to remodel the vasculature, the end-point of tumor formation by invasive 
glioma cells is the greater overall aggressiveness of tumors formed, as observed with 
both ELM cells and U87/376a*A cells. 
Although miR-376a* is expressed in primary gliomas, glioma cell lines examined here 
had low endogenous levels of miRNAs from miR-376 cluster. The differences 
between serum-cultured glioma cells and primary gliomas are well-documented, 
especially the inability of cultured cells to form invasive orthotopic tumors when 
xenografted (Lee et al., 2006). It is speculated that during long-term culture, loss of 
expression of miR-376 cluster occurs due to in vitro selection pressure conferring  a 






observations that unedited miR-376a* is expressed in GBMs and has anti-
proliferative effect on glioma cells, a property that is likely diluted during long-term 
culture. Furthermore, from the results obtained in this study it can be speculated that 
the low levels of unedited miR-376a* is one of the contributing factors for the non-
invasive nature of glioma cells cultured in vitro, as by introducing unedited miR-376a* 
the invasiveness of glioma cells was enhanced. 
Significantly, a role for miR-376a* in invasion promotion in GBMs or any other cancer 
has previously explicitly not been demonstrated. However, using a non-conventional 
approach to study the role of miRNAs in tumorigenesis,  a recent in vitro study 
showed that the expression of precursor miR-376a (pre-miRNA, encoding both miR-
376a and miR-376a*) or the whole miR-376 cluster promoted the migration and 
invasion of otherwise non-migratory tumor cells derived from in vitro transformation of 
non-human primate kidney cells (Teferedegne et al., 2010).  In this study, increased 
expression of miR-376a coincided with the acquisition of invasiveness during the 
process of spontaneous in vitro transformation of cells, although it was not made 
clear if levels of miR-376a* was measured. It would be interesting to delineate if 
unedited miR-376a* from the pre-miR-376a is responsible for the enhanced 
migratory phenotype. It has been reported that in GBMs, glutamate receptors 
assembled from the unedited (Q-containing) GluR-B subunit, are highly Ca2+-
permeable and expression of this form of the receptor can promote glioma cell 
invasion (Ishiuchi et al., 2002), suggesting a general role of unedited substrates in 
promoting invasiveness. No other target of A-to-I editing (mRNA or miRNA) has been 
functionally characterized in gliomas. 
Other miRNAs from miR-376 cluster have previously been implicated in various 
cancers, including miR-376c which promotes ovarian cancer cell survival (Ye et al., 
2011) and is also overexpressed in a subset of acute myeloid leukemia (Dixon-






cancer cells (Lee et al., 2007b) and it also negatively regulates erythroid 
differentiation (Wang et al., 2011). ADAR1 and ADAR2 expression has been 
detected in mouse pancreatic islets and ß-cells, where ADAR2 expression was 
regulated under conditions of metabolic stress in vivo together with 100% editing at 
the Q/R site of GluR-B RNA (Gan et al., 2006). As the editing machinery is 
expressed in other cell types with nearly ubiquitous expression of miRNAs from miR-
376 cluster in various tissues (kidney, bone marrow, pancreas) the occurrence and 
consequence of normal and abnormal editing of these miRNAs in other cell types 
represents an avenue worth investigating. 
Finally, a recent study on GBM subclasses and miRNA expression, identified miR-
376a and 376a* to be associated with ‘neural’ subtype of GBMs (Kim et al., 2011). 
This subtype has significantly shorter survival compared to those with ‘oligoneural’ 
classification, which coincides with the ‘proneural’ classification based on mRNA 
expression (Phillips et al., 2006; Verhaak et al., 2010). Interestingly, the proneural 
classification also encompasses most grade III gliomas. Considering that miR-376a* 
is unedited specifically in GBMs and not in grade III gliomas, the association of miR-
376a* with a subtype of GBMs with poorer prognosis, coincides with the poorer 
prognosis of GBM patients compared to patients with grade III gliomas. Therefore, 
several lines of evidence presented in this chapter, including the specific 
accumulation of unedited miR-376a* in selected invasive cells leads to the 
conclusion that the aberrant accumulation of unedited miR-376a* in GBMs due to 
attenuated A-to-I editing has functional consequences related to GBM malignancy. 
Thus, unedited miR-376a* is a GBM-specific functional miRNA sequence variant that 







5 CHAPTER 5. Genome-wide transcriptional changes 
by unedited and edited miR-376a* in cancer-related 
pathways 
5.1 Introduction and aims 
As unedited and edited miR-376a* differ only by a single base, their opposing 
morphological and migratory effects in glioma cells were particularly striking. To 
investigate their cellular effects in a broader context, a study of genome-wide 
transcriptional effects was undertaken. miRNAs can establish and maintain 
transcriptional networks that are highly informative of their cellular function (Lim et al., 
2005). Genome-wide analysis is typically performed using microarrays to understand 
global effects of miRNA function in an environment or cellular context in which the 
miRNA and its targets are expressed (Li et al., 2009; Sarver et al., 2010; Wei et al., 
2008). Overexpression or knockdown of a particular miRNA will respectively 
exaggerate or relieve the regulation of its direct target genes and associated 
downstream effectors, translating to a global perturbation of relevant components of 
the cellular transcriptome constituting networks or pathways. These networks or 
pathways can be gleaned using genome-wide transcriptional analysis. Thus, in this 
chapter, the aim was to identify genome-wide changes effected by miR-376a* in 
edited and unedited forms using microarray analysis. 
5.2 Distinct global gene expression profiles regulated by 
edited and unedited miR-376a* in cancer cells 
The overexpression strategy was used to investigate the genome-wide expression 
profiles of miR-376a*. U87 glioma cells were used as these cells have low level of 
expression of both forms of miR-376a* and provide the appropriate cellular context 
for study, as they are derived from GBMs and harbour a glioma-relevant 






376a*G) were transfected into U87 glioma cells.Transfection was carried out for 72 
hours, to allow transcriptional changes to accumulate, as these would be more 
informative from a global perspective and more representative of the cellular 
transcriptome maintained by miRNA in their natural context. Using Affymetrix 
microarrays, genome-wide transcriptional changes in U87 cells transfected with miR-
376a*A or miR-376a*G compared to control miRNA were identified.  
In line with broad regulatory functions of miRNAs, expression of several transcript 
probesets were found to be substantially changed when miR-376a*A or miR-376*G 
was introduced in U87 cells. A fold-change of 2-fold, statistical significance of p< 0.05, 
and Benjamini-Hochberg multiple testing correction was imposed to identify the most 
significantly affected transcripts. Differentially expressed probesets corresponded to 
the following number of differentially expressed genes:  for miR-376a*A- 686 up-
regulated and 894 down-regulated, and for miR-376a*G-1220 up-regulated and 1237 
down-regulated genes. The range of differential expression was very wide for both 
miR-376a*A and miR-376a*G, and reached up to 40 to 50-fold differential expression 
for some transcripts. When the differentially expressed genes (compared to control 
miRNA) were clustered by unsupervised hierarchical clustering, the overall gene 
expression pattern rendered by miR-376a*A and miR-376a*G were found be 
dramatically different. Clusters of genes that were up-regulated by miR-376a*A were 
found be unchanged or oppositely regulated by miR-376a*G (Figure 5.1). Similarly, 
genes down-regulated by miR-376a*A were up-regulated or unchanged by miR-
376a*G. In effect, very limited groups of transcripts were similarly regulated by miR-
376a*A and miR-376a*G. This shows that in U87 cells, miR-376a*A and miR-376a*G 
differing only by a single base in their seed sequence have very distinct and non-
























Figure 5.1 Global transcriptional changes caused by miR-376a* in U87 
cells.Hierarchical clustering of normalized expression levels of transcripts that are 
significantly differentially expressed in miR-376a*A or miR-376a*G-transfected cells 
compared to control miRNA. The list of differentially genes for each miRNA was filtered 
based on fold-change > |2|, p < 0.05 and Benjamini-Hochberg multiple testing correction. 






To gain a deeper understanding of the nature of gene expression modulation by miR-
376a*, the functions of differentially expressed genes were probed. DAVID 
bioinformatics resources is an online data analysis tool that can identify enriched 
associated gene annotation terms (such as Gene Ontology) and therefore functions 
or pathways among gene lists generated from high-throughput analysis such as 
microarrays (Huang da et al., 2009a; Huang da et al., 2009b). The results of DAVID 
analysis of up- and down-regulated genes from miR-376a*A and miR-376a*G are 
summarized in Table 5.1, listing the ‘representative’ cluster annotation term, 
enrichment scores (which ranks importance of annotation groups), p-value of 
enrichment and false-discovery rate (FDR) to control discovery of false-positives. In 
strong agreement with cellular changes related to migration and invasion, “cell 
adhesion” and “cell motion” functions were significantly enriched in genes up-
regulated by miR-376a*A (Table 5.1). In contrast, a very significant proportion of 
genes up-regulated by miR-376a*G were involved in “cell cycle”, confirming earlier 
results that miR-376a*G increased proliferation rate and cell cycle progression. 
Reciprocally, genes down-regulated by miR-376a*A were related to “cell cycle”, and 
those down-regulated by miR-376a*G were involved in “cell migration”. 
Interestingly, by DAVID analysis the functional enrichment of “development”, both 
multicellular organsimal and vasculature, and “cell differentiation”, were also 
identified among genes up-regulated by miR-376a*A and those down-regulated by 
miR-376a*G. Developmental pathways are often exploited by malignant cells for 
gaining advantages for tumor growth and invasion (Ma and Weinberg, 2008). In 
gliomas, these include the neurodevelopment-related PDGF and TGF signaling 
pathways (Golestaneh and Mishra, 2005; Hoelzinger et al., 2007; Louis, 2006). Heat 
map clustering of genes involved in the processes of development, vasculature,cell 
motion and cell cycle highlight the particularly contrasting pattern of transcript-level 






Annotated Biological Process Enrichment Score p-value FDR Gene Count % 
 
     
Genes up-regulated by miR-376a*A 
     
GO:0007275~multicellular organismal development 15.20 3.8E-21 6.9E-18 199 29.3 
GO:0001944~vasculature development 8.50 6.3E-11 1.1E-07 35 5.2 
GO:0007155~cell adhesion 8.17 2.0E-11 3.6E-08 65 9.6 
GO:0001501~skeletal system development 6.44 2.9E-09 5.3E-06 37 5.4 
GO:0030154~cell differentiation 5.82 2.8E-12 5.0E-09 117 17.2 
GO:0006928~cell motion 5.29 4.9E-07 8.8E-04 42 6.2 
GO:0009605~response to external stimulus 4.81 9.5E-10 1.7E-06 73 10.8 
 
     
Genes down-regulated by miR-376a*A 
     
GO:0022403~cell cycle phase 4.06 1.5E-06 2.7E-03 42 4.7 
GO:0044248~cellular catabolic process 2.22 3.8E-04 6.7E-01 70 7.9 
 
     
Genes up-regulated by miR-376a*G 
     
GO:0007049~cell cycle 35.13 1.6E-47 2.8E-44 166 13.7 
GO:0006259~DNA metabolic process 10.54 2.1E-28 3.8E-25 105 8.7 
GO:0000226~microtubule cytoskeleton organization 8.64 1.8E-11 3.2E-08 35 2.9 
GO:0051726~regulation of cell cycle 7.81 9.5E-16 1.8E-12 64 5.3 
GO:0007059~chromosome segregation 7.68 2.9E-17 5.2E-14 32 2.6 
      
Genes down-regulated by miR-376a*G 
     
GO:0001944~vasculature development 6.59 4.4E-09 7.9E-06 44 3.6 
GO:0009653~anatomical structure morphogenesis 4.47 1.6E-07 2.9E-04 124 10.1 
GO:0009966~regulation of signal transduction 4.15 8.9E-07 1.6E-03 95 7.8 
GO:0030154~cell differentiation 2.73 5.2E-05 9.4E-02 146 11.9 
GO:0016477~cell migration 2.37 5.2E-04 9.5E-01 34 2.8 
 
     
Table 5.1 Functional enrichment analysis of genes differentially regulated by miR-376a*. Genes differentially expressed after treatment of U87 cells 
with miR-376a*A or miR-376a*G relative to control miRNA were identified by Affymetrix microarray. Gene lists were analyzed by DAVID Bioinformatics 
Resources. The most significantly enriched GO Biological Process annotation terms in the gene lists, are presented with enrichment score, p-value, false 
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Figure 5.2 Heat maps of expression of differentially regulated genes in miR-376*A- and 
miR-376a*G-transfected cells. Subsets of genes falling in GO Biological Process enrichment 
clusters from Table 5.1 were used to generate heat maps. Genes related to development, cell 
motion and vasculature were selected to emphasize the opposite effects on expression elicited 
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Using a similar method applying DAVID analysis, associated KEGG pathway 
annotations of differentially expressed genes were also interrogated. This analysis 
revealed that miR-376a*A had a significant effect on the ECM-receptor and focal 
adhesion pathways, while miR-376a*G affected the cell cyle and DNA replication 
pathways (Figure 5.3).  ECM-receptor interaction is critical to the motility and 
invasion of cells and its enrichment among genes regulated by miR-376a*A further 
strengthened a role for this miRNA in cell invasion. The distinct effect of miR-376a*G 
on cell cycle suggests that its role is related to controlling cell cycle progression. 
Overall, the functions of miR-376a*A and miR-376a*G are highly distinct and inclined 





Figure 5.3 Summary of pathway enrichment analysis of differentially expressed genes. 
Lists of transcripts regulated by miR-376a*A or miR-376a*G were analyzed for enrichment of 
KEGG pathway terms. Significance of enrichment (-log10 [p-value]) and the number of 






From among the genes that are differentially regulated by miR-376a*A, a set of 
genes which are known to pleiotropically regulate glioma cell invasion, migration and 
angiogenesis (Hoelzinger et al., 2007; Louis, 2006) were used to validate the 
microarray results by qRT-PCR (Figure 5.4). Almost consistently, miR-376*A 
increased while miR-376a*G decreased the expression of selected growth factors 
receptors, angiogenesis regulators, chemokines and ECM-receptor genes (Figure 
5.4A). Additionally, the similar transcript-level changes brought about by miR-376a*G 
and miR-376a*I for these key regulatory mRNAs (Figure 5.4B) strengthened the 
equivalency of their cellular effects.   
We are limited by the use of “G”-containing miR-376a* as edited miRNA, for stable 
expression required for long-term in vivo studies, as inosine cannot be encoded in 
the DNA, but is only introduced posttranscriptionally. For valid comparison between 
transient and stable expression experiments, miR-376a*G was used consistently for 
experiments. The fact that miR-376a*G and miR-376a*I produced similar cellular 
effects in glioma cells as well as transcriptional level changes suggests a strong 
consistency in their function as miRNAs. This equivalency of “I” and “G” in miRNA 
base-pairing has been demonstrated before (Borchert et al., 2009; Kawahara et al., 








































































































































































Figure 5.4 Verification of expression of genes involved in glioma migration, invasion and 
angiogenesis. A. Relative mRNA expression quantified by qRT-PCR in U87 cells transfected 
with miR-376a*A or 376a*G. B. Comparison of expression levels of a set of genes in U87 cells 
transfected with miR-376a*G and miR-376a*I. Expression was normalized to 18S rRNA. Data 








In addition to the validated effects of unedited and edited miR-376a* on cell migration 
and invasion described in previous chapter, the global effects of these miRNAs on 
the transcriptome of glioma cells was investigated. The opposing effects of miR-
376a*A and miR-376a*G on transcripts relevant to cell migration, invasion and 
growth factor signaling pathways were readily apparent from the global transcriptome 
changes effected by each miRNA. Apart from these, transcripts involved in 
vasculature development, potentially relevant to angiogenesis during glioma 
development, were also upregulated by miR-376a*A. Such broad effects on cancer-
related pathways is in support of the ability of a single miRNA to pleiotropically 
impact cancer-related pathways (Valastyan et al., 2009). The regulation of miR-
376a*G on cell cycle was obvious from the gene expression changes and deserves 
further investigation into its impact on the modulation of cell migration. As edited and 
unedited miR-376a* differ by a single base, the nearly opposing regulatory effects of 
the two miRNAs are a unique phenomenon that possibly ties into a regulatory switch 
that is normally imposed during development. It is conceivable that such a switch 
would cause a migratory cell to become non-migratory due to editing-mediated single 
base-change of a regulatory miRNA. 
Indeed, a role for unedited transcripts in early development and edited transcripts in 
functional adult brain has been suggested previously (Wahlstedt et al., 2009). 
Interestingly, a neural progenitor cell (NPC) origin for primary human gliomas has 
been proposed (Louis, 2006). Also, A-to-I editing is a developmentally regulated 
process in the brain that progressively increases over developmental time, as 
measured by the increasing editing frequency of editing substrates, and is highly 
restricted during early development (Wahlstedt et al., 2009).  Interestingly, a study in 
human NPCs found that the GluR-B Q/R site is unedited in NPCs but upon 






(Whitney et al., 2008). During embryonic development and also during NPC 
differentiation, levels of ADAR2 are upregulated (Paupard et al., 2000; Whitney et al., 
2008).  Perturbation of this developmentally regulated phenomenon by altered 
function of editing enzymes, ADARs, possibly represents a mechanism of 
gliomagenesis. From a cancer development view-point a change to ADARs presents 
a greater opportunity for tumor cells to collectively manipulate the function of several 
targets. The link between A-to-I editing and development and differentiation and the 
presence of unedited transcripts in GBMs supports a reversal to a developmentally 
earlier stage by glioma cells due to lowered ADAR function or levels, and acquisition 







6 CHAPTER 6.  Identification of target genes of 
unedited and edited miR-376a* 
6.1 Introduction and aims 
The aim of this chapter was to investigate the mechanism by which miR-376a*A is 
able to promote glioma cell migration and invasion by identifying its direct target 
genes. Notably as shown in the Chapters 4 and 5, miR-376a*G, the edited 
counterpart, suppresses glioma cell migration and invasion and is associated with 
global transcription changes supporting suppressed invasion characteristics. As 
shown in Chapter 3, due to altered editing in GBMs, a switch from miR-376a*G in 
normal cells to miR-376a*A in glioma cells occurs. Given this switch and its opposing 
effects (manifest as effects of miR-376a*A and miR-376a*G), it was hypothesized 
that the function of miR-376a*A in glioma cells is dependent on two simultaneous 
aspects of miRNA targeting: gained accessibility to certain target genes (represented 
by targets of miR-376a*A) and lost accessibility to other target genes (represented by 
targets of miR-376a*G). The pro-invasive property of miR-376a*A in GBMs would 
therefore be the sum of these two aspects. Evidently, this would exclude targets 
common to both miR-376a*A and 376a*G from playing a role in their unique 
functions. Thus, in this section, the aim was to identify unique target genes of both 
miR-376a*A and miR-376a*G that could account for the observed cellular effects in 







6.2 Distinct potential target gene sets of miR-376a*A and 
miR-376a*G 
To identify potential target genes of the two miRNA forms, miR-376a*A and 376a*G 
were separately transfected in U87 and SW1783 glioma cells and by microarray, 
genes differentially regulated by each of them compared to control, at early time-
points (P <0.05; fold-change > 1.5 at 24 hours) were identified.  Among these, the 
down-regulated transcripts potentially represent direct targets of miRNAs (Lim et al., 
2005). This analysis depends on the ability of miRNAs to affect the stability of target 
transcripts which in previous studies have been shown to be highly enriched within 
their 3'UTRs for motifs corresponding to complementary miRNA seed sequence (He 
et al., 2007; Lim et al., 2005; Linsley et al., 2007). This strategy has been 
successfully applied for identification of targets of let-7 (Johnson et al., 2007), miR-
372 and miR-373 (Voorhoeve et al., 2006) and miR-24 (Lal et al., 2009). 
The 24 hours-post transfection time-point was selected as this allows a higher 
possibility of detection of transcripts directly down-regulated by miRNAs when mRNA 
silencing is maximal, as compared to indirect targets whose mRNA levels may be 
secondarily affected due to protein depletion of upstream regulatory factors (Jackson 
et al., 2003). The 1.5-fold change (compared to control miRNA) cut-off was imposed 
as large changes in transcript abundances are not expected due to miRNA regulation 
(Baek et al., 2008; Selbach et al., 2008). Although this method has the advantage of 
being high-throughput, miRNA targets that are exclusively regulated by translational 
repression and whose mRNA transcript abundance is not affected by miRNA 
regulation will not be identified by this method. Nonetheless, recent studies indicate 
that the predominant mode of action of miRNAs is reduction of target mRNA levels 
and that the fraction of targets that are exclusively regulated by translational 
repression is very small (Baek et al., 2008; Guo et al., 2010), so the potential utility of 






Based on this analysis, a number of array probesets were found down-regulated by 
miR-376a*A and miR-376a*G, compared to control miRNA, in both U87 and SW1783 
cells (Figure 6.1). Interestingly, a number of probesets were also up-regulated in 
miR-376a*A and miR-376a*G-transfected cells compared to control miRNA-
transfected cells at the same 24-hour time-point (Figure 6.1). Although, potentially 
functionally relevant, the up-regulated genes are unlikely to be direct target genes of 









As a first step, transcripts that were commonly down-regulated by both miR-376a*A 
and miR-376a*G were isolated in each cell line, U87 and SW1783. In agreement with 
the redirection of target gene specificity by editing of miRNAs, the proportion of 
commonly down-regulated transcripts among total down-regulated transcripts was 
small (~10%)  (Figure 6.2A). These transcripts were removed from consideration as 
targets. The remaining genes down-regulated exclusively by miR-376a*A or by miR-
376a*G, potentially represent unique target genes for each miRNA. By overlapping 
these gene lists from U87 and SW1783 experiments, the list of candidate target 
genes was further narrowed down. Using this strategy 116 genes uniquely down-
regulated by miR-376a*A and 142 genes for miR-376a*G were identified (Figure 
6.2B). Transcripts representing candidate target genes are listed in Appendix Tables 
A1 and A2. 
 Down-regulated genes Up-regulated genes 
 
miR-376a*A miR-376a*G miR-376a*A miR-376a*G 
U87 315 491 241 360 
SW1783 239 354 191 258 
Figure 6.1 Microarray analysis of genes differentially regulated by miR-376a*A and 
miR-376a*G. Number of genes down-regulated or up-regulated by miR-376a*A or miR-
376a*G in U87 and SW1783 cells, 24 hours after transfection. Comparison was done 






























Figure 6.2 Potential target genes of miR-376a*A and miR-376a*G identified by 
microarray. A. Overlap of genes down-regulated by miR-376a*A and miR-376a*G to 
isolate those that are commonly or uniquely down-regulated by each miRNA in U87 and 
SW1783 cells lines. B. Candidate target genes of miR-376a*A and miR-376a*G identified 
by overlap of gene lists from A. derived for both U87 and SW1783 cells. 116 potential 
candidate genes for miR-376a*A and 142 potential candidates for miR-376a*G were 
narrowed down by this analysis. 
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It is to be noted that the degree of down-regulation of transcripts does not directly 
represent the targeting efficacy and is likely also determined by the half-life of 
transcripts, as long-lived transcripts will undergo relatively more destabilization than 
relatively short-lived ones (Gu et al., 2009), therefore the degree of down-regulation 
was not considered a significant factor and all genes that were significantly down-
regulated >1.5-fold were equally considered as potential targets. 
The microarray results were verified for selected genes that were highly down-
regulated for each miRNA. U87 cells transfected with miR-376a*A or miR-376a*G 
were analyzed for mRNA levels of RRAS2, PEX19, FAM55C and ELOVL5 (down-
regulated by miR-376a*A) and for TCF7 and ACVR1 (down-regulated by miR-
376a*G) using qRT-PCR (Figure 6.3A). In accordance with microarray data, only one 
of the two miRNAs suppressed mRNA levels of each of the genes, in the expected 
pattern (Figure 6.3A). Furthermore, the fold-change determined by qRT-PCR was 

















Figure 6.3 Verification of microarray results by qRT-PCR for top down-regulated genes. 
A. Relative levels of mRNAs indicated genes measured by qRT-PCR. 18S rRNA was used for 
normalization. Data represents mean ± SD. B. Down-regulation fold-change determined by 
microarray for U87 and SW1783 cells.  
 
  
  Down-regulation fold-change determined by 
microarray 
  U87 SW1783 
miR-376a*A 
targets 
RRAS2 6.26 5.37 
PEX19 5.12 3.34 
FAM55C 3.16 2.38 
ELOVL5 4.8 2.3 
miR-376a*G 
targets 
TCF7 4.58 3.16 








6.3 Prediction of miRNA-binding sites in candidate target 
genes 
For the potential candidate target genes of each of miR-376a*A and miR-376a*G that 
were identified from the microarray analysis, it was important to demonstrate the 
presence of specific miRNA-binding sites in their 3’UTRs. At the same time, it would 
be expected that potential targets of miR-376a*A would only harbour binding sites for 
miR-376a*A, and not for miR-376a*G, although the two miRNAs differ only by a 
single base. Similarly, the opposite would apply for miR-376a*G target genes.  
The 3’UTR sequences for each potential target gene were retrieved and miRNA-
binding sites for both miR-376a*A and miR-376a*G in 3’UTRs were searched for 
using the online program RNA22 (Miranda et al., 2006). This program allows 
flexibility of inputting “custom” miRNA sequences necessary to distinguish miR-
376a*A and miR-376a*G. This option is not available in other popular prediction 
softwares such as PicTar or miRanda (Betel et al., 2008; Krek et al., 2005), which 
predict target genes only for currently known miRNAs annotated in Sanger miRBase 
– precluding predictions for edited miR-376a* (miR-376a*G).  
The program RNA22 identifies regions of 3’UTR (or any other input mRNA sequence) 
that have the potential to form thermodynamically favorable duplex with a miRNA 
sequence of interest. RNA22 does not use cross-species conservation of target site 
as a criteria for prediction and is resilient to noise (Brodersen and Voinnet, 2009; 
Miranda et al., 2006). Also, this program allows the presence of G:U pairs in the 
miRNA  seed region, which broadens the scope of potential binding sites (Brodersen 
and Voinnet, 2009; Miranda et al., 2006).   
Using RNA22, for majority of genes down-regulated by miR-376a*A, at least one 
miR-376a*A-binding site was found in their 3’UTRs. Similarly, most genes down-






proportion of candidate targets of miR-376a*A, equivalent numbers of miR-376a*G 
sites were also predicted either distinct or overlapping with miR-376a*A sites. The 
same was reciprocally applicable to miR-376a*G targets. As miR-376a*A and 
376a*G differ only by a single-base, this was not surprising for computational 
prediction. Nonetheless, those targets with nearly equal numbers and strengths of 
target site predictions for both miR-376a*A and 376a*G were not further investigated 
as targets, in order to increase the likelihood of identifying genuine specific targets of 
each. The presence of a putative miRNA-binding site in the 3’UTR, although the 
given miRNA was unable to down-regulate the mRNA of target gene, raises the 
possibility that under certain other experimental conditions these sites may be 
functional. Additionally, although the miRNA may not be able to induce the 
degradation of mRNA of a target gene, it may still be able to inhibit protein translation, 
not detectable by microarray analysis. To streamline the process of target validation, 
an additional criterion of significantly higher numbers and strengths of miRNA-
targeting sites only for the miRNA that was identified to initially down-regulate target 
mRNAs was imposed. This further led to the elimination of several genes, leaving 
those targets which are only down-regulated at mRNA level by either miR-376a*A or 
miR-376a*G and have predicted sites for the appropriate miRNA in their 3’UTR. The 
overall strategy used for candidate gene identification is summarized in Figure 6.4. 
Furthermore, combined with the a priori knowledge of the role of miR-376a* in cell 
migration and invasion, the focus was on candidate targets that are known to be 




























Figure 6.4 Strategy for identification of potential candidate genes specific to miR-
376a*A and miR-376a*G. Genes identified to be down-regulated either by miR-376a*A 
or by miR-376a*G but not by both were selected for analysis of their 3’UTRs for miRNA 
binding sites using RNA22. Genes with similar prediction for miR-376a*A and miR-
376a*G binding were removed leaving a list of candidate genes that are both regulated 
uniquely by either miR-376a*A or miR-376a*G and have 3”UTR binding sites for one of 
the two appropriate miRNAs. 
Microarray data of genes down-
regulated by miR-376a*A or by miR-
376a*G 
Genes commonly down-
regulated excluded from 
future analysis 
Retrieve 3’UTR sequences from 
Biomart for Affymetrix probes IDs of 
down-regulated genes  
Run RNA22 to obtain binding 
energies and heteroduplexes 
between 3’UTRs and miR-376a*A 
and miR-376a*G  
minimum seed of 6 nt 
G:U wobbles permitted 
Binding energy < -15 
kcal/mol 
Filter results to exclude targets with 
highly similar predictions for miR-
376a*A and miR-376a*G 
Similar number of 
predicted sites 




Candidate targets specific 
to miR-376a*A and targets 






6.4 STAT3 is specifically targeted by unedited miR-376a* 
Based on the microarray and target site prediction analysis, STAT3 from the signal 
transducer and activators of transcription (STAT) family was identified as a potential 
target with functions relevant to cancer cell migration. Four binding sites for miR-
376a*A were identified in STAT3 3’UTR, which failed to be predicted as miR-376a*G-
binding sites, although an independent site for miR-376a*G was also predicted 
downstream (nucleotides 1877-1898 of 3’UTR) (Figure 6.5A). Folding energies of the 
predicted heteroduplexes are shown in Figure 6.5B. It was noted that the predicted 
heteroduplexes formed contained one or more G:U wobbles in the miRNA seed 
region. It has been previously demonstrated that despite the presence of multiple 
G:U pairs in the seed region, miRNA binding can still be functionally productive and 
be able to mediate target repression (Brodersen and Voinnet, 2009; Miranda et al., 
2006), especially when present multiply miRNA (Brennecke et al., 2005), as in 
STAT3 3’UTR. Furthermore, additional Watson-Crick base-pairing at the 3’ end of the 
miRNA from positions 12, 13 or 14, as seen for most sites predicted for miR-376a*A 
binding (Figure 6.5B), is known to enhance miRNA targeting (Grimson et al., 2007). 
Overall, the predictions for miR-376a*A-binding sites in STAT3 3’UTR suggest 
multiplicity of action of at least four miRNA binding sites. Conservation of target sites 


















































Figure 6.5 Conserved miR-376a*A binding sites in STAT3 3’UTR. A. Schematic 
representation of STAT3 3’UTR. Red bars show predicted miR-376a*A-binding sites. Green 
bar shows predicted miR-376a*G-binding site. Sequence of binding site 3 is shown aligned to 
miR-376a*A and seed region in underlined. Single base difference between miR-376a*A and 
376a*G is highlighted. B. Folding energies of predicted miRNA:mRNA heteroduplexes 
between (i) miR-376a*A and STAT3 3’UTR and (ii) miR-376a*G and STAT3 3’UTR C. 
Alignment of potential miR-376a*A binding sites in STAT3 3’UTRs of different species 
indicating evolutionary conservation. Non-conserved residues within binding region are written 








To validate the specificity of miRNA targeting, luciferase-reporter assays were 
performed. In the luciferase-reporter asay, the 3’UTR of the gene of interest 
encompassing the miRNA target sites is cloned downstream of the luciferase coding 
sequence in a luciferase reporter vector (pmiR-Report) (Figure 6.6A). Binding of 
miRNA to the target sites reduces the luciferase activity which is measurable in a 
luciferase assay. A plasmid encoding ß-galactosidase, was co-transfected to serve 
as a control for transfection efficiency. For STAT3, two luciferase reporter vectors 
were constructed: first, containing a 1002 bp STAT3 3’UTR region encompassing 
four miR-376a*A sites but excluding the miR-376a*G site; second, containing the 
entire 2449 bp STAT3 3’UTR (Figure 6.6B). 
The luciferase assays were performed in HeLa cells as they have low expression of 
miR-376a* (Kawahara et al., 2007b) and avoids intereference from endogenous 
miRNA expression. Glioma cells were not used for the luciferase assays given the 
extensive changes mediated by both miR-376a*A and miR-376a*G in glioma cell 
lines, which may produce secondary effects on expression from the luciferase 
reporter constructs.  
Only miR-376a*A decreased luciferase activity by 70% for both reporter constructs 
while both miR-376a*G and miR-376a*I were ineffective in suppressing luciferase 
expression below control levels (Figure 6.6C). This indicates that the single base 
difference between miR-376a*A and miR-376a*G/I determines in an “on/off” manner 
the ability of miR-376a* to target STAT3 3’UTR as there were no incremental 
changes to the luciferase targeting ability when miRNA sequence was changed from 
having an ‘A’ in the seed sequence to having a ‘G’ or ‘I’ in the seed sequence. The 
full-length STAT3 3’UTR luciferase reporter, containing the predicted miR-376a*G 
binding site failed to respond to both forms of edited miRNA, miR-376a*G and miR-
376a*I (Figure 6.6C), suggesting that this predicted site is non-functional, at least 



























Figure 6.6 Specific targeting of STAT3 3’UTR by miR-376a*A. A. The pmiR-Report vector 
used for constructing luciferase reporter vectors. CMV promoter drives the expression of firefly 
luciferase, downstream of which appropriate 3’UTR sequence is cloned. B. Two luciferase 
reporter constructs used for verification of STAT3 targeting by miR-376a*A. Red bars show 
predicted miR-376a*A binding sites. Green bar shows predicted miR-376a*G binding site 
within 3’UTR. STAT3 3’UTR full-length includes the entire 2449 bp STAT3 3’UTR. STAT3 
3’UTR-1002 represents the fragment of the 3’UTR which includes all predicted miR-376a*A 
binding sites but excludes the predicted miR-376a*G binding site. C. Targeting of STAT3 
3’UTR by miR-376a*A. Luciferase reporter constructs for partial or full-length STAT3 3’UTR 
were cotransfected with miR-376a* or control miRNA in HeLa cells. Luciferase readings were 
normalized to ß-galactosidase activity and for each construct, expressed relative to readings 













































In U87 and SW1783 cells, it was verified that STAT3 mRNA levels were subject to 
extensive down-regulation by 50-70% by miR-376a*A, but not by miR-376a*G as 
validated by qRT-PCR (Figure 6.7A). Similarly, STAT3 protein was reduced 
specifically by 60-70% by miR-376a*A (Figure 6.7B). These results confirmed the 
direct and specific regulation of STAT3 by miR-376a*A via the predicted miRNA 
binding sites. Thus, STAT3 represents a direct specific target of miR-376a*A, subject 












Figure 6.7 Specific mRNA and protein down-regulation of STAT3 by miR-376a*A.  
A. Quantification of STAT3 expression by qRT-PCR in transfected glioma cells. 18S rRNA 
was used for normalization. Data represents mean ± SD. **p<0.01 by t-test vs. control. B. 
Immunoblotting for total STAT3 levels in transfected glioma cells. ß-actin was used as 
loading control. Densitometric analysis was done by Image J software and protein amounts 







































































































































































To investigate if in primary glioma samples, there was a correlation between STAT3 
expression and miR-376a*A expression, STAT3 mRNA levels were quantified by 
qRT-PCR. Gliomas were stratified according to the frequency of editing of miR-376a* 
determined from the direct sequencing of pri-miR-376a1. “Low” and “high” frequency 
editing distinguished tumors with base-line editing of 0-5% and those with 
measurably substantial editing of >12% for +9 site of pri-miR-376a1. Under the 
premise that total expression of miR-376a* in human GBMs is not subject to major 
deregulation (0.853-fold of normal brain), editing frequency of miR-376a* is a 
surrogate measure for miR-376a*A expression. Based on this, a correlation was 
found between STAT3 mRNA levels and the editing frequency of miR-376a* (Figure 
6.8). In most tumors with low % editing of miR-376a*, miR-376a*A accumulates 
down-regulating STAT3 mRNAs. Conversely, tumors with relatively high-level editing 
have more miR-376a*G which does not target STAT3, allowing the accumulation of 









Figure 6.8 Correlation between STAT3 mRNA and miR-376a* editing frequency in 
glioma samples. Quantification of STAT3 mRNA levels by qRT-PCR in normal brain (NB) 
and 22 tumor samples. Samples were grouped by % editing of miR-376a*. high % 
editing: >12% editing. In samples with low % editing it is inferred that levels of miR-376*A are 






6.5 Inhibition of STAT3 function promotes cell migration 
STAT3 has been reported to function as a tumor suppressor in PTEN-deficient 
glioblastomas (de la Iglesia et al., 2009). U87 and SW1783 glioma cells both exhibit 
PTEN-deficiency as noted from the Catalogue of Somatic Mutations In Cancer 
database (Bamford et al., 2004; de la Iglesia et al., 2008a). In the context of the 
findings reported in this thesis, as miR-376a*A promotes glioma cell migration and 
negatively regulates STAT3, STAT3 should assume an inhibitory role in cell 
migration. As such, attempts were made to silence STAT3 using siRNA to assess its 
effects on migration, a prerequisite for invasion. However, STAT3 knockdown by 
siRNA even at low doses (0.625 nM) resulted in cell death, making any effects on cell 
migration secondary to the effects on cell viability and hence not a reliable 
measurement. Additionally by Western blot it was determined that siRNA-mediated 
knockdown of STAT3 caused significantly more depletion of STAT3 protein than did 
miR-376a*A treatment, and it was difficult to observe a dose-dependence even when 
the dose was varied 80-fold, suggesting limits to the ability to adjust dose (Figure 6.9). 
As such, this imposed limitations on the use of STAT3 siRNA to phenocopy the 







Figure 6.9 siRNA-mediated knockdown of STAT3. U87 cells were transfected with high 
(50 nM) or low (0.625 nM) dose of siRNA and STAT3 protein knockdown was assessed by 
Western blot. ß-actin was used as loading control. Densitometric analysis was done by 







To overcome these issues, we took advantage of a small-molecule inhibitor of 
STAT3 function, Stattic for blocking STAT3 function (Schust et al., 2006).  At a 
relatively low dose (0.05-0.5 µM) where cell viability was not adversely affected, 
Stattic treatment significantly increased migration in both U87 and SW1783 cells 
(Figure 6.10A). As Stattic does not reduce the levels of total STAT3 protein but 
inhibits phosphorylation at tyrosine 705 and subsequent dimerization (and nuclear 
translocation), the levels of phosphorylated STAT3 (p-STAT3) was quantified in 
treated cells. In U87 and SW1783 cells, the levels of p-STAT3 were reduced to 
similar levels (70%) in both conditions that promote cell migration, miR-376a*A 
transfection and 0.05-0.5 µM Stattic treatment (Figure 6.10B). These data suggest 
that partial but not total inhibition of STAT3 function promotes glioma cell migration.  
In summary, STAT3 is a target specific to the unedited miR-376a* which 
accumulates in GBMs and partial inhibition of STAT3 function by miR-376a*A or by 









































































Figure 6.10 Inhibition of STAT3 activity promotes glioma cell migration. A. Inhibition of 
STAT3 activity by small molecule inhibitor Stattic promotes migration of U87and SW1783 cells 
in a wound-healing assay. Images were taken at indicated time-points after wound was made 
to a confluent cell monolayer and indicated concentrations of Stattic were added to the 
replacement medium. Graph shows relative % wound gap closure. Data represents mean ± 
SD. *p<0.05 by t-test. B. Immunoblotting of phosphorylated STAT3 (p-STAT3) in miR-376a*A-
transfected and Stattic-treated cells. ß-actin was used as loading control. Densitometric 
analysis was done by ImageJ. p-STAT3 amounts are shown relative to control miRNA or to 







6.6 AMFR is specifically targeted by edited miR-376a* 
Using the strategy described previously, a specific target of miR-376a*G was 
identified next. The autocrine motility factor receptor (AMFR) represents a potential 
specific target of miR-376a*G, ‘untargetable’ to miR-376a*A .The 3’UTR of AMFR 
harbours two predicted conserved binding sites for miR-376a*G, while none were 
predicted for miR-376a*A (Figure 6.11A). The folding energies for the predicted 
heteroduplex are shown in Figure 6.11B. Conservation of one of the two predicted 
sites is high across mammalian species, but a single mismatch (C-to-T) in the seed 
region for the second binding site is present in all species except H. sapiens (Figure 
6.11C). As a consequence of this mismatch, this binding site is no longer accessible 
(by computational prediction) to miR-376a*G but interestingly, becomes’ accessible’ 
to miR-376a*A. 
Also, the two predicted sites for miR-376a*G overlap one another. It is possible that 
only one of the two sites is functional as it is unlikely that both predicted sites can be 
simultaneously occupied by miRNA; binding of miRNA to one site will occupy a 









































To validate targeting of AMFR 3’UTR by miR-376a*G, luciferase reporter assays 
were carried out. Two luciferase reporter vectors were constructed for AMFR, first, 
fused to full-length 1411 bp AMFR 3’UTR and second, containing or partial 417 bp 
AMFR 3’UTR (Figure 6.12A). In the luciferase reporter assay, only miR-376a*G was 
able to suppress luciferase expression by 50% for both reporter constructs, 




Figure 6.11 Conserved miR-376a*G binding sites in AMFR 3’UTR. A. Schematic 
representation of AMFR 3’UTR. Green bars show predicted miR-376a*G-binding sites. No 
binding sites for miR-376a*A were predicted, Sequence of binding site 1 is shown aligned to 
miR-376a*G and seed region in underlined. Single base difference between miR-376a*G and 
376a*A is highlighted. B. Folding energies of predicted miRNA:mRNA heteroduplexes between 
miR-376a*G and AMFR 3’UTR C. Alignment of potential miR-376a*G binding sites in AMFR  
3’UTRs of different species indicating evolutionary conservation. Non-conserved residues within 






measurable difference between the degree of luciferase suppression by miR-376a*G 
when using the partial or full-length constructs, suggesting that extending the 3’UTR 
to include potential endogenous miRNA bindings sites did not mask the suppressive 
effect of miR-376a*G. As expected with redirection of targeting specificity, miR-
376a*A was unable to target the 3’UTR of AMFR. This confirms that the single base 
difference between miR-376a*G and miR-376a*A determines the specificity of 






























































Figure 6.12 Specific targeting of AMFR 3’UTR by miR-376a*G. A. Two luciferase reporter 
constructs used for verification of AMFR targeting by miR-376a*G. Green bar shows 
predicted miR-376a*G binding site within 3’UTR. AMFR 3’UTR full-length indicates the whole 
1411 bp AMFR 3’UTR. AMFR 3’UTR-417 represents a 417 bp fragment of the AMFR 3’UTR. 
B. Targeting of AMFR 3’UTR by miR-376a*G. Luciferase reporter constructs for partial or 
full-length AMFR 3’UTR were cotransfected with miR-376a* or control miRNA in HeLa cells. 
Luciferase readings were normalized to ß-galactosidase activity and for each construct, 
expressed relative to readings for control miRNA. Data represents mean ± SD. *p<0.05 and 






At the mRNA level it was confirmed that both miR-376a*G and miR-376a*I were able 
to down-regulate AMFR mRNA by ~50% (Figure 6.13A). Accordingly, protein levels 
of AMFR were robustly suppressed (40-70%) by miR-376a*G but not by miR-376a*A 
(Figure 6.13B). However, in tumor samples, a direct correlation between editing 
frequency of miR-376a* and absolute AMFR mRNA levels could not be found, 
suggesting in tumors protein accumulation of AMFR may be more sensitive to miR-






















Figure 6.13 Specific mRNA and protein down-regulation of AMFR by miR-376a*G. A. 
Quantification of AMFR expression by qRT-PCR in transfected glioma cells. 18S rRNA was 
used for normalization. Data represents mean ± SD. **p<0.01 by t-test vs. control. B. 
Immunoblotting for total AMFR levels in transfected glioma cells. ß-actin was used as loading 
control. Densitometric analysis was done by Image J software and protein amounts are shown 






































6.7 Knockdown of AMFR inhibits glioma cell migration 
As a receptor for the tumor autocrine motility factor, AMFR has been shown to 
promote sarcoma metastasis (Tsai et al., 2007) and is present in high-grade 
astrocytomas (Tanizaki et al., 2006). Given that AMFR is a specific target of miR-
376a*G and miR-376a*G is able to reduce migration ability of glioma cells, blocking 
the function of AMFR is expected to produce a similar phenotype of suppressed 
migration. 
Knockdown of AMFR by low concentration of siRNA (0.625 nM) was done in U87 
and SW1783 cells. This suppressed migratory ability of U87 and SW1783 cells to 
nearly half of control siRNA-transfected cells, as assessed in a wound-healing assay 
(Figure 6.14A). Knockdown of AMFR protein by siRNA even at 0.625 nM 
concentration of siRNA was highly effective as confirmed by Western blotting (Figure 
6.14B). As it is technically challenging to lower the dose of siRNA further because of 
limitations of transfection reagents and as this dose did not affect cell viability, 
attempts were not made to further lower the dose of siRNA used to achieve a more 
moderate knockdown of AMFR.  
Thus, reduction in AMFR protein by siRNA, as by miR-376a*G, is able to inhibit 
glioma cell migration. In summary, AMFR is a target specific to the edited miR-376a*, 
which is normally present in the brain but due to altered A-to-I editing is not present 
in GBMs. Due to this, the regulation of AMFR by miR-376a*G is lost, enhancing the 












































































Figure 6.14 Inhibition of AMFR inhibits glioma cell migration. A. Knockdown of AMFR by 
siRNA (si-AMFR) suppresses migration of U87and SW1783 cells in a wound-healing assay. 
Images were taken at indicated time-points after wound was made to a confluent monolayer of 
trasfected cells. si-control: control siRNA. Graph shows relative % wound gap closure. Data 
represents mean ± SD. **p<0.01 vs. control. B. Immunoblotting of AMFR protein in glioma cells 






In order to demonstrate in vivo specificity of targeting by miRNAs, AMFR and STAT3 
mRNA levels were measured in xenograft tumors formed by U87 cells expressing 
miR-376a*A or miR-376a*G. The target of edited miR-376a*, AMFR was relatively 
lower in U87/376a*G tumors, and the target of unedited miR-376a*, STAT3 was 
lower in U87/376a*A tumors, confirming the expected specificity of targeting in vivo 
(Figure 6.15). The expression data coincides with the observed features of 
U87/376a*A tumors formed in vivo which displayed overall greater aggressiveness 
and invasion, as would be expected of tumors formed by highly migratory and 
invasive cells. Together, these results suggest that blocking the migration-promoting 
effect of AMFR by miR-376a*G accounts for its anti-migratory property. More 
importantly, the data suggests that in addition to its ability to target STAT3, the 
inability of miR-376a*A to target AMFR may further contribute to its pro-migratory and 












































Figure 6.15 Relative expression of AMFR and STAT3 mRNA in xenograft tumors 
formed by U87 cells stably expressing miR-376a*. U87/376a*A cells stably express 
miR-376a*A and U87/376a*G cells stably express miR-376a*G. (Section 4.7). RNA was 
isolated from tumor sections. 18S rRNA was used for normalization. Values are relative to 







Attenuated A-to-I editing in glioma may exert a dual effect: increased inhibition to the 
migration-restraining effect of STAT3 by the accumulation of unedited miR-376a* 
(miR-376a*A) coupled with failure in blocking AMFR function of promoting cell 
migration due to the decrease of edited miR-376a* (miR-376a*G/I) level, as 
summarized in Figure 6.16. These effects may collectively contribute to the migratory 





















Figure 6.16 Schematic diagram summarizing the roles of AMFR and STAT3 in glioblastoma 
migration. Summary of findings indicating opposite roles of AMFR and STAT3 in regulating glioma 
cell migration, being subject to regulation by miR-376a*. When A-to-I editing of miR-376a* is 
attenuated in glioblastoma, the accumulation of unedited miR-376a* (miR-376a*A) down-regulate 
STAT3 while a decreased level of edited miR-376a* (miR-376a*I) leads to up-regulation of AMFR, 







The presence of unedited and edited variants of miR-376a* in diseased and normal 
states respectively suggest that each form establishes a distinct cell-type specific 
transcriptome, subject to alteration with miRNA sequence alteration. Using enforced 
miRNA expression in glioma cell lines, genes that are down-regulated by miR-
376a*A and miR-376a*G respectively were identified, representing elements of the 
transcriptome subject to regulation by each miRNA. In agreement with redirection of 
target gene specificity by miRNA seed sequence editing, few genes were found to be 
under common regulation by miR-376a*A and miR-376a*G (Kawahara et al., 2007b). 
Using a combination of microarray-based target gene analysis and computational 
prediction of miRNA-binding sites, specific target genes for each miRNA form were 
identified to account for their function in glioma cells.  
STAT3 was identified as a specific target of unedited miR-376a*, through down-
regulation of which, the pro-migratory program of this miRNA is enacted. STAT3 is a 
member of the STAT (Signal Transducers and Activators of Transcription) family of 
transcription factors that serve as signaling hubs downstream of extracellular 
signaling molecules including cytokines (Levy and Darnell, 2002). As a transcription 
factor mediating growth factor and cytokine signaling, STAT3 regulates cell growth, 
differentiation and survival  (Hirano et al., 2000; Takeda and Akira, 2000) and has 
been linked to oncogenesis (Bromberg, 2002; Calo et al., 2003). Critically, STAT3 
plays a crucial role in the differentiation of neural stem cells (NSCs) to astrocytes 
(Bonni et al., 1997; Rajan and McKay, 1998). 
The role of STAT3 in GBM pathology is controversial as it can act as either an 
oncogene or a tumor suppressor depending on the genetic context of tumors (de la 
Iglesia et al., 2008b; de la Iglesia et al., 2009). In PTEN-deficient tumors STAT3 acts 







As reported in this thesis, at least in the context of cellular migration, suppression of 
STAT3 function has a pro-migratory effect. It has been shown that STAT3 knockout 
transforms normal mouse astrocytes, increasing their proliferation rate, invasiveness 
and tumor-forming ability (de la Iglesia et al., 2008b). Furthermore, in glioma cells, 
introduction of constitutively active STAT3 suppressed cellular proliferation and 
invasiveness (de la Iglesia et al., 2008a). While a basal level of endogenous 
phospho-STAT3  (Tyr 705), presumably still signaling-competent, was detected for 
PTEN-deficient U87 and A172 glioma cells, the effects of suppression of endogenous 
STAT3 in these cells was left unexplored (de la Iglesia et al., 2008a). This thesis 
extends these findings by showing that partial inhibition of the endogenous level of 
phospho-STAT3 using a small-molecule inhibitor promotes migration of U87 and 
SW1783 cells. It is noteworthy that both U87 and SW1783 cells are PTEN-negative. 
Further investigation into these observations will need to be carried out in a larger 
panel of glioma cell lines.   
In contradiction to the findings presented here, studies have shown that inhibition of 
STAT3 by siRNA, curcumin and small-molecule inhibitors AG490 and JSI-124 can 
inhibit proliferation, migration and invasion of glioma cells (Chen et al., 2010; Liu et 
al., 2010; Senft et al., 2011; Weissenberger et al., 2010). For these studies, it cannot 
be ruled out that the observed effect on migration/invasion were partly due to cell 
death induced by the treatment. Further, curcumin, JSI-124 (cucurbitacin I) and 
AG490 have pleiotropic effects on several signaling pathways and are not specific 
inhibitors of STAT3, as demonstrated by their successful application in the inhibition 
of other signaling pathways (Aggarwal et al., 2003; Caceres-Cortes, 2008; Sun et al., 
2005). Thus, although these compounds have potent anti-cancer effects, it is difficult 
to attribute the observed reduction in glioma cell migration and invasion solely to 
STAT3 suppression. On the other hand, in this study, small-molecule STAT3 inhibitor, 






STAT3, required for both tyrosine phosphorylation and dimerization for nuclear 
translocation, and does not affect activation or levels of other members of the 
Jak/STAT pathway (Schust et al., 2006). Thus, the use of inhibition methods with 
varying specificities, and the low concentration of Stattic used to achieve partial 
STAT3 inhibition are likely the reasons the results diverge from some of the previous 
studies.  
Evidence for a cytostatic effect in contrast to the oncogenic role assumed for STAT3 
in gliomas comes from differentiation studies. Activation of STAT3 is required for 
differentiation of glioblastoma-initiating cells (GICs) to both astrocytes and 
oligodendrocytes following exposure to LIF or IFN-ß, respectively (Lee et al., 2008b; 
Yuki et al., 2009). By effectively reducing the pool of tumor-initiating cells due to 
differentiation, animals receiving injection of GICs primed for differentiation had much 
better survival compared to those injected with GICs unable to undergo differentiation 
– translating to a role for STAT3 in reducing tumorigenecity of GICs. In terms of 
mechanism of cancer cell migration and invasion, STAT3 dominant negative mutant, 
which cannot be phosphorylated, was shown to induce a constitutive pro-invasive 
activity in human colonic and kidney cancer cells, while the constitutively active form 
of STAT3 was permissive to invasion through HGF/c-Met signaling (Rivat et al., 
2004). It is interesting to note that in the absence of any external signaling, cells in 
which STAT3 function was abrogated had a much higher migration rate than those 
with wild-type STAT3. It was reasoned that STAT3 regulates both positive and 
negative regulators of invasion in tumor cells, maintaining a balance between the two. 
Whether this applies to glioma cells will need to investigated in the future and can 
potentially address the dichotomous role of STAT3 in gliomas. The narrow range of 
phosphorylated STAT3 reduction by miR-376a*A or by Stattic, necessary to promote 
migration in glioma cells in the curent study, is in line with the hypothesis of a 






Due to the change in miRNA sequence by altered editing, target genes that would 
normally be accessible to the edited miR-376a*, become ‘untargetable’ in GBMs, 
further contributing to disruption of miRNA function. One such target identified here is 
the autocrine motility factor receptor (AMFR), a target specific to edited miR-376a* in 
gliomas.  A mechanistic role for AMFR in promotion of glioma cell migration and 
invasion has not yet been demonstrated. Nonetheless, it has been shown that in 
normal brain tissue, there is no expression of AMFR or AMF in glial cells, while 
abundant mRNA levels of both are found in majority of grade III astrocytomas and 
GBMs (Tanizaki et al., 2006). The observation that AMFR positivity is particularly 
abundant in pseudopalisading cells in necrotic region suggests that actively migrating 
glioma cells express AMFR (Brat et al., 2004). AMFR expression correlates with poor 
prognosis in several carcinomas due to increased invasion and metastatic 
predisposition (Hirono et al., 1996; Maruyama et al., 1995; Takanami et al., 2001). 
The autocrine cytokine AMF is known to produce directional and random motility in 
tumor cells (Liotta et al., 1986). Significantly, in this thesis, it was demonstrated for 
the first time that knockdown of AMFR is sufficient to inhibit migration of glioma cells. 
At the mRNA level a direct correlation of editing frequency of miR-376a* and AMFR 
expression in human gliomas could not be established. It cannot be ruled out that 
there exists such a correlation at the protein level. This will need to be further 
investigated. Nonetheless, the abolishment of edited miR-376a* function due to loss 
of editing could be additionally responsible for promotion of migration of glioma cells. 
In summary, based on miRNA targeting of STAT3 and AMFR, the redirection of 
target gene specificity of miR-376a* was confirmed in glioma cells. Significantly, this 
redirection mediated by a single base change in miRNA seed sequence was shown 
to have functional consequences in promoting glioma cell migration. The 
consequence of altered editing of miR-376a* is based on the dual effect of aberrantly 






7 CHAPTER 7.  General discussion  
The aim of this thesis was to establish a link between post-transcriptional regulation 
of miRNAs by A-to-I editing and tumorigenesis. It is known that in the normal adult 
brain, miRNAs from miR-376 cluster undergo regulated high-level seed sequence 
editing that specifically replaces an adenosine with inosine, which possesses the 
same base-pairing affinities as guanosine. As A-to-I editing is generally misregulated 
in GBMs, it was hypothesized that among several substrates of ADAR enzymes, 
miRNAs are critical mediators of ADAR dysfunction that regulate tumor growth and 
invasiveness. The main findings of this study support a role for altered A-to-I editing 
of miRNAs in promoting GBM invasiveness. 
7.1 Summary and conclusions 
In Chapter three, it was first established that in comparison to normal brain, A-to-I 
editing of miRNAs from miR-376 cluster is significantly reduced in high-grade gliomas, 
including GBMs due to low expression of ADARs.  Consequently, the seed sequence 
of mature miRNAs are underedited or unedited in gliomas, contributing to a miRNA 
sequence composition distinct from that in the normal situation. Furthermore, among 
various cell types of the brain, normal astrocytes were found to have high level 
(nearly 100%) editing of mature miRNAs. In gliomas, the various editing sites within 
miR-376 cluster demonstrate variable extents of loss of editing, but some sites are 
more affected than others. From the analysis of twenty-four human glioma samples, 
it was observed that specifically, miR-376a* aberrantly accumulates entirely in the 
unedited form in GBMs.   
To investigate the consequences of aberrant accumulation of unedited miR-376a* in 
GBMs, in Chapter four, functional analysis of this miRNA was carried out. First, it was 
demonstrated that during the establishment of a highly invasive glioma cell 
population from parental non-invasive cells using the experimental lung metastasis 






accumulation in human GBMs. Furthermore, in glioma cell lines, introduction of 
unedited miR-376a* (adenosine-containing form) promoted their migration and 
invasion in vitro. Remarkably, edited miR-376a*, differing by a single base in the 
seed sequence (guanosine-containing form) was able to suppress these features. 
Additionally, knockdown of unedited miR-376a* in highly invasive ELM cells was 
sufficient to suppress their highly-migratory property. Using the orthotopic glioma 
model, it was also established that the expression of unedited miR-376a* promotes 
invasive tumor growth by otherwise non-invasive U87 glioma cells. These tumors 
also recapitulated features of human GBMs such as necrosis and high degree of 
vascularization. Thus, unedited miR-376a* is a functional tumor specific- sequence 
variant, the aberrant accumulation of which, promotes malignant properties of glioma 
cells. 
In Chapter five, a genome-wide transcriptome analysis was undertaken to delineate 
the differences in cellular effects of unedited miR-376a* and edited miR-376a* which 
oppositely regulated glioma cell migration and invasion. This analysis showed that 
although differing by only a single base unedited and edited miR-376a* produce 
highly distinct gene expression changes in glioma cells with remarkably limited 
overlap. Specifically, unedited miR-376a* causes the up-regulation of gene clusters 
associated with invasion, motility and angiogenesis in agreement with its ability to 
promote cell invasion and induce aggressive tumor growth.  
In Chapter six, the mechanism underlying the invasion-promoting effect of miR-376a* 
was investigated by identifying its target gene specificity in glioma cells. Based on the 
redirection of target gene specificity due to seed sequence modification by A-to-I 
editing, targets genes exclusively targeted by unedited or by edited miR-376a* were 
identified to account for their cellular effects of respectively, promoting and 
suppressing glioma cell migration and invasion. STAT3 was identified as a specific 






miR-376a* and mRNA and protein levels of STAT3 were down-regulated only by 
unedited miR-376a*. Furthermore, specific inhibition of STAT3 by a small-molecule 
inhibitor, was able to promote cell migration, phenocopying the effects of unedited 
miR-376a* on cell migration. Thus, STAT3 is a migration-suppressing gene in GBMs, 
the down-regulation of which, by unedited miR-376a* promotes glioma cell migration. 
AMFR was identified as a target gene of edited miR-376a*. AMFR 3’UTR was 
targeted only by edited miR-376a*, remaining ‘untargetable’ to unedited miR-376a*. 
Similarly, mRNA and protein levels of AMFR were diminished only by edited miR-
376a* while unedited miR-376a* had no effects on these. Furthermore, specific 
knockdown of AMFR by RNA interference suppressed the migration of glioma cells 
phenocopying the effects of edited miR-376a* on cell migration. Significantly, these 
results suggest a dual effect of attenuated A-to-I editing in GBMs: increased inhibition 
of the migration-restraining effect of STAT3 by the accumulation of unedited miR-
376a*coupled with failure in blocking AMFR function of promoting cell migration due 
to the decrease of edited miR-376a* level. These effects likely collectively contribute 
to the migratory and invasive properties of GBMs.  
In summary, this study demonstrates for the first time that A-to-I editing of miRNAs in 
gliomas in altered and this has significant functional consequences in promoting 
malignant properties of glioma cells, mediated through the function of unedited 
miRNA sequence variants present in glioma cells. 
7.2 Significance 
7.2.1 miRNA sequence variations in cancer 
The sequence of mature miRNAs dictates potent modulation of several target genes 
simultaneously and thus, harbours enormous potential both for normal regulation and 
for malignant exploitation. A significant contribution of this study is in the identification 






miRNA sequence variants has long been speculated (Calin and Croce, 2006; 
Kloosterman and Plasterk, 2006), but specific examples of genome-derived 
functional miRNA polymorphisms or mutations have thus far not been identified or 
functionally characterized, possibly due to their rare occurrence (Saunders et al., 
2007). In this study, the “epigenetic space” generated by post-transcriptional 
processes  such as A-to-I editing was considered a source of miRNA sequence 
variation introduced in a regulated and functionally-relevant manner. Accordingly, 
due to loss of regulated A-to-I editing, one of the miRNAs regulated by editing- miR-
376a*- was shown to be present as the unedited variant in glioma cells and as the 
edited variant in normal cells. Recently, sequencing studies have determined that 
other than miRNAs from miR-376 cluster editing of mature miRNAs itself is also very 
rare (de Hoon et al., 2010). Therefore, the example of sequence variation due to 
aberrant A-to-I editing uncovered in this study may represent an exceptional and 
important case of tumor specific miRNA sequence variations. It is also noteworthy 
that even among miRNAs from miR-376 cluster, only miR-376a* demonstrated a 
consistently negligible level of editing in GBMs. Therefore, specifically, unedited miR-
376a* may be a major regulator of GBM progression.  
7.2.2 Regulation of miRNA function by single base change  
It was also identified in this study that while unedited miR-376a* promotes glioma cell 
invasion, edited miR-376a* was able to suppress this feature. While it is conceivable 
that miRNAs differing by a single base would have distinct but overlapping functions 
or one of the miRNAs may be non-functional, it was remarkable that these miRNAs in 
fact have opposite regulatory functions in cancer cells. The unedited miR-376a* may 
have an important function related to migration in undifferentiated cells such as 
neural stem cells, and by regulated A-to-I editing this function gets “edited out” in 
edited miR-376a* which then assumes a migration-suppressing  function in fully 






unedited mR-376a* by attenuated A-to-I editing then allows this miRNA to promote 
migration. This scenario illustrates a potential post-transcriptional mechanism for 
elegantly switching and appropriating miRNA functions by just a single base change 
in the miRNA sequence depending on the cellular environment and differentiation 
state. Such a mechanism would present several advantages over transcriptional 
changes to regulatory entities and is in support of a functional role for A-to-I editing of 
specific substrates instead of genomic recoding of these substrates (Nishikura, 2010; 
Wahlstedt et al., 2009). 
7.3 Future work 
From the miR-376 cluster, editing of other sites corresponding to mature miRNAs 
were also highly reduced in gliomas, although not as consistently as miR-376a*. This 
includes the site corresponding to mature miR-376a2-5p which shares the seed 
sequence with miR-376a* and differs by 3 nucleotides in total. Thus, together with 
miR-376a*, unedited miR-376a2-5p may also have a role in tumor growth and 
invasiveness. This will need to be further investigated. Also, for other sites a 
fractional reduction in editing frequency that produces an intermediate ratio of edited 
to unedited mature miRNA forms in the diseased state may also be of functional 
relevance but are considerably more challenging to investigate experimentally.   
Although A-to-I editing is commonly thought to result in I-to-C pairing it has been 
suggested that in the context of miRNA function I-to-U and I-to-A wobble base pairs 
may also be involved (Das and Carmichael, 2007). How and if this relevant to base-
pairing of edited miR-376a* will need to be further investigated, as this property of the 
I-base can potentially expand the target gene repertoire beyond that predictable by 
current computational methods. The presence of I-A wobble base has not been 
considered during miRNA binding to mRNAs and will inevitably to be overlooked by 
the traditional methods of miRNA target gene prediction. Nonetheless, results from 






functions in miRNA base-pairing with target gene (Borchert et al., 2009; Kawahara et 
al., 2007a) and substituting G for an I should adequately represent the I-containing 
miRNA. 
The identification of unedited miR-376a* as a pro-invasive factor in GBMs, leads to 
the possibility of inhibiting its function for therapeutically addressing the greatest 
challenge in treatment of GBMs - infiltration into the normal brain. Inhibition of 
miRNAs can be achieved by anti-miRNA molecules such as LNAs, 2’-O-methyl 
antisense oligos or  by the vector-based expression of transcripts antisense to target 
miRNAs (Garzon et al., 2010). However, in the case of edited miR-376a* knockdown 
in diseased cells in brain tumors presents considerable challenges as normal cells 
express unedited miR-376a* differing only by a single base from the target of 
antagonism. Among potential knockdown systems, LNA molecules can discriminate 
single-base mismatches in RNA and DNA molecules (Johnson et al., 2004; Lee et al., 
2008a), however, their utility in specifically knocking down one of two miRNAs 
differing by a single base has yet to be demonstrated. Alternatively, considering that 
restoring ADAR2 activity restored editing of miR-376a* in glioma cells, the 
introduction of the enzyme in diseased cells can also be considered. However, this is 
most likely to have effects on several editing substrates and the possibility of creating 
unwanted or deleterious editing events cannot be ruled out. A related but 
unanswered question includes how and why ADAR dysfunction occurs in gliomas.  
Investigation into the identity of regulatory factors of ADARs, either transcriptional, or 
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Appendix Figure A1. qRT-PCR amplification of unedited miR-376a* with primers 
corresponding to unedited miR-376a* (right) and edited miR-376a* (left), differing by a single 
base. Note the similar Cts for both primers, indicating similar efficiency of amplification and 














Appendix Table A1 Genes downregulated by miR-376a*A in U87 and SW1783 cells 




SEPT10 septin 10 
ADAM17 ADAM metallopeptidase domain 17 
ALG2  asparagine-linked glycosylation 2, alpha-1,3-mannosyltransferase homolog (S. cerevisiae)  
ARL6  ADP-ribosylation factor-like 6  
ARMCX5  armadillo repeat containing, X-linked 5  
ATP10D  ATPase, class V, type 10D  
B3GAT3  beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I)  
BAG5  BCL2-associated athanogene 5  
BRI3BP  BRI3 binding protein  
BZW1  basic leucine zipper and W2 domains 1  
C18orf54  chromosome 18 open reading frame 54  
C18orf55  chromosome 18 open reading frame 55  
C7orf58  chromosome 7 open reading frame 58  
CAST  calpastatin  
COMMD2  COMM domain containing 2  
DENR  density-regulated protein  
DIP2A  DIP2 disco-interacting protein 2 homolog A (Drosophila)  
DKFZP564C1
52  DKFZP564C152 protein  
DPYD  dihydropyrimidine dehydrogenase  
ELOVL5  ELOVL family member 5, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast)  
EPB41L5  erythrocyte membrane protein band 4.1 like 5  
ERLIN2  ER lipid raft associated 2  
FAM168A  family with sequence similarity 168, member A  
FAM18B  family with sequence similarity 18, member B  
FAM20B  family with sequence similarity 20, member B  
FAM55C  family with sequence similarity 55, member C  
FGF2  fibroblast growth factor 2 (basic)  
FRMD5  FERM domain containing 5  
G3BP2  GTPase activating protein (SH3 domain) binding protein 2  
GALNT11  UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 11 (GalNAc-
T11)  
GFPT1  glutamine-fructose-6-phosphate transaminase 1  
GIGYF2  GRB10 interacting GYF protein 2  
GLT8D3  glycosyltransferase 8 domain containing 3  
GNE  glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase  
GOLPH3L  golgi phosphoprotein 3-like  
HDAC9  histone deacetylase 9  
HNRNPAB  heterogeneous nuclear ribonucleoprotein A/B  
ISOC1  isochorismatase domain containing 1  
KCTD12  potassium channel tetramerisation domain containing 12  
KDSR  3-ketodihydrosphingosine reductase  
KIF16B  kinesin family member 16B  
KPNA6  karyopherin alpha 6 (importin alpha 7)  
LARS2  leucyl-tRNA synthetase 2, mitochondrial  
LOC643287  similar to prothymosin alpha  
LOC727914  BMS1-like, ribosome assembly protein (yeast) pseudogene  
LRRFIP2  leucine rich repeat (in FLII) interacting protein 2  
LYRM7  Lyrm7 homolog (mouse)  
MAP2  microtubule-associated protein 2  
MDH1  malate dehydrogenase 1, NAD (soluble)  
MED28  Mediator complex subunit 28  
MELK  maternal embryonic leucine zipper kinase  
MIS12  MIS12, MIND kinetochore complex component, homolog (yeast)  
MLF1IP  MLF1 interacting protein  
MUS81  MUS81 endonuclease homolog (S. cerevisiae)  
MYH9  myosin, heavy chain 9, non-muscle  
NAPG  N-ethylmaleimide-sensitive factor attachment protein, gamma  
NHLRC3  NHL repeat containing 3  
NSUN2  NOL1/NOP2/Sun domain family, member 2  
NUDT15  









NUP50 nucleoporin 50kDa 
ORAI3 ORAI calcium release-activated calcium modulator 3 
PANK4 pantothenate kinase 4 
PEX19 peroxisomal biogenesis factor 19 
PIP4K2A phosphatidylinositol-5-phosphate 4-kinase, type II, alpha 
PITRM1 pitrilysin metallopeptidase 1 
POMGNT1 protein O-linked mannose beta1,2-N-acetylglucosaminyltransferase 
PPP2R2A protein phosphatase 2 (formerly 2A), regulatory subunit B, alpha isoform  
PTPRJ protein tyrosine phosphatase, receptor type, J 
RAB8B RAB8B, member RAS oncogene family 
RAP2A RAP2A, member of RAS oncogene family 
RAPGEF6 Rap guanine nucleotide exchange factor (GEF) 6 
RBM17 RNA binding motif protein 17 
RNF138 ring finger protein 138 
RNF141 ring finger protein 141 
RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypeptide 3 
RPS6KB1 ribosomal protein S6 kinase, 70kDa, polypeptide 1 
RRAS2 related RAS viral (r-ras) oncogene homolog 2 
RSPRY1 ring finger and SPRY domain containing 1 
RTN4 reticulon 4 
SCML1 sex comb on midleg-like 1 (Drosophila) 
SEC23B Sec23 homolog B (S. cerevisiae) 
SKP2 S-phase kinase-associated protein 2 (p45) 
SLC25A43 solute carrier family 25, member 43 
SLC2A14  solute carrier family 2 (facilitated glucose transporter), member 14  
SLC35A1 solute carrier family 35 (CMP-sialic acid transporter), member A1  
SLC38A1 solute carrier family 38, member 1 
SLC39A10 solute carrier family 39 (zinc transporter), member 10 
SLC7A11 solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 
SLC7A6OS solute carrier family 7, member 6 opposite strand 
SMN1  survival of motor neuron 1, telomeric  
SNRPA1 small nuclear ribonucleoprotein polypeptide A' 
SQSTM1 sequestosome 1 
STAT3 signal transducer and activator of transcription 3 (acute-phase response factor) 
SUB1 SUB1 homolog (S. cerevisiae) 
TDG thymine-DNA glycosylase 
THUMPD1 THUMP domain containing 1 
TOR1B torsin family 1, member B (torsin B) 
TPK1 thiamin pyrophosphokinase 1 
TTC39C tetratricopeptide repeat domain 39C 
UGCG UDP-glucose ceramide glucosyltransferase 
USP53 ubiquitin specific peptidase 53 
VEZT vezatin, adherens junctions transmembrane protein 
VMA21 VMA21 vacuolar H+-ATPase homolog (S. cerevisiae) 
VTA1 Vps20-associated 1 homolog (S. cerevisiae) 
WDR37 WD repeat domain 37 
YPEL5 yippee-like 5 (Drosophila) 
YRDC yrdC domain containing (E. coli) 
ZCCHC10 zinc finger, CCHC domain containing 10 
ZFYVE26 zinc finger, FYVE domain containing 26 
 Full length insert cDNA clone ZB81B12 
 
Full-length cDNA clone CS0DK008YI09 of HeLa cells Cot 25-normalized of Homo sapiens 
(human) 
 CDNA FLJ30661 fis, clone DFNES2000526 
 Homo sapiens, clone IMAGE:4294444, mRNA 
 Full-length cDNA clone CS0DF022YM06 of Fetal brain of Homo sapiens (human) 
 MRNA; cDNA DKFZp586F1523 (from clone DKFZp586F1523) 













Appendix Table A2 Genes downregulated by miR-376a*G in U87 and SW1783 cells 




AASDHPPT aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase 
ABHD2 abhydrolase domain containing 2 
ABL1 c-abl oncogene 1, receptor tyrosine kinase 
ACVR1 activin A receptor, type I 
AFF1 AF4/FMR2 family, member 1 
AFG3L2 AFG3 ATPase family gene 3-like 2 (yeast) 
AHCYL2 S-adenosylhomocysteine hydrolase-like 2 
AMFR autocrine motility factor receptor 
AP3M1 adaptor-related protein complex 3, mu 1 subunit 
APC adenomatous polyposis coli 
ARF1 ADP-ribosylation factor 1 
ARHGAP21 Rho GTPase activating protein 21 
ARHGAP26 Rho GTPase activating protein 26 
ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 
ARL4C ADP-ribosylation factor-like 4C 
ARMC8 armadillo repeat containing 8 
ARNTL aryl hydrocarbon receptor nuclear translocator-like 
ARRDC3 arrestin domain containing 3 
BRD3 bromodomain containing 3 
C10orf26 chromosome 10 open reading frame 26 
C13orf23 chromosome 13 open reading frame 23 
C15orf57 chromosome 15 open reading frame 57 
C17orf39 chromosome 17 open reading frame 39 
C17orf80 chromosome 17 open reading frame 80 
C19orf2 chromosome 19 open reading frame 2 
C1orf96 chromosome 1 open reading frame 96 
C2orf64 chromosome 2 open reading frame 64 
C5orf51 chromosome 5 open reading frame 51 
C9orf126 chromosome 9 open reading frame 126 
CASP7 caspase 7, apoptosis-related cysteine peptidase 
CBLB Cas-Br-M (murine) ecotropic retroviral transforming sequence b 
CDC26 cell division cycle 26 homolog (S. cerevisiae)  
CHD6 chromodomain helicase DNA binding protein 6 
CYB5R4 cytochrome b5 reductase 4 
DHTKD1 dehydrogenase E1 and transketolase domain containing 1 
DPYSL3 dihydropyrimidinase-like 3 
DUSP14 dual specificity phosphatase 14 
ELK4 ELK4, ETS-domain protein (SRF accessory protein 1) 
EML4 echinoderm microtubule associated protein like 4 
EMP2 epithelial membrane protein 2 
EZH1 enhancer of zeste homolog 1 (Drosophila) 
FAM120B Family with sequence similarity 120B 
FAM122B family with sequence similarity 122B 
FAM171A1 family with sequence similarity 171, member A1 
FBXO46  F-box protein 46 
FNIP2 folliculin interacting protein 2 
FOXJ3 forkhead box J3 
FZD5 frizzled homolog 5 (Drosophila) 
GAS2L3 Growth arrest-specific 2 like 3 
GDAP1 ganglioside-induced differentiation-associated protein 1 
GLOD4 glyoxalase domain containing 4 
GPR157 G protein-coupled receptor 157 
GPR180 G protein-coupled receptor 180 
GRK5 G protein-coupled receptor kinase 5 
HDAC4 histone deacetylase 4 
HIPK2 homeodomain interacting protein kinase 2 
HRSP12 heat-responsive protein 12 
IL6R interleukin 6 receptor 
IMPA2 inositol(myo)-1(or 4)-monophosphatase 2 
IRGQ immunity-related GTPase family, Q 









JMJD6 jumonji domain containing 6 
JOSD1 Josephin domain containing 1 
KIAA2018 KIAA2018 
KIF1B kinesin family member 1B 
KIRREL kin of IRRE like (Drosophila) 
KLF13 Kruppel-like factor 13 
LMAN2L lectin, mannose-binding 2-like 
LMLN leishmanolysin-like (metallopeptidase M8 family) 
LOC149832 hypothetical protein LOC149832 
LPP LIM domain containing preferred translocation partner in lipoma  
LRRC58 leucine rich repeat containing 58 
MALT1 mucosa associated lymphoid tissue lymphoma translocation gene 1 
MAP2K4 mitogen-activated protein kinase kinase 4 
MCC mutated in colorectal cancers 
MED14 mediator complex subunit 14 
MLXIP MLX interacting protein 
MOBKL1B MOB1, Mps One Binder kinase activator-like 1B (yeast) 
MYCBP c-myc binding protein 
NAV1 neuron navigator 1 
NRN1 neuritin 1 
NUCKS1 nuclear casein kinase and cyclin-dependent kinase substrate 1 
NUCKS1 Nuclear casein kinase and cyclin-dependent kinase substrate 1 
OXSR1 oxidative-stress responsive 1 
PAFAH1B1 platelet-activating factor acetylhydrolase, isoform Ib, subunit 1 (45kDa) 
PDLIM5 PDZ and LIM domain 5 
PEG10 paternally expressed 10 
PI4K2A phosphatidylinositol 4-kinase type 2 alpha 
PLS1 plastin 1 (I isoform) 
PPFIA1 protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), 
alpha 1 
PRICKLE2 prickle homolog 2 (Drosophila) 
PRKAB2 protein kinase, AMP-activated, beta 2 non-catalytic subunit 
PRKACB protein kinase, cAMP-dependent, catalytic, beta 
PRNP prion protein 
PRRC1 proline-rich coiled-coil 1 
PRSS23 Protease, serine, 23 
PSEN1 presenilin 1 
PTCH1 patched homolog 1 (Drosophila) 
RAB31 RAB31, member RAS oncogene family 
RBM23 RNA binding motif protein 23 
SCLY selenocysteine lyase 
SEC22B SEC22 vesicle trafficking protein homolog B (S. cerevisiae) 
SETBP1 SET binding protein 1 
SLC1A1 solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 
1 
SLC30A6 solute carrier family 30 (zinc transporter), member 6 
SLC38A7 solute carrier family 38, member 7 
SNX21 sorting nexin family member 21 
SOCS3 suppressor of cytokine signaling 3 
ST5 suppression of tumorigenicity 5 
SYT1 synaptotagmin I 
TCF7 transcription factor 7 (T-cell specific, HMG-box) 
TFG TRK-fused gene 
TMEM183A  transmembrane protein 183A  
TMEM33 transmembrane protein 33 
TNFRSF10B tumor necrosis factor receptor superfamily, member 10b 
TNFRSF21 tumor necrosis factor receptor superfamily, member 21 
TPRG1L tumor protein p63 regulated 1-like 
TRIM69 tripartite motif-containing 69 
TTC7B tetratricopeptide repeat domain 7B 
TWSG1 twisted gastrulation homolog 1 (Drosophila) 
UBE2I Ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast) 













UBP1 upstream binding protein 1 (LBP-1a) 
UFM1 ubiquitin-fold modifier 1 
UNC13B unc-13 homolog B (C. elegans) 
WAPAL wings apart-like homolog (Drosophila) 
WBP4 WW domain binding protein 4 (formin binding protein 21) 
XPNPEP3 X-prolyl aminopeptidase (aminopeptidase P) 3, putative 
YIPF6 Yip1 domain family, member 6 
ZAK sterile alpha motif and leucine zipper containing kinase AZK 
ZCCHC24 zinc finger, CCHC domain containing 24 
ZDHHC5 zinc finger, DHHC-type containing 5 
ZNF23 zinc finger protein 23 (KOX 16) 
ZNF271 zinc finger protein 271 
ZNF317 zinc finger protein 317 
ZNF35 zinc finger protein 35 
ZXDB zinc finger, X-linked, duplicated B 
 CDNA FLJ30652 fis, clone DFNES2000011 
 CDNA FLJ39585 fis, clone SKMUS2006633 
 CDNA FLJ31233 fis, clone KIDNE2004579 
 CDNA FLJ37302 fis, clone BRAMY2016009 
 CDNA FLJ34250 fis, clone FCBBF4000529 
 
 
